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Summary 
Malaria is still a disease of global health significance. Its causative agent, Plasmodium, 
has a complex lifecycle alternating between the female Anopheles mosquito and the 
vertebrate host. The blood stage of the infection is thought to cause the clinical 
symptoms of the disease and is also targeted by the humoral immune response of the 
host. Natural acquired immunity to malaria is largely mediated by immunoglobulins 
and is reflected both by a lower prevalence of infection with age and lower rates of 
disease. Previous studies have generally focussed on understanding the protective 
role of naturally acquired functional antibodies targeting the mature infected 
erythrocyte (mIE) and highly immunogenic merozoite. However, the ring-infected 
erythrocyte (rIE), has hardly been explored to date in the context of naturally acquired 
protective immunity. As it is the stage of the infection that is predominantly found in 
the peripheral circulation, its immunological significance is uncertain. This thesis was 
aimed at contributing to this knowledge gap by investigating the role and significance 
of rIEs in protective immunity. 
Firstly, to investigate the immunogenicity of rIEs, I tested whether they were 
recognised by malaria-immune antibodies using immunofluorescence and flow 
cytometry. I confirmed that malaria-immune antibodies do bind to rIEs using both 
laboratory-adapted (lab) and field isolates. This binding was strongly correlated with 
that directed against mIEs and merozoites, both of which have been shown to be 
important targets of protective immunity. Malaria-immune antibody binding to rIEs had 
no direct inhibitory effect on parasite survival and maturation. In separate assays, I 
tested whether rIEs were retained in the spleen independently of antibody using a 
microsphiltration assay. As has been previously reported, rIEs were retained in the 
spleen and I demonstrated for the first time that the retention rate was comparable 
between lab and field parasite isolates of the same age, suggesting that this may be 
a mechanism of parasite clearance that contributes to the low parasite densities 
observed in malaria endemic areas. 
Secondly, to investigate the likely physiological relevance of antibody binding to rIEs 
during P. falciparum infection, I tested whether the in vitro opsonic phagocytosis of 
rIEs predicted the outcome of infection in a controlled human malaria infection (CHMI) 
study. I established the flow cytometry based opsonic phagocytosis assay (OPA) of 
rIEs in our laboratory. I showed for the first time, to the best of my knowledge, that 
opsonic phagocytosis of rIEs was significantly associated with the outcome of infection 
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(lower parasite densities and the need for treatment) in the CHMI study. Interestingly, 
phagocytosis of uninfected erythrocytes (uEs) in the ring culture was higher in 
untreated as compared to the treated individuals, suggesting a potential contribution 
to anaemia, as others have reported. In addition, I developed competition OPAs and 
used stage-specific spent media, to demonstrate that merozoite specific antibodies 
mediated the observed opsonic phagocytosis of the ring culture cells and uEs 
incubated in spent media respectively. 
Finally, to investigate the specific parasite antigens on the surface of ring culture cells 
and uEs incubated in spent media, I employed surface trypsinization, followed by mass 
spectrometry of supernatants. This is the first surface proteomics study to be 
conducted on rIEs and in this single study I was able to identify parasite proteins on 
the surface of rIEs and uEs that had previously been identified singly, in a piecemeal 
fashion (EBA140, EBA175, RAP1, RAP2, RhopH1, RhopH2, RhopH3 and MCP1), 
and ENO which I showed for the first time. These proteins have been speculated to 
be transferred by the merozoite to the surface of the newly invaded erythrocyte during 
invasion and have also been shown to be correlates of protective immunity, with the 
exception of MCP1, whose role in parasite clearance and protective immunity has not 
yet been explored. 
This thesis shows for the first time that antibody mediated clearance of rIEs in vitro, is 
correlated with the outcome of P. falciparum infection in a CHMI study and was 
mediated by anti-merozoite antibodies. This study also demonstrates that there are 
shared parasite targets between merozoites and rIEs. I conclude that rIEs are not 
immunologically inert and are targeted by antibodies leading to parasite clearance 
through mechanisms such as phagocytosis. This activity was significantly associated 
with lower parasite densities and resistance against clinical symptoms in a human 
malaria challenge study suggesting that it contributes to protective immunity. The 
enhanced phagocytosis of uEs in protected individuals suggest a potential detrimental 
impact of anaemia that requires further investigation.  
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Zusammenfassung 
Malaria ist nach wie vor eine Krankheit von globaler gesundheitlicher Bedeutung. Der 
Malaria-Erreger Plasmodium hat einen komplexen Lebenszyklus, der zwischen der 
weiblichen Anopheles-Mücke und dem Wirbeltierwirt alterniert. Die klinischen 
Symptome der Krankheit werden durch das Blutstadium des Malariaparasiten 
verursacht und auch von der humoralen Immunantwort des Wirts beeinflusst. Die 
natürlich erworbene Immunität gegen Malaria wird größtenteils durch Immunglobuline 
vermittelt und spiegelt sich sowohl in einer geringeren Prävalenz von Infektionen mit 
dem Alter als auch in geringeren Krankheitsraten wider. Frühere Studien 
konzentrierten sich im Allgemeinen auf das Verständnis der Schutzfunktion von 
natürlich erworbenen funktionellen Antikörpern gegen die reifen, infizierten 
Erythrozyten und die hoch immunogenen Merozoiten. Der ringinfizierte Erythrozyt 
(rIE) ist jedoch im Zusammenhang mit einer natürlich erworbenen, schützenden 
Immunität, bisher kaum erforscht worden. Da sich dieses Infektionsstadium 
überwiegend im peripheren Kreislauf befindet, ist seine immunologische Bedeutung 
ungewiss. Ziel dieser Arbeit war es, einen Beitrag zur Schließung dieser Wissenslücke 
zu leisten, indem die Rolle und Bedeutung von rIEs bei der protektiven Immunität 
untersucht wurde. 
Um die Immunogenität von rIEs zu untersuchen, habe ich zunächst mithilfe von 
Immunfluoreszenz und Durchflusszytometrie getestet, ob rIEs von Malaria-
spezifischen Antikörpern erkannt werden. Ich konnte bestätigen, dass Malaria-
spezifische Antikörper an rIEs binden, was sowohl für laborangepasste Parasiten als 
auch für Feldisolate gezeigt werden konnte. Diese Antikörperbindung korrelierte stark 
mit der Bindung an reife, infizierte Erythrozyten (mIEs) und Merozoiten, von denen 
bekannt ist, dass sie wichtige Ziele der schützenden Immunität sind. Die Bindung von 
Malaria-spezifischen Antikörpern an rIEs hatte keine direkt hemmende Wirkung auf 
das Überleben und die Reifung der Parasiten. In separaten Assays testete ich mithilfe 
eines „Mikrosphiltrationstests“, ob rIEs unabhängig von Antikörpern in der Milz 
zurückgehalten werden. Wie bereits zuvor berichtet, wurden rIEs in der Milz 
zurückgehalten, und ich konnte zum ersten Mal nachweisen, dass die Retentionsrate 
„gleichalter“ Ringstadien zwischen Labor- und Feldisolaten vergleichbar war, was 
vermuten lässt, dass dieser Mechanismus der Eliminierung von Parasiten einen 
Beitrag zu den in Endemiegebieten beobachtbaren. niedrigen Parasitendichten leistet. 
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Zweitens testete ich, um die physiologische Relevanz der Antikörperbindung an rIEs 
während einer P. falciparum-Infektion zu untersuchen, ob die antikörperabhängige in 
vitro Phagozytose („opsonic phagocytosis“) von rIEs das Ergebnis einer kontrollierten 
humanen Malaria-Infektion (CHMI) vorhersagen konnte. Hierzu habe ich in unserem 
Labor den auf Durchflusszytometrie basierten „Opsonic Phagocytosis Assay“ (OPA) 
von rIEs etabliert. Ich habe in der CHMI-Studie, nach meinem Wissen, zum ersten Mal 
gezeigt, dass die antikörperabhängige Phagozytose von rIEs signifikant mit dem 
„Outcome“ der Infektion (geringere Parasitendichten und Behandlungsbedarf) 
assoziiert ist. Interessanterweise war die Phagozytose nicht infizierter Erythrozyten 
(uEs) aus einer Ringstadien-Kultur in der Gruppe der nicht-behandelten (geschützten) 
Personen höher, was auf einen möglichen Beitrag zur Anämie hindeutet, wie bereits 
in anderen Studien berichtet wurde. Darüber hinaus entwickelte ich kompetitive OPAs 
und verwendete stadienspezifische, für die Parasitenkultur zuvor gebrauchte Medien 
(„used media“), um zu zeigen, dass merozoitenspezifische Antikörper die beobachtete 
antikörperabhängige Phagozytose, der in verbrauchten Medien inkubierten 
Ringstadien und uEs, vermittelten. 
Um die spezifischen Parasiten-Antigene auf der Oberfläche von Ringstadien und in 
verbrauchten Medien inkubierten uEs zu untersuchen, setzte ich eine 
Oberflächentrypsinierung ein, gefolgt von einer massenspektrometrischen Analyse 
der Überstände. Dies ist die erste Studie, die das Oberflächen-Proteom von rIEs 
untersuchte. In dieser Einzelstudie konnte ich Parasitenproteine auf der Oberfläche 
von rIEs und uEs identifizieren, die zuvor einzeln in anderen Studien identifiziert 
wurden (EBA140, EBA175, RAP1, RAP2, RhopH1, RhopH2, RhopH3 und MCP1), 
wobei ich das Protein Enolase (ENO) zum ersten Mal in diesem Zusammenhang 
detektieren konnte. Es wurde bereits zuvor spekuliert, dass diese Proteine vom 
Merozoiten während der Invasion auf die Oberfläche des neu infizierten Erythrozyten 
übertragen werden, und es wurde auch gezeigt, dass diese Antigene mit einer 
schützenden Immunantwort korrelieren, mit Ausnahme von MCP1, dessen Rolle bei 
der Beseitigung von Parasiten und der schützenden Immunität noch nicht erforscht 
wurde. 
Diese Arbeit zeigt zum ersten Mal, dass die antikörpervermittelte Eliminierung von rIEs 
in vitro mit dem Ausgang einer P. falciparum-Infektion in einer CHMI-Studie korreliert 
und durch Anti-Merozoit-Antikörper vermittelt wird. Diese Studie zeigt auch, dass es 
gemeinsame Parasitenantigene zwischen Merozoiten und rIEs gibt. Ich schließe 
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daraus, dass rIEs nicht immunologisch inert sind und von Antikörpern angegriffen 
werden, die durch Mechanismen wie Phagozytose zur Beseitigung von Parasiten 
führen. Diese Aktivität war in einer humanen Malaria-Expositionsstudie signifikant mit 
einer geringeren Parasitendichte und Resistenz gegen klinische Symptome 
verbunden, was darauf hindeutet, dass sie zur schützenden Immunität beiträgt. Die 
verstärkte Phagozytose von uEs bei geschützten Personen deutet auf eine mögliche, 
nachteilige Verursachung von Anämie hin, was weiterer Untersuchungen bedarf. 
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Chapter 1 
Introduction 
 
1.1. Malaria: epidemiology and burden of disease 
Malaria is a vector-borne parasitic disease transmitted in about 91 tropical countries 
globally. As shown in Figure 1.1, it has been eradicated in temperate countries (Ashley 
et al., 2018). The absolute number of people at risk of malaria globally has increased 
between the 20th and 21st century, from 0.9 to 3 billion. However, when one considers 
the proportion of people at risk, this has actually decreased from 70% to 48% during 
the same time period (Hay et al., 2004). As it stands, the estimated global burden of 
malaria in 2018 was 228 million cases and 405 000 related deaths with Africa 
accounting for the largest share, 93% and 94% respectively (WHO, 2019). 
The global burden of malaria has substantially declined since the beginning of the 21st 
century due to implementation of long-lasting insecticide treated bed nets and 
artemisinin-based combination therapies (Ashley et al., 2018). However, there is a 
challenge in maintaining their effectiveness due to increasing drug and insecticide 
resistance (Hemingway et al., 2016), and thus the need to develop a highly efficacious 
vaccine to complement the existing malaria eradication strategies (Healer et al., 2017). 
Figure 1. 1: Map showing countries with indigenous cases in 2000 and their status by 2018. 
Countries with zero indigenous cases over at least the past 3 successive years are considered to be 
malaria free. In 2018, China and El Salvador reported the second year of zero indigenous cases, and 
Iran, Malaysia and Timor-Leste for the first time reported zero indigenous cases. The incidence rate of 
malaria has globally declined between 2010 and 2018, from 71 to 57 cases per 1000 population at risk. 
However, the progress has stagnated in the period between 2015-2018. In figures, the estimated 
worldwide malaria cases were 228 million in 2018, which was fewer than the recorded 251 million cases 
in 2010, but consistent with 231 million cases reported in 2017. Similarly, malaria related deaths 
estimated globally were 405 000 in 2018, 416 000 in 2017 and 585 000 in 2010. Figure adapted from 
WHO 2019. 
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Malaria is caused by a protozoan parasite of the Plasmodium genus. Over 120 
Plasmodium species infecting mammals, reptiles and birds, but only six Plasmodium 
species are known to infect humans: P. falciparum, P. vivax, P. malariae, P. ovale 
curtisi, P. ovale wallikeri and P. knowlesi (Ashley et al., 2018). The most predominant 
species worldwide include P. falciparum which the most dominant and fatal malaria 
parasite, and P. vivax which is the dominant parasite accountable for majority of 
malaria cases in America (WHO, 2018). P. malariae and P. ovale have a global 
distribution with low incidence whereas P. knowlesi is a zoonotic parasite found only 
in South East Asia where it is reported to cause severe malaria (Ashley et al., 2018). 
 
1.2. Malaria pathogenesis 
1.2.1. The Plasmodium life cycle 
The Plasmodium species have a complex life cycle that alternates between an infected 
female Anopheles mosquitoes and the vertebrate hosts as shown in Figure 1.2 
(Cowman et al., 2016). Plasmodium sporozoites are injected into the host dermis 
during a blood meal, move by gliding motility to traverse different cells from the site of 
bite to encounter and invade a blood vessel (Amino et al., 2006). The sporozoites that 
remain in the skin are drained into the lymphatic system, where an immune response 
is generated by the host leading to their destruction (Vanderberg and Frevert, 2004). 
From the dermal vasculature, sporozoites are passively transferred in the blood 
stream to the liver where they switch form a migratory mode to an invasive mode 
(Coppi et al., 2007). The sporozoites access the liver by crossing the sinusoidal barrier 
which consists of fenestrated endothelial cells and macrophage like Kupffer cells 
(Tavares et al., 2013). The interaction of the sporozoite and the liver is made possible 
by masking of some epitopes of the key surface antigen, circumsporozoite protein 
(CSP), in order to evade the immune system (Herrera et al., 2015). 
Once hepatocyte infection is established, the sporozoite gets enclosed within a 
parasitophorous vacuole membrane and develops asexually in the liver for 2-10 days 
to form tens of thousands of merozoites which are packed in vesicles known as 
merosomes (Vaughan et al., 2012). The liver stage infection is asymptomatic and thus 
cannot be detect during natural human infections. In P. falciparum infection, this liver 
stage lasts for 6-7 days while in P. vivax infection it lasts for 8-12 days with a dormancy 
phase which accounts for periodic relapse of vivax malaria (Mo and McGugan, 2018). 
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The hepatocyte-derived merosomes are thought to limit the presentation of 
phosphatidyl serine on the host membrane, thus ensuring their protection from the 
host immune system and successful migration into the blood stream (Sturm et al., 
2006).  
Once the merosomes are released into the hepatic circulation, the free merozoites 
invade the erythrocytes and develop in their own compartment enclosed by the 
parasitophorous vacuole membrane. The P. falciparum parasite thrives in this niche 
by modifying the host cell through trafficking numerous parasite proteins (Gruring et 
al., 2011). The newly invaded erythrocyte, ring stage, rapidly grows by utilizing 
haemoglobin and develops to trophozoite containing hemozoin in the food vacuole. 
Finally, the parasite enters into asexual reproductive state, schizogony, during which 
it undergoes cell division and generates up to 32 merozoites that invade new 
erythrocytes after host cell rupture (Cowman et al., 2016). During P. falciparum 
infection, only the ring stages are found in circulation whereas the trophozoite and 
schizont infected erythrocytes sequester in capillaries of different organs via parasite 
proteins on the host cell surface (Gruring et al., 2011). The continuous asexual 
development every 48 hours is responsible for the clinical symptoms of malaria (Aly 
et al., 2009).  
During cycles of schizogony in the bloodstream, a small subset of the asexual 
parasites undergoes a developmental switch that initiates commitment to sexual 
growth to form male and female gametocytes. The immature P. falciparum 
gametocytes develop in tissues, preferably the bone marrow, for 6-8 days and are 
present in the human blood circulation after maturity for uptake by a feeding mosquito 
(Joice et al., 2014). Consequently, each male and female gametocyte taken up during 
a blood meal differentiates into eight flagellate male gametes and an immotile 
extracellular female gamete respectively. The differentiation is due to an increase in 
pH as a result of exposure of the infected blood in air (Nijhout and Carter, 1978) and 
the presence of xanthurenic acid in the mosquito midgut (Arai et al., 2001). The male 
microgamete fertilizes a female macrogamete to form a diploid zygote which matures 
into an invasive form, ookinete, in the mosquito midgut. The ookinete starts to traverse 
the midgut epithelial cell layer from the apical side and egresses from the basal end 
to reach the basal lamina, where the surviving ookinetes become sessile and 
transform into oocysts (Matuschewski, 2006). The oocysts undergo sporogony, during 
which they asexually replicate extracellularly to form motile sporozoites which are then 
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released into the haemocoel upon oocyst rapture (Klug and Frischknecht, 2017). The 
midgut sporozoites are passively dispersed through the haemolymph until they reach 
and actively invade the salivary gland, where they remain in the ducts awaiting 
transmission during a blood meal (Aly et al., 2009). 
 
Figure 1. 2: The Plasmodium life cycle. The Plasmodium life cycle is complex and switches between 
the vertebrate host (human) and the vector (female Anopheles mosquito). (A) The mosquito infects the 
human host with sporozoites during a blood meal. (B) The sporozoites migrate from the site of bite to 
the liver establishing a pre-erythrocytic latent infection. (C) The merozoites released from the liver enter 
into the blood circulation and invade erythrocytes establishing the asexual erythrocytic stage 
responsible for the clinical symptoms of malaria. (D) A proportion of the asexual blood stages undergo 
sexual development to form gametocytes, which are taken up by mosquito during a blood meal. (E) 
The male and female gamete fuse to form a zygote which matures to a motile form, ookinete, that 
traverses the midgut and transform into oocysts. The oocyst undergoes asexual reproduction, 
sporogony, to form sporozoites that migrate and invade the salivary glands awaiting transmission during 
a blood meal. Figure is adapted from Cowman et al., 2016. 
 
1.2.2. Erythrocyte invasion during P. falciparum infection 
The interaction between merozoites and erythrocytes is a multi-step sequence of 
events as shown in Figure 1.3. It begins with the pre-invasion step that involves a 
robust interaction between the merozoite ligands, such as erythrocyte binding-like 
proteins (EBLs) and P. falciparum reticulocyte-binding homologs (PfRhs), and their 
erythrocyte receptors, namely glycophorin A, B, C and complement receptor 1 (CR1) 
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respectively. This interaction results in an actomyosin motor driven deformation of the 
host cell (Weiss et al., 2015). After deformation of the erythrocyte, the merozoite re-
orientates by means of a PfRh5 complex. Its apical end touches the basigin receptor 
of the erythrocyte membrane (Reddy et al., 2015, Chen et al., 2011, Crosnier et al., 
2011). The PfRh5-basigin interaction is associated with influx of calcium ions into the 
host cell (Weiss et al., 2015). Subsequently, the merozoite and erythrocyte form an 
irreversible attachment, tight junction, mediated by secretion of the rhoptry neck 
protein 2 (RON2). RON2 is deposited on the host erythrocyte membrane, bound by 
apical membrane antigen 1 (AMA1) and translocated on to the merozoite surface 
(Riglar et al., 2011). After the tight junction formation, the merozoite is propelled into 
the erythrocyte by force generated by the actomyosin motor of the parasite (Besteiro 
et al., 2011). The active invasion is culminated by the fusion of membranes at the 
posterior end of the merozoite sealing the parasite within the parasitophorous vacuole 
and erythrocyte. Following successful invasion, the erythrocytes appear to shrink and 
exhibit spiky protrusions, echinocytosis, due to influx of calcium ions into the 
erythrocyte during the previous PfRh5-basigin interaction (Weiss et al., 2015). 
 
Figure 1. 3: Model showing sequence of interactions during P. falciparum invasion of an 
erythrocyte. The merozoite attaches itself weakly to the erythrocyte surface with the help of its surface 
proteins leading to a weak deformation of the erythrocyte surface. Merozoite proteins secreted from the 
microneme and rhoptry (PfEBAs and PfRhs respectively) interact robustly with their receptors on the 
erythrocyte surface leading to an actomyosin motor driven deformation of the host cell. Thereafter, the 
PfRh5 ligand secreted form the rhoptry interacts with basigin receptor on the host cell forming a tight 
junction which marks the commitment of merozoites to invade the erythrocyte. The merozoite is 
propelled into the erythrocyte by force generated by the actomyosin motor of the parasite and invasion 
is culminated by the sealing of the parasite within the parasitophorous vacuole and erythrocyte. The 
evidence of successful invasion is demonstrated by echinocytosis. Figure is adapted from Weiss et al., 
2015.  
 28 
1.2.3. Clinical features of human malaria 
The clinical symptoms of malaria are experienced during the erythrocytic stage of the 
Plasmodium life cycle. They occur simultaneously with the rupture of infected 
erythrocytes (IEs), which involves the release of parasite and erythrocyte debris, such 
as hemozoin and glycophosphatidylinositol, leading to activation of peripheral blood 
mononuclear cells and release of cytokines (Mawson, 2013). Additionally, decreased 
oxygen delivery to tissues caused by low haemoglobin levels leads to metabolic 
acidosis which is a principle pathophysiological feature during severe malaria (Miller 
et al., 2002).  
The majority of malaria cases present as non-specific febrile illnesses with symptoms, 
such as malaise, headache, diarrhoea, abdominal pain and muscle aches, which are 
easily terminated by antimalarial treatment and/or host responses. With the exception 
of naïve individuals or in cases of poor drug compliance or lack of treatment, relatively 
few malaria infections progress to severe life-threatening disease (Milner, 2018, 
Mackintosh et al., 2004). Severe malaria is predominantly caused by P. falciparum 
parasite proteins, primarily P. falciparum erythrocyte membrane protein 1 (PfEMP1), 
found on the surface of mature IEs. These proteins mediate adherence of the IEs to 
the endothelial lining of the microvasculature and organs, such as placenta, brain, 
liver, kidney and lungs. The gravity of the disease depends on the organ involved, 
namely placental malaria, coma, liver, kidney and respiratory failure respectively (Aird 
et al., 2014). Moreover, these host cell modifications aggravate microvascular 
obstruction by mediating the binding of the infected erythrocytes to uninfected cells, 
erythrocyte rosetting, and reduction of the infected erythrocyte deformability as shown 
in Figure 1.4 (Ashley et al., 2018).  
 
 
 
 
 
 
 
 
 
 
Figure 1. 4: Molecular aspects of severe malaria. The binding of P. falciparum mature infected 
erythrocytes to endothelial lining and to uninfected erythrocytes, rosetting, contributes to occlusion of 
blood flow and resultant severe disease. Figure is adapted from Chen et al., 2000.  
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1.2.4. Diagnosis of human malaria 
In malaria endemic areas, malaria is primarily diagnosed clinically, based on the 
patients’ signs and symptoms, but this is challenging as there are non-specific 
(Tangpukdee et al., 2009). On the other hand, the laboratory diagnosis of malaria is 
effective and reliable because it involves the identification of the malaria parasites or 
parasite products in patient blood. Multiple techniques exist including, microscopic 
diagnosis by the staining of thin and thick peripheral blood smears as shown in Figure 
1.5, concentration techniques e.g. quantitative buffy coat (Bhandari et al., 2008), rapid 
diagnostic tests e.g. OptiMAL (Tagbor et al., 2008), and molecular diagnostic 
methods, such as polymerase chain reaction (Holland and Kiechle, 2005). Early and 
accurate diagnosis of malaria is a key component of the global malaria control strategy 
and reduce the misuse of antimalarials, mortality and morbidity (WHO, 2005).  
 
Figure 1. 5: Thin blood smears showing microscopic appearance of the human malarias. All 
parasite stages are detectable in peripheral blood except in the case of P. falciparum infection, during 
which mature trophozoites sequester in the microvasculature. Figure is adapted from Ashley et al., 2018  
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1.3. Genetic resistance to malaria 
1.3.1. Hemoglobinopathies 
Thalassemia 
Thalassemia refers to the alteration in the synthesis of the globin chains of the 
haemoglobin molecule (Vento et al., 2006). An abnormality in the synthesis of the α-
globin and ß-globin leads to α-thalassemia and ß-thalassemia respectively (Richer 
and Chudley, 2005). α -thalassemia is the predominant genetic disorder found in the 
human population and is caused by decreased synthesis of α-globin due to deletion 
of the duplicated α-globin genes (Allen et al., 1997), whereas ß-thalassemia is caused 
by decreased synthesis of ß-globin owing to more than 180 different mutations within 
a single ß-globin gene (Yuthavong and Wilairat, 1993). α- and ß-thalassemia have 
been proposed to confer protection against clinical disease and severe forms of P. 
falciparum infection in malaria endemic areas (Williams, 2006). This cause has been 
linked to in vitro recognition of the parasitized α- and ß- thalassaemic erythrocytes by 
malaria-immune sera leading to significantly higher phagocytosis compared to normal 
infected erythrocytes (Yuthavong and Wilairat, 1993, Luzzi et al., 1991). Furthermore, 
α-thalassemia has been associated with deficiency of a rosetting erythrocyte receptor, 
complement receptor 1 (CR1), leading to enhanced parasite clearance and protection 
from severe malaria during P. falciparum infection (Cockburn et al., 2004). 
Sickle cell anaemia (HbS) 
The heterozygous sickle cell haemoglobin (HbAS) is the first recognized cause for 
genetic resistance to malaria in humans (Allison, 1954). It is caused by a single 
nucleotide polymorphism in position 6 of the ß-globin gene where alanine is 
substituted with thymidine (GAG to GTG) leading to replacement of the hydrophilic 
glutamic acid with a hydrophobic valine (E6V). This causes HbS polymerization upon 
deoxygenation and alteration of the erythrocyte shape (Hedrick, 2011, Lopez et al., 
2010). The HbAS has been shown to confer protection against severe malaria using 
various underlying mechanisms, such as: (i) inhibition of intra-erythrocytic parasite 
growth due to HbS polymerization when oxygen levels drop below 5% (Roberts and 
Williams, 2003, Akide-Ndunge et al., 2003), (ii) enhanced phagocytosis of ring-
infected sickle erythrocytes compared to ring-infected normal erythrocytes (Ayi et al., 
2004), (iii) acquisition of cross reactive antibodies recognizing and responding to 
different variant surface antigens on the parasitized erythrocytes (Cabrera et al., 
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2005), (iv) reduced surface expression of PfEMP1 leading to reduced cytoadherence 
and pathogenicity of the disease (Cholera et al., 2008), and (v) redox imbalance 
mediated remodelling of the host actin, which is required for vesicular trafficking of 
parasite adhesins, leading to reduced cytoadherence of parasitized erythrocytes and 
increased parasite clearance (Cyrklaff et al., 2016). 
Haemoglobin C (HbC) 
HbC originates from a single nucleotide polymorphism in position 6 of the ß-globin 
chain leading to the substitution of a glutamic acid residue with a lysine residue (E6K) 
and is most prevalent in Western Africa (Fairhurst et al., 2005, Modiano et al., 2001). 
Unlike other hemoglobinopathies, HbC doesn’t follow the Haldane’s hypothesis of 
balanced polymorphism, where the homozygous form (HbC) and not the heterozygous 
form has been shown to correlate with reduced P. falciparum infection and density 
(Lopez et al., 2010). The association of HbC with protection has been explained by 
various mechanisms, such as: (i) inability of parasites to proliferate in vitro in HbC 
erythrocytes (Friedman et al., 1979) due to their abnormal pressure which interferes 
with rupture of schizont-infected erythrocytes and release of infective merozoites 
(Olson and Nagel, 1986). These lead to a reduction intra-erythrocytic parasites in 
individuals with mild or severe malaria infection (Rihet et al., 2004), and (ii) display of 
abnormal PfEMP1 which causes reduction of PfEMP1 mediated cytoadherence 
leading to enhancement of parasite clearance (Fairhurst et al., 2005). 
Haemoglobin E (HbE) 
HbE originates from a single nucleotide polymorphism in position 26 of the ß-globin 
chain leading to the substitution of a glutamic acid residue with a lysine residue (E26K) 
and is the most prevalent hemoglobinopathy in Southeast Asia (Deng et al., 2018, 
Ohashi et al., 2004). The heterozygous form, HbAE, has been shown to ameliorate 
the course of acute P. falciparum malaria using various strategies, such as reduced 
merozoite invasion into the HbAE erythrocyte (Roberts and Williams, 2003, 
Chotivanich et al., 2002), reduced parasite growth of HbAE infected erythrocytes 
(Nagel et al., 1981), and enhanced phagocytosis of the parasitized erythrocytes by 
monocytes (Bunyaratvej et al., 1986). Furthermore, HbAE has been shown to protect 
against acute P. vivax infection (Deng et al., 2018).  
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1.3.2. Erythrocyte polymorphisms 
Ovalocytosis  
The disease originates from a structural polymorphism in the major transmembrane 
protein of the erythrocyte, band 3, attributable to a deletion of codons 400-408 of band 
3 causing a loss of 9 amino acids (Williams, 2006, Jarolim et al., 1991). The ovalocytic 
phenotype has been shown to confer protection against malaria by in vitro resistance 
to invasion in a range of malaria parasite strains (Kidson et al., 1981). This is thought 
to be due to the increased membrane rigidity and reduced deformability of the 
ovalocytes (Mohandas et al., 1984). Additionally, ovalocytosis confers protection 
against cerebral malaria (Genton et al., 1995) but exacerbates malaria anaemia (Allen 
et al., 1999). Interestingly, ovalocytes have an increased binding to CD36 in vitro 
(Cortes et al., 2005) which may seem contradictory to their protective role in cerebral 
malaria. This can be explained by the fact that CD36 are found in high levels in non-
vital organs, such as skin and muscles (Turner et al., 1994), but in low levels in brain 
endothelial cells (Silamut et al., 1999). 
Duffy antigen 
The antigen is postulated to be an obligative invasion receptor on erythrocytes for P. 
vivax merozoites and a chemokine receptor also known as Duffy antigen receptor for 
chemokines (DARC) (Neote et al., 1994). It is a 35-43 kDa transmembrane protein 
which spans the erythrocyte 7 times (Lopez et al., 2010, Hadley et al., 1984). The lack 
of DARC expression is mediated by a point mutation in position 46 of the GATA box 
of the DARC promoter where an aromatic tyrosine is substituted by a sulphur 
containing cysteine (T46C) (Michon et al., 2001). The duffy null phenotype has been 
shown to confer complete resistance to P. vivax infection since individuals lacking the 
duffy antigen are refractory to invasion by P. vivax merozoites (Michon et al., 2001, 
Hamblin and Di Rienzo, 2000). This duffy negativity is predominant in West Africa 
(Culleton and Ferreira, 2012) and Papua New Guinea (Zimmerman et al., 1999) and 
this explains why P. vivax malaria is unusual in these geographical regions (Cooke et 
al., 2004). 
Dantu antigen 
Dantu signifies a serologically distinct blood group that results from the loss of 
glycophorin B (GYPB) and gain of two glycophorin B-A (GYPB-A) hybrid genes 
resulting to a novel sialoglycoprotein. The protein contains the extracellular domain of 
GYPB fused with the intracellular domain of GYPA, and is present in Sub-Saharan 
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Africa but absent in West African (Kariuki et al., 2018, Leffler et al., 2017). This variant 
has been associated with reduced risk for severe malaria (Leffler et al., 2017), 
probably due to impaired merozoite invasion caused by increased tension of the Dantu 
erythrocytes (Kariuki et al., 2018). 
 
1.3.3. Enzymopathies 
Glucose-6-phosphate dehydrogenase (G6PD) deficiency 
Glucose-6-phosphate dehydrogenase (G6PD) is a cytoplasmic enzyme that catalyses 
the first and rate limiting step in the hexose monophosphate pathway leading to 
synthesis of pentose phosphate (Ruwende and Hill, 1998). It also catalyses 
conversion of nicotinamide adenine dinucleotide phosphate (NADP) to its reduced 
form (NADPH) in the pentose phosphate pathway leading to protection of erythrocytes 
from oxidative damage (Frank, 2005). The G6PD deficiency is one of the most 
common enzymopathies in human population affecting over 400 million people 
worldwide as shown in Figure 1.6. The disease results from single nucleotide 
polymorphisms that lead to reduced enzyme activity and not complete absence 
(Ruwende et al., 1995). The common deficiency allele in Africa is G6DP A- resulting 
from two mutations, an asparagine to aspartate substitution in position 376 and a 
valine to methionine substitution in position 202. These mutations are associated with 
a significant reduction in the threat of severe malaria in both G6DP female 
heterozygotes and male hemizygotes (Ruwende and Hill, 1998). The G6PD deficiency 
has been shown to confer resistance to P. falciparum infection through various 
underlying mechanisms, such as impaired in vitro growth of P. falciparum parasites in 
G6PD-deficient erythrocytes (Roth et al., 1983) and phagocytosis of G6PD-deficient 
ring-infected erythrocytes (rIEs) by human adherent monocytes (Cappadoro et al., 
1998). 
Pyruvate kinase (PK) deficiency 
Pyruvate kinase is a glycolytic enzyme which catalyses the irreversible conversion of 
phosphoenolpyruvate to pyruvate. This is a paramount step in anaerobic glycolysis 
and production of Adenosine triphosphate (ATP) in erythrocytes since they lack 
mitochondria (Durand and Coetzer, 2008). PK deficiency is caused by over 180 point 
mutations in the PK gene leading to clinical manifestations in homozygote and 
heterozygote carriers of the abnormal allele (Durand and Coetzer, 2008). The 
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deficiency has been shown to be protective against malaria in mice (Min-Oo et al., 
2003) and in humans (Durand and Coetzer, 2008). The mutant PK alleles in malaria 
endemic areas have been proposed to confer resistance to P. falciparum infection by 
phagocytosis of PK deficient rIEs and impaired invasion of homozygous PK deficient 
erythrocytes (Ayi et al., 2008), probably due to increased membrane rigidity (Min-Oo 
et al., 2003). 
 
1.3.4. Immunogenic variants 
HLA-Bw53/HLA-DRB1*1302-DQB1*0501 
The human major histocompatibility complex (MHC) is a set of polymorphic genes 
coding for proteins which allow essential cellular interactions required for development 
of an immune response. It is also known as human leukocyte antigen complex (HLA) 
(Babbitt et al., 1985). The complex is subdivided into various classes, namely class I 
and II which encode for membrane bound molecules capable of activating T-cells to 
provoke or enhance an immune response and class III which codes for soluble 
complement cascade proteins, heat shock proteins, and some cytokines (Lopez et al., 
2010). Two malaria protective HLA alleles have been identified, namely class I HLA 
antigen (HLA-Bw53) which restricts cytotoxic T lymphocyte recognition of a conserved 
nonamer peptide of the parasite liver stage specific antigen 1 (Hill et al., 1992) leading 
to protection against severe anaemia and cerebral malaria (Wilkinson and Pasvol, 
1997, Hill et al., 1991), and class II HLA haplotype (DRB1*1302-DQB1*0501) which is 
associated with reduced susceptibility to severe anaemia (Wilkinson and Pasvol, 
1997). 
Complement receptor 1 (CR1) polymorphism 
The complement receptor 1 (CR1) is a 190-280 kDa complement-regulatory protein 
localized on the erythrocyte membrane and is also known as CD35 (Stoute, 2005, 
Thathy et al., 2005). It is the erythrocyte receptor which the PfEMP1 parasite ligand 
binds to form rosettes. Rosettes form when late stage infected erythrocytes bind to 
uninfected erythrocytes in vitro. The process is proposed to exacerbate disease 
pathogenesis (Rowe et al., 1997). The CR1 encoding gene is speculated to undergo 
unequal gene crossover leading to formation of polymorphic variants that have been 
related to different levels of CR1 expression on erythrocytes (Lopez et al., 2010). Two 
CR1 African allele variants resulting from absence of two Knops blood group antigens, 
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Swain-langley (Sl2) and McCoy (McCb), have been correlated with low CR1 copy 
number on erythrocyte and associated with protection from cerebral malaria, however 
not malaria anaemia in Kenyan children (Stoute, 2005, Thathy et al., 2005). On the 
contrary, the CR1 knop blood group alleles have been reported to have no association 
with severe malaria in The Gambia (Zimmerman et al., 2003). 
Nitric oxide synthase 2 (NOS2) promoter polymorphism 
The nitric oxide synthase 2 (NOS2) enzyme produces nitric oxide which is a mediator 
of immunity to malaria (Lopez et al., 2010). Nitric oxide production can be modulated 
by single nucleotide polymorphisms in the promoter of the inducible NOS2 gene 
(Hobbs et al., 2002), such as −1173 C/T and - 969 G/C which are significantly 
associated with protection from symptomatic malaria and antimalarial resistance in 
children respectively (Kun et al., 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 6: Map showing the geographical distribution of genetic resistant traits to malaria. a) 
Thalassemia and b) Glucose 6 phosphate dehydrogenase (G6PD) deficiency are the most predominant 
traits. Figure is adapted from Lopez et al., 2010.  
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1.4. Immunity 
1.4.1. Immune response to P. falciparum in Anopheles mosquitoes 
The P. falciparum parasite faces various hurdles before it can successfully establish 
infection in the Anopheles mosquito vector (Demarta-Gatsi et al., 2017). The mosquito 
uses various physical barriers and elicits cellular and humoral innate immune 
responses to protect itself against the parasite. The physical barriers are the first line 
of defence and includes the midgut peritrophic membrane (Osta et al., 2004), the 
formation of capsule around the parasite by mosquito melanin (Crompton et al., 2014), 
and microbiota which stimulate basal innate immune responses against the parasite 
(Clayton et al., 2014). Additionally, the cellular innate immune response in mosquitoes 
is mediated primarily by haemocytes which are involved in phagocytosis, 
melanisation, agglutination, secretion of antimicrobial peptides, nodule formation, an 
and the production of reactive oxygen species (Smith et al., 2016, Clayton et al., 2014, 
Molina-Cruz et al., 2008, Osta et al., 2004). Humoral innate immune responses in 
mosquitoes involves the complement C3-like, also known as thioester-containing 
protein 1 (TEP1), which binds to the surface of the ookinete and marks them for killing 
(Clayton et al., 2014).  
It is important to note that mosquitoes rely entirely upon the innate immune system 
since it lacks an adaptive immune response (Dennison et al., 2015). However, 
mosquitoes can obtain transmission blocking antibodies from the host during a blood 
meal. These have been shown to reduce infection in the mosquito by: (i) preventing 
gamete fusion by targeting the HAP2 male sterility gene (Blagborough and Sinden, 
2009), (ii) inducing complement killing of gamete or ookinetes (Volohonsky et al., 
2010), and (iii) averting ookinete motility, penetration of the midgut wall and formation 
of oocyst by targeting the Pbs21, P25 and P28 ookinete surface antigens (Baton and 
Ranford-Cartwright, 2005, Ranawaka et al., 1994). These transmission blocking 
vaccines can be produced by vaccination but unfortunately the humoral immune 
response cannot be enhanced by repeated infections because the gamete and 
ookinete are not present in the mammalian host during infection. 
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1.4.2. Immune response to P. falciparum in humans 
1.4.2.1. Innate immunity 
Innate immunity is the first line of defence in humans against pathogens and consists 
primarily of pattern recognition receptors (PRRs) (Mellouk et al., 1994). In case of 
malaria infection, the PRRs identify pathogen associated molecular patters (PAMPs), 
such as hemozoin, glycosylphosphatidylinositol (GPI) anchors and immunostimulatory 
nuclei (Gazzinelli et al., 2014). The recognition of PAMPs leads to the induction of the 
type 1 interferon pathway and the subsequent production of cytokines - IFNγ, IL-6, 
and TNFα that recruit leukocytes through induction of the inducible nitric oxide 
synthase enzyme (Goh et al., 2019, Bliss et al., 2018, Mellouk et al., 1994). The 
recruited cellular innate immune cells include: (i) CD8α Dendritic cells, which are 
triggered just a few hours after an infective mosquito bite and directly take up the 
sporozoite before priming the CD8 T cells in the draining lymph nodes of the skin 
(Radtke et al., 2015, Chakravarty et al., 2007), (ii) NK cells, which are abundant in the 
hepatocytes and directly inhibit parasite development and also prime CD4 T cells to 
bridge the gap between innate and acquired immunity (Ing and Stevenson, 2009), and 
(iii) NKT and γδ T cells, which are innate-like T cells involved in killing late stage liver 
parasites and priming adaptive T cell responses respectively (Zaidi et al., 2017). 
 
1.4.2.2. Natural acquired immunity 
Natural acquired immunity refers to the protective immunity an individual achieves 
after being naturally exposed to a pathogen. Robert Koch observed that natural 
immunity to malaria in endemic areas is acquired after years of repeated exposure to 
the Plasmodium parasite but is less efficient and achieves only partial protection (Ly 
and Hansen, 2019). In high transmission areas, children suffer few symptomatic 
infections and later develop immunity against severe malaria but remain at risk of 
uncomplicated malaria as shown in Figure 1.7 (Griffin et al., 2015). Following years of 
repeated infections, individuals gradually develop clinical immunity with age and are 
able to reduce parasite burdens (Ndungu et al., 2015). However, this form of protection 
does not culminate in sterile immunity that prevents re-infection (Tran et al., 2013). 
Adults continue to experience asymptomatic infections with low parasite densities 
which remain a possible source for human-to-mosquito transmissions (Okell et al., 
2012). On the other hand, in low transmission areas both children and adolescents 
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are susceptible to severe malaria and adults continue to experience mild malaria and 
asymptomatic malaria as shown in Figure 1.7.  
Although natural acquired immunity requires both cellular and humoral immune 
responses, natural acquired clinical immunity to malaria targets parasites in the blood 
stages (Ly and Hansen, 2019) and is governed by antibodies (Cohen et al., 1961). 
The clinical immunity may depend on the cumulative acquisition of a breath of 
antibodies that respond to a diverse range of parasite antigens (Murungi et al., 2013) 
and has been shown to increase with age in malaria endemic areas (Crompton et al., 
2010). The slow acquisition of immunity to malaria in endemic areas has been 
attributed to antigen variation and substantial decline in Plasmodium specific antibody 
responses after reduced parasite exposure (Weiss et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 7: A typical age pattern for incidence of severe and mild malaria and prevalence of 
asymptomatic malaria infection. The upper and lower graphs represent malaria infection in areas of 
high and low transmission respectively. Figure is adapted from Kinyanjui et al., 2012. 
 
1.4.2.3. Adaptive immune response to skin and liver stages 
At the skin stage, antibodies protect the host by limiting pre-erythrocytic stage infection 
and development. More specifically, they do so by inhibiting sporozoite motility in the 
dermis (Vanderberg and Frevert, 2004) and mediating cytotoxicity against sporozoites 
in the host skin (Aliprandini et al., 2018). Despite the immune response at the skin, 
some sporozoites manage to enter the blood stream, where the circulating antibodies  
prevent hepatocyte invasion (Nudelman et al., 1989), and opsonize the sporozoites 
facilitating their phagocytosis by monocytes and macrophages in the liver and spleen 
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(Schwenk et al., 2011). The neutralizing capacity of circulating antibodies is more at 
the site of inoculation than in the blood circulation (Flores-Garcia et al., 2018). 
Once the sporozoite is inside the liver, it can be attacked by CD4 and CD8 T cells 
(Renia et al., 1991) since the hepatocytes express both MHC class I and class II 
molecules that can be loaded with parasite antigens (Pichugin et al., 2016, Renia and 
Goh, 2016). CD8 T cytotoxic cells are the principal effector cells providing protection 
against malaria (Goh et al., 2019). The significance of CD8 T cells in protective 
immunity was first shown in mice vaccinated with irradiated sporozoites (Schofield et 
al., 1987). Cytotoxic T cells mediate protection against murine malaria in mice by killing 
the parasites directly or indirectly through lysis of infected hepatocytes or IFNγ-
mediated protection respectively (Goh et al., 2019). Moreover, CD8 T cells have been 
associated with protection from severe malaria in humans (Hill et al., 1992).  
On the other hand, the role of CD4 T cells in malaria is not well understood, but it is 
clear that they are activated to amplify responses against the parasite by driving B cell 
germinal responses and assisting CD8 T cell activation (Goh et al., 2019). Additionally, 
antibodies also act in the liver stage by inhibiting sporozoite development inside the 
hepatocytes (Nudelman et al., 1989) and binding to neo-antigens expressed on the 
surface of infected hepatocytes. The binding induces parasite death by involving 
Kupffer cells or NK cells (Renia et al., 1990). Furthermore, it is important to note that, 
in addition to high levels of antibodies, the quality of antibodies is also imperative. 
Various in vitro assays have been established to examine the functionality of 
antibodies induced after vaccination with pre-erythrocytic stage vaccines (Goh et al., 
2019). These pre-erythrocytic stage antibody functional assays include; gliding motility 
assay (Behet et al., 2014), sporozoite traversal and invasion inhibition assay 
(Kaushansky et al., 2012) and liver stage development inhibition assay (Zou et al., 
2013, Mazier et al., 1985). 
 
1.4.2.4. Adaptive immune response to asexual blood stages 
Adaptive immunity against blood stage parasites is primarily conferred by humoral 
immune response due to the absence of antigen processing mechanism in 
erythrocytes (Yazdani et al., 2006). It is more complex than adaptive immunity against 
the liver stage since it targets different asexual forms of the parasite that present 
different antigens (Renia and Goh, 2016). 
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The mature intraerythrocytic parasites express several variant surface antigens (Frech 
and Chen, 2013) encoded by multigene families, namely: (i) the var (Su et al., 1995), 
(ii) sub-telomeric variable open reading frame (stevor) (Cheng et al., 1998), (iii) 
surface-associated interspersed (surf)  (Winter et al., 2005) and (iv) repetitive 
interspersed family (rifins) for P. falciparum (Kyes et al., 1999) or the Plasmodium 
interspersed repeats (pir) gene family for P. vivax (vir) and P. knowlesi (kir) (Janssen 
et al., 2004). These genes encode for antigens which enhance disease by several 
adhesive phenomena, such as cytoadherence to endothelial lining of tissues (David 
et al., 1983), rosette formation (Udomsangpetch et al., 1989) and agglutination of 
infected erythrocytes by bridging platelets (Pain et al., 2001). Antibodies targeting 
these variant surface antigens, primarily the PfEMP1 coded by the var gene family, 
have been shown to limit progression of the blood stage in vitro by preventing 
sequestration and rosette formation (Chan et al., 2014), mediating phagocytosis of 
infected erythrocytes (Celada et al., 1982), facilitating agglutination of infected 
erythrocytes (Renia and Goh, 2016) and promoting antibody dependent cellular 
cytotoxicity (Arora et al., 2018). Furthermore, broad reactive antibodies present in 
African individuals have undergone somatic hypermutation and thus contain insertion 
of a collagen binding protein, LAIR1, which enhances their binding to infected 
erythrocytes via the rifin family (Pieper et al., 2017, Tan et al., 2016). 
Merozoite specific antibodies impede the progression of the erythrocytic stage and the 
following has been demonstrated in vitro using various mechanisms, such as: (i) 
prevention of merozoite egress from schizont-infected erythrocytes by targeting 
SERA5 which are papain like proteins located in the parasitophorous vacuole (Collins 
et al., 2017a), (ii) inhibition of erythrocyte invasion by either directly targeting P. 
falciparum reticulocyte binding homologue 2 (PfRh2) (Reiling et al., 2010), apical 
membrane antigen 1 (AMA1) (Dutta et al., 2007), region II of erythrocyte binding 
antigen 175 (EBA175), or in conjunction with complement factors via merozoite 
surface proteins 1 and 2 (MSP1 and MSP2) (Boyle et al., 2015), (iii) agglutination of 
released merozoites (Miller et al., 1975), (iv) promotion of phagocytosis (Khusmith et 
al., 1982) by targeting merozoite surface protein 2 and 3 (MSP2 and MSP3) (Osier et 
al., 2014), (v) generation of reactive oxygen species in a neutrophil-based antibody 
dependent respiratory burst (ADRB) assay (Joos et al., 2010), (vi) facilitation of 
monocyte mediated clearance of intraerythrocytic parasites in an antibody-dependent 
cellular inhibition (ADCI) assay (Bouharoun-Tayoun et al., 1990), where antibodies 
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bind to the merozoite surface antigens and stimulate phagocytes to release cytokines, 
which in turn activate the phagocytes to produce mediators leading to killing of 
surrounding intraerythrocytic parasites (Bouharoun-Tayoun et al., 1995), and (vii) 
activation of NK cells which leads to lysis of merozoites through degranulation and 
production of IFNγ in an antibody-dependent cellular cytotoxicity (ADCC) assay 
(Odera, unpublished). 
Toxins released by the parasite could also be targets of the immune system (Renia 
and Goh, 2016). These toxins contribute to disease pathogenicity by inducing 
inflammation and they include hemozoin which is a by-product of haem degradation 
(Boura et al., 2013), GPI moieties present in many merozoite proteins (Renia and Goh, 
2016), a TatD-like DNase which counteracts activated neutrophil cells (Chang et al., 
2016), a tyrosine-tRNA synthase, which is a housekeeping protein translation enzyme 
(Bhatt et al., 2011), and lipids extracted from P. vivax schizont-infected erythrocytes 
(Wijesekera et al., 1996). The ability of anti-toxin antibodies to protect from disease 
has been shown experimentally by a mouse model using synthetic glycans that mimic 
GPI (Schofield et al., 2002). 
Despite the lack of MHC antigens on the surface of infected erythrocytes, T cells are 
also significant immune effectors against the blood stage. B cell maturation and 
multiplication depend on cytokines released by CD4 T helper cells for optimal 
production of parasite specific antibodies (Langhorne et al., 2008). Interestingly, CD8 
T cells, which were once thought to have minimal significance in blood stage immunity, 
have been shown to inhibit blood stage infection in mice (Podoba and Stevenson, 
1991). More specifically, the perforin and IFNγ-secreting CD8 T cells are key in 
preventing chronic murine blood stage malaria infection in mice (Imai et al., 2010). 
 
1.4.2.5. Adaptive immune response to sexual blood stages 
Similar to the asexual blood stages, the sexual parasite forms in the blood are also 
targets of the immune system. The sexual forms, gametocytes, are targeted by 
antibodies which induce their complement-mediated elimination in the host blood 
(Margos et al., 2001, Read et al., 1994). These gametocyte-specific specific antibodies 
rely on CD4 T helper cells for optimal production.  
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Figure 1. 8: Immune responses that control the different parasite stages in the human. At the 
skin, the sporozoites are drained into the lymph nodes, where they activate T and B cells. Antibodies 
(Ab) prevent sporozoite invasion in the liver. When in the liver, IFN-γ–producing CD4+ and CD8+ T 
cells prevent parasite development into merozoites inside the hepatocyte. Despite the immune 
response, some merozoites emerge from the liver and invade the erythrocytes. Merozoite-specific 
antibodies agglutinate merozoites, prevent invasion and opsonise merozoites to mediate Fc effector 
cellular functions. Antibodies targeting variant surface antigens prevent cytoadherence and rosette 
formation, enhance agglutination and opsonise infected erythrocytes to mediate Fc effector cellular 
functions. Gametocyte specific antibodies fix complement that lyse parasite in the human host. In the 
vector, innate mosquito immunity and transmission blocking antibodies from the human host prevent 
gamete fusion, ookinete development and oocyst rupture to release sporozoites. Figure is adapted from 
Riley et al., 2013. 
 
1.4.3. Immune evasion of P. falciparum 
1.4.3.1. Immune evasion mechanisms in Anopheles mosquitoes 
The parasite evades the vector’s innate immune response primarily by the help of the 
Pfs47 gene which is a female gamete-specific protein. The Pfs47 prevents activation 
of the TEP1 complement-like lysis by suppressing the nitration response in the midgut 
(Molina-Cruz et al., 2013). Additionally, the host complement factor H (FH) obtained 
from the blood meal also prevents complement attack. More specifically, the P. 
falciparum glideosome-associated protein 50 (PfGAP50), which is a FH receptor, 
binds the host FH leading to the inactivation of complement protein C3b which 
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subsequently protects the extracellular gamete from complement-mediated lysis 
(Simon et al., 2013).  
 
1.4.3.2. Immune evasion mechanisms of liver stage in humans 
The sporozoites must evade the resident macrophages of the liver, Kupffer cells, in 
order to establish the liver stage infection. Once the sporozoites come in contact with 
the Kupffer cells, they are able to manipulate the macrophage functions and 
immunosuppress the microenvironment in various ways, such as: (i) inhibition of 
reactive oxygen species formation by binding to the Kupffer cells surface proteins and 
proteoglycans via the CSP (Usynin et al., 2007), (ii) downregulation of inflammatory 
Th1 cytokines (TNFα and IL-6) and upregulation of anti-inflammatory Th2 cytokines 
(IL-10) (Ikarashi et al., 2013), (iii) induction of T cell tolerance by stimulating apoptosis 
of Kupffer cells and reducing expression of MHC class I molecules (Casares and 
Richie, 2009, Steers et al., 2005) and finally (iv) upregulation of the host haem 
oxygenase 1 which modulates the host inflammatory response thereby enhancing 
development of intrahepatic parasites (Pamplona et al., 2007). Additionally, the 
sporozoites interfere with the mammalian target of rapamycin (mTOR) pathway, which 
is the central regulator of cell metabolism, leading to altered levels of proteins involved 
in cell growth, survival and proliferation (Hanson et al., 2013). After successful 
establishment of the liver infection, the parasite stays within a parasitophorous vacuole 
which physically separates itself from the host cytoplasm preventing lysosomal 
degradation (Gomes et al., 2016). For successful establishment of the blood stage 
infection, the merozoites leave the hepatocytes covered in membranes derived from 
the host, merosomes, which protect them from the phagocytic cells of the liver (Sturm 
et al., 2006). 
 
1.4.3.3. Immune evasion mechanisms of intraerythrocytic stages in humans 
The intraerythrocytic stage is the most primitive survival strategy of the parasite, where 
it avoids direct contact with the host immune system. Moreover, the parasites’ decision 
to invade the non-nucleated erythrocytes is favourable because red blood cells do not 
express MHC class I molecules on their surface and thus avoid recognition by CD8 T 
cells (Bowen and Walker, 2005). Additionally, the mature intraerythrocytic parasites 
sequester from the immune system and avoid splenic clearance by expressing 
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adhesive parasite proteins on their surface which mediates their adherence to 
endothelial lining of tissues (Belachew, 2018, Gomes et al., 2016). Clustering with 
uninfected erythrocytes to form rosettes is an additional escape strategy (Moll et al., 
2015). These adhesive proteins are expressed by multigene families and thus undergo 
antigen variation making it difficult for them to be recognised by the host immune 
system. More specifically, each parasite carries approximately 150-200 rif, 50-60 var 
and 30-35 stevor gene copies per genome which encode for RIFIN, STEVOR and 
PfEMP1 antigens respectively (Mwakalinga et al., 2012, Kraemer and Smith, 2006). 
Furthermore, sequestration of the intracellular parasite can also be mediated by host 
platelets which enhance parasite agglutinating with uninfected erythrocytes (Gomes 
et al., 2016), and non-specific IgM which recognises PfEMP1 and promote rosette 
formation (Dennison et al., 2015, Ghumra et al., 2008). Interestingly, hemozoin 
hinders phagocytic functions of the immune system since monocytes containing 
hemozoin can only take up few infected erythrocytes (Belachew, 2018).  
 
1.4.3.4. Immune evasion mechanisms by merozoites in humans 
The merozoite sheds and secretes erythrocyte binding like proteins, such as MSPs, 
PfEBA, PfRHs and PfAMA1, which bind to their respective erythrocyte receptors for 
successful invasion (Weiss et al., 2015). These erythrocyte invasion ligands show a 
high degree of polymorphisms because they exist in numerous alleles in the genome. 
This enables the merozoite to evade the host immune system thereby establishing the 
blood stage infection and disease progression (Holder et al., 1999). Moreover, 
invasion ligands such as the EBA and RH families have redundant functions that 
evolved to promote antigenic diversity and immune evasion (Souza-Silva et al., 2014). 
Furthermore, merozoites protect themselves from complement-mediated lysis by 
binding to the CCP5 module of the complement regulator FH via a transmembrane 
protein, Pf92, which inactivates the complement component C3b thereby preventing 
lysis (Kennedy et al., 2016). 
 
1.4.3.5. Immune evasion mechanism of gametocytes in humans 
The developing stage 1-1V gametocytes are absent in the peripheral circulation during 
malaria because they sequester in the spleen and bone marrow to avoid splenic 
clearance (Joice et al., 2014). This unique maturation process has made it difficult to 
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investigate the underlying molecular mechanism of P. falciparum gametocytes using 
rodent models. However, certain adhesive parasite proteins have been observed on 
the infected erythrocyte surface of the developing gametocytes and they include: 
PfEMP1, which mediates adhesive interactions with host endothelial receptors and 
STEVOR, which is implicated with enhance deformability (Sanyal et al., 2012).  
 
1.5. Control strategies for P. falciparum malaria 
1.5.1. Chemoprophylaxis 
1.5.1.1. Introduction to malaria treatments 
The design of antimalarial drugs is based on the major metabolic differences between 
the Plasmodium parasite and the mammalian host (Alam et al., 2009). Interestingly, 
the apicoplast and mitochondria of the parasite have a separate prokaryotic-like 
genome which defines the specificity of the drug targets and prevent attack of the 
eukaryotes (Yadav et al., 2019). These metabolic differences include: (i) the apicoplast 
mevalonate-independent isoprenoid biosynthesis pathway, where the parasite utilizes 
1-deoxy-d-xylulose-5- phosphate (DOXP) as a precursor molecule while the 
mammalian host depends on mevalonate for isoprenoid synthesis (Goodman and 
McFadden, 2013, McFadden and Roos, 1999); (ii) the parasite ubiquinone/coenzyme 
Q in the mitochondrial electron transport chain is different from the mammalian 
ubiquinone and plays an important role in ATP synthesis (Ellis, 1994); (iii) the 
shikimate pathway, absent in mammals, responsible for production of precursor 
chorismate required for synthesis of ubiquinone, aromatic amino acids, folate and 
vitamin K (McConkey, 1999); and (iv) the enzymes used in purine and pyrimidine 
synthesis during nucleic acid metabolism differ between the parasite and the humans 
(Heikkila et al., 2007, Keough et al., 1999).  
Despite the numerous attempts to design antimalarial treatments, drug resistance 
remains a recurring issue. The parasite is able to develop resistance using various 
mechanisms, such as: (i) direct catalysis of the drug leading to detoxification; (ii) a 
stress response, which mitigates the toxicity induced by the drug; (iii) mutations and/or 
amplifications of the gene coding the target enzyme(s) and transporter(s) which pump 
and remove the drug out of the parasite (Ross and Fidock, 2019, Haldar et al., 2018). 
Moreover, resistance of most antimalarial drugs emerged from Southeast Asia and 
this is due to various factors: (i) low malaria transmission intensity causing reduced 
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frequency of human exposure to malarial parasites and subsequently leading to low 
immunity against malaria; (ii) the monoclonal nature of P. falciparum infections which 
encourages relatively unfit mutations to disseminate because of lack of competition; 
and finally (iii) prevalence of hemoglobinopathies and G6PD deficiency causing 
alteration of the erythrocytes’ redox state and possibly influencing the efficiency of 
drugs which act by increasing oxidative stress (Ross and Fidock, 2019, Blasco et al., 
2017). Currently, initiatives are in place to develop new and effective antimalarial 
molecules by combining previously effective drugs, identifying new drugs for the 
validated targets and novel targets for malaria treatment (Yadav et al., 2019). 
 
1.5.1.2. Classification of antimalarial drugs 
Aryl-amino alcohols 
Aryl-amino alcohols are organic substances that contain both aryl and amino 
functional groups and include quinine, lumefantrine and mefloquine. Importantly, 
quinine was discovered from cinchona tree bark in Peru and was the first antimalarial 
drug to be employed in Europe in the 1630s until early twentieth century (Blasco et al., 
2017, Achan et al., 2011). Aryl-amino alcohols are speculated to be involved in 
haemoglobin transportation from the cytosol and haem detoxification in the digestive 
vacuole but the exact mechanism is unknown (Tse et al., 2019, Yadav et al., 2019). 
Resistance to quinine is associated with amplification of P. falciparum chloroquine 
resistance transporter (pfcrt) gene whereas resistance to lumefantrine and mefloquine 
are associated with amplification of the P. falciparum multidrug resistant protein 1 
(pfmdr1) transporter gene (Blasco et al., 2017).  
4-amino quinolines 
4-amino quinolones are organic compounds that contain an amino group at the fourth 
position of the quinoline structure and include chloroquine, amodiaquine, piperaquine 
and pyronaridine. Importantly, chloroquine was the first line antimalarial drug to be 
used from 1940s to 1980s because of its safety, efficacy and affordability (Ross and 
Fidock, 2019). Chloroquine is permeable in its unprotonated form and can freely 
diffuses into the erythrocyte where it gets protonated in the acidic digestive vacuole 
thereby becoming impermeable (Chinappi et al., 2010). Consequently, chloroquine 
accumulates in the digestive vacuole, similar to the other 4-amino quinolines and 
quinine, where it prevents detoxification of haem by binding to hematin and thus 
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preventing formation of ß hematin (hemozoin) which is non-toxic and chemically inert 
(Egan et al., 2002, Robert et al., 2002). Hence, chloroquine action is effective against 
intraerythrocytic trophozoite stages involved in haemoglobin degradation but 
ineffective against parasite stages that don’t consume haemoglobin, such as liver 
schizonts and mature gametocytes (Chimanuka et al., 2001). Resistance to 
chloroquine is due to parasite-mediated drug efflux resulting from point mutations in 
the pfcrt and pfmdr1 transporters located in the digestive vacuole membrane (Blasco 
et al., 2017). Additionally, resistance to piperaquine is associated with copy number 
variation of plasmepsin 2 and 3 which encode for proteases involved in haemoglobin 
digestion (Witkowski et al., 2017).  
Antifolates 
Antifolates are chemical compounds that disrupt folic acid metabolism in the parasite 
and include pyrimethamine, sulfadoxine and proguanil. Folic acid is converted to 
dihydropteroate by dihydropteroate synthase (dhps) enzyme and then reduced by 
dihydrofolate reductase (dhfr) to form tetrahydrofolate which is essential in DNA 
synthesis (Hyde, 2005). Antifolate agents used in malaria treatment interrupt folate 
metabolism in the cytosol by inhibiting the enzymes dhps and dhfr (Nzila, 2006). 
Resistance to sulfadoxine is associated with mutation in the dhps enzyme whereas 
resistance to pyrimethamine and proguanil are associated with mutation in the dhfr 
enzyme .(Blasco et al., 2017). 
Naphthoquinone 
Naphthoquinone is a group of organic compounds that structurally relates to 
naphthalene. A good example is atovaquone which is a ubiquinone analogue. 
Atovaquone prevents the binding of ubiquinone to cytochrome b (cytb) which disrupts 
the mitochondrial electron transport chain (Srivastava et al., 1997) and, consequently, 
leads to the inhibition of the ubiquinone-dependent mitochondrial enzyme 
dihydroorotate dehydrogenase (DHODH) required for pyrimidine biosynthesis (Blasco 
et al., 2017). Additionally, the combination of atovaquone and proguanil yields an 
effective antimalarial drug, malarone, which is used for both treatment and prophylaxis 
(Radloff et al., 1996). Resistance to atovaquone is associated with a single point 
mutation in the cytb subunit of the cytochrome bc1 complex, which has a significant 
fitness cost in the sexual stage development in the mosquitoes and thus the resistance 
is not transmissible in the field (Goodman et al., 2016). 
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8-amino quinolines 
8-amino quinolines are organic compounds that contain amino group at the eighth 
position of the quinoline structure and include primaquine and tafenoquine. 
Importantly, primaquine is the only 8-aminoquinoline currently in clinical use (Flannery 
et al., 2013). Additionally, it is the only available antimalarial drug that prevents relapse 
in ovale and vivax malaria and the only effective gametocytocidal drug in falciparum 
malaria (Ashley et al., 2014). The mode of action of 8-amino quinolines is unknown, 
and no genetic change has been associated with clinical resistance to primaquine 
(Blasco et al., 2017). 
Antibiotics 
Antibiotics are antibacterial drugs which are also active in fighting malaria infection 
and they include clindamycin, doxycycline and tetracycline (Tse et al., 2019). They 
function by inhibiting protein synthesis in the apicoplast. Resistance is associated with 
mutations in the ribosomal ribonucleic acid (rRNA) of the apicoplast (Blasco et al., 
2017). 
Endoperoxides 
Endoperoxides are sesquiterpene lactones and the main antimalarial endoperoxide is 
artemisinin whose active metabolite is dihydroartemisinin (Tilley et al., 2016). 
Artemisinin, also known as qinghaosu, was first isolated in 1970 from a Chinese sweet 
wormwood plant, Artemisia annua, by a Chinese scientist called Tu Youyou, who was 
awarded the 2015 Nobel Prize (Tse et al., 2019). Artemisinin can be derived from 
methyl, hemisuccinate and ethyl ether to form Artemether, Artesunate and Arteether 
respectively (Ashley et al., 2018).  
Artemisinin activation is centred on the reductive scission of the endoperoxidase ring. 
The cleavage of the endoperoxidase depends on its contact with ferrous-haem, a by-
product of haem degradation, during the mature intraerythrocytic parasite stages 
(Wang et al., 2015), and free ferrous iron during early ring stage (Xie et al., 2016). The 
mode of action of dihydroartemisinin is by provoking the parasites’ stress mechanism 
using two main ways: (i) protein damage, which is achieved by alkylation of already 
folded proteins and unfolding of newly synthesised proteins (Mok et al., 2015) and (ii) 
inhibition of the parasite proteasome function, which leads to accumulation of 
polyubiquitinated proteins (Bridgford et al., 2018).  
Artemisinin resistance is defined as parasite survival above 1% in vitro and parasite 
clearance half-life of more than 5 hours in vivo and is associated with kelch13 mutation 
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(Ariey et al., 2014). The exact mechanism of kelch13 mutant remains unknown, but is 
thought to encourage the parasite survival by antagonizing the dihydroartemisinin 
activity through various ways, such as: (i) the unfolded protein response, which 
induces a transcriptional program that alleviates the cellular stress (Tilley et al., 2016); 
(ii) the ubiquitin-proteasome system, which inhibits the function of the ubiquitin-
activating enzyme thereby reducing the level of polyubiquitinated proteins and 
alleviating the cellular stress (Dogovski et al., 2015); and (iii) dysregulation of the 
proteostasis control of P. falciparum phosphatidylinositol 3 kinase (PfPI3K) by 
reducing its interaction with dihydroartemisinin, which leads to less PfPI3K 
ubiquitination and in turn increases production of phosphatidyl 3 phosphate (P13P) 
signalling molecule (Mbengue et al., 2015). 
 
 
Figure 1. 9: The P. falciparum life cycle stages that are targets of the antimalarial drugs. All 
antimalarial drugs target the asexual trophozoite and schizont blood stage. The antifolates, primaquine 
and atovaquone also target the liver stage parasites. Artemisinins also target the asexual ring stage 
and the early sexual blood stages. Figure adapted from Haldar et al., 2018. 
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1.5.1.3. Future for malaria chemoprophylaxis 
Improvement of existing antimalarial drugs 
The effect of the rapid acting artemisinin can be enhanced by combination therapy 
which in turn helps prevent the parasite from developing resistance to artemisinin. 
Artemisinin-based combination therapies (ACTs) include: (i) the recently approved 
combination of artemisinin and pyronaridine (West African Network for Clinical Trials 
of Antimalarial, 2018); (ii) the combination of artesunate with ferroquine, a third 
generation 4-aminoquinoline, which proves promising in treating falciparum malaria 
especially in areas that have developed resistance to ACTs (Held et al., 2015); and 
(iii) the triple combination therapies, such as artemisinin + lumefantrine + amodiaquine 
and dihydroartemisinin + piperaquine + mefloquine, that show increased efficacy in 
clinical trials (Ross and Fidock, 2019). In addition, next generation endoperoxides 
have been developed. One example is OZ439 which shows longer plasma half-life of 
23 hours as compared to 30 minutes in the case of dihydroartemisinin (Charman et 
al., 2011) and further example - tetraoxane which has desirable rapid killing and 
lifelong properties (O'Neill et al., 2017).  
Discovery of drugs with new modes of action 
Newly discovered antimalarial drug targets are shown in Figure 1.10. Membrane 
biosynthesis, where a new choline analogue, G25, targets the phosphatidylcholine 
and phosphatidylethanolamine plasma fatty acid synthesis pathways and thus inhibit 
malarial infection in vitro and in vivo (Roggero et al., 2004). Transporters inhibitors, 
where an O-3 hexose derivative inhibits uptake of fructose and glucose by targeting 
the hexose transporter in mouse model (Joet et al., 2003) and a spiroindolone 
compound KAE609/ciparagamin enhances the cell membrane rigidity which in turn 
inhibits parasite development and transmission to mosquitoes by targeting the P-type 
Na+ ATPase PfATP4 (Blasco et al., 2017). Shikimate pathway, where compounds 
targeting the enzymes involved in the aromatic biosynthetic pathway inhibit 
progression of malaria infection due to the specificity of the targets and avoidance of 
off-target effects (McRobert et al., 2005, McConkey, 1999). Plasmodial proteases in 
the food vacuole, where potent synthetic inhibitors prevent haemoglobin degradation 
by targeting various aspartic and cysteine proteases such as plasmepsin (Coombs et 
al., 2001) and falcipain proteins (Lee et al., 2003) respectively. Mitochondrial 
isoprenoid biosynthesis, where the antibacterial fosmidomycin and its derivative FR-
900098 inhibit parasite development by targeting the DOXP reductase (DXR) which is 
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a key enzyme in the mevalonate-independent isoprenoid biosynthesis pathway 
(Wiesner et al., 2007, Lell et al., 2003). Mitochondrial redox system, where the 5,8-
Dihydroxy-1,4-naphthoquinone and 5-nitro-2-furanacrolein target the thioredoxin 
reductase thus prevent the intraerythrocytic parasite from overcoming oxidative stress 
in vitro (Yadav et al., 2019) and methylene blue which inhibits glutathione reductase 
thereby reducing mature gametocyte survival (Siciliano et al., 2017). Nucleic acid 
metabolism, where DSM265 targets the mitochondrial located plasmodial 
dihydroorotate dehydrogenase (DHOODH) enzyme which is essential for pyrimidine 
synthesis (McCarthy et al., 2017). Fatty acid metabolism, where antimicrobials such 
as thiolactomycin analogues, triclosan and cerulenin target enzymes in the type II fatty 
acid biosynthesis subunit thereby inhibiting the parasite growth (Yadav et al., 2019, 
Surolia and Surolia, 2001, Waller et al., 1998).  
Moreover, drugs targeting multiple life stages of the parasite have been discovered. 
These drugs include: an imidazolopiperazine compound, KAF156, which cures 
uncomplicated malaria by acting against the liver stage, asexual and sexual blood 
stages (Kuhen et al., 2014) and MMV390048, which is effective against all stages of 
the parasites’ life cycle in a mouse model except from the liver hypnozoites (Paquet 
et al., 2017). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 10: Potential drug targets of P. falciparum intraerythrocytic parasite stage. The possible 
new therapeutic targets within various cellular structures of the parasite. Figure adapted from Yadav et 
al., 2019.  
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1.5.2. Vector control 
1.5.2.1. Introduction to vector control 
The major malaria vectors in Africa, include Anopheles funestus and Anopheles 
gambiae sensu lato which is also known as the Anopheles gambiae complex 
(Hemingway, 2014, Halcrow, 1956). The complex consists of the following eight 
cryptic species; Anopheles arabiensis, Anopheles merus, Anopheles melas, 
Anopheles bwambae, Anopheles gambiae which is recognised as Anopheles sensu 
stricto and Anopheles coluzzi in the S and M form respectively, and Anopheles 
quadriannulatus which is also known as Anopheles amharicus (Coetzee et al., 2013, 
Sinka et al., 2010). Vector control depends primarily on indoor residual sprays (IRS) 
and long-lasting insecticide nets (LLINs), which resulted to reduced malaria deaths by 
a third in the period between 2000 to 2010 (WHO, 2012). However, insecticide 
resistance is already a major issue in Africa (Hemingway, 2014). 
 
1.5.2.2. Classification of insecticides 
Organochlorines and pyrethroids. 
The most effective organochlorine was dichlorodiphenyltrichloroethane (DDT). It 
superseded the use of pyrethrum extract obtained from flowers and was considered 
the magic bullet in malaria control in 1950s after the second world war (Hargreaves et 
al., 2000). However, the widespread effective use of organochlorine insecticides for 
agricultural reasons and house spraying during malaria control led to selection 
pressure and development of resistant malaria mosquitoes strains in malaria endemic 
areas (Brown, 1986).  
Recently, DDT was replaced by a new generation of highly potent photostable 
synthetic pyrethroids, which resemble natural pyrethrins obtained from the flowers of 
pyrethrums, and include deltamethrin, permethrin and alpha-cypermethrin (Chrustek 
et al., 2018). Additionally, pyrethroids are cheap to produce, easy to formulate and 
relatively safe to use in close proximity to humans thereby making them the only 
insecticide recommended for use in LLINs (WHO, 2012). Consequently, the intense 
use of pyrethroids resulted to emergence of resistance, to the extent that there is 
currently no country in Africa that has fully pyrethroid susceptible malaria vectors 
(Hemingway, 2014). 
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Pyrethroids and DDT have a similar mode of action involving binding to the sodium 
channels of the nervous system (Lund and Narahashi, 1983). They modify the kinetics 
of the voltage-sensitive sodium channel causing the channels to close slowly after 
each potential causing repetitive nerve excitation and ultimately lead to paralysis and 
death (Bloomquist, 1996). However, knockdown resistance (kdr) to DDT and 
pyrethroids occurs and is caused by mutations in the voltage-gated sodium ion 
channel gene, which involve a leucine-phenylalanine substitution at position 1014 
(L1014F) observed in West Africa (Martinez-Torres et al., 1998) and a leucine-serine 
substitution at the same codon (L1014S) observed in East Africa (Ranson et al., 2000), 
thereby leading to insensitivity of the target site. Furthermore, metabolic resistance to 
pyrethroids is correlated with increased activity of cytochrome P450 enzymes which 
play a role in metabolism of xenobiotics (Berge et al., 1998). 
Organophosphates and carbamates 
The malathion organophosphate and bendiocarb carbamate IRS were adopted 
following the emergence of resistant malaria vector strains to organochlorines. They 
have short residual activity and are more expensive compared to DDT and pyrethroids 
(WHO, 2012). Organophosphates and carbamates impede the activity of 
acetylcholinesterase (AChE) in the malaria vector by phosphorylating and 
carbamoylating the serine found in the active site of the enzyme respectively (Mutero 
et al., 1994). Following the inactivation of AChE, the breakdown of acetylcholine 
neurotransmitter is prevented, thereby resulting in neuromuscular overstimulation and 
ultimate death of the vector (WHO, 2012). However, resistance to organophosphates 
and carbamates occurs and is associated with insensitivity of the AChE which is 
caused by several point mutations in the catalytic subunit of the enzyme (Feyereisen, 
1995), such as glycine-serine substitution at position 119 of the ace-1 gene (Aizoun et 
al., 2013). 
 
1.5.2.3. Future for vector control strategies 
Larval control interventions 
Larvicides are control measures that target the mosquito larval habitats. They offer a 
promising solution because larvae cannot change their behaviour to avoid control 
intervention and thus could mitigate the observed insecticide resistance (Killeen et al., 
2002). Chemical larvicides, such as Paris green (copper acetoarsenite) and heavy 
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petroleum are cheap, highly effective but cannot be implemented because they are 
unsafe and highly toxic. Additionally, bacterial larvicides products based on Bacillus 
thuringiensis var. israelensis and Bacillus sphaericus are promising because they are 
highly effective and they selectively kill the larvae with insignificant toxicity to non-
target organisms (Derua et al., 2019, Walker and Lynch, 2007). Furthermore, plant-
based larvicides provide mosquito repellents and substances that are toxic to the 
mosquito with minimal toxicity to humans, but this research area is still in the 
preliminary phase (Beier et al., 2018). 
 
Wolbachia 
Wolbachia are endosymbionts that are vertically transmitted and maternally inherited 
in a wide range of arthropods. They have a significant contribution to the mating 
behaviour of mosquito vectors and thus could be used as a gene drive system for 
regulating the population of the mosquito vector and ultimately aid in reducing the 
transmission of the parasite (Wiwatanaratanabutr et al., 2010). 
Eave tubes and attractive toxic sugar baits 
Eave tube technology was initiated based on the architectural structure of African 
houses, where a ventilation gap exists between the walls and roof and thus exposing 
the residents to infective mosquito bites. It is a new way of delivering insecticides by 
employing plastic tubes containing insecticides coated mesh under the roofline and 
fitting of a screen to cover the remaining gap, thereby ensuring the houses are 
protected from mosquitoes (Knols et al., 2016). Additionally, the control of mosquito 
vectors can be enhanced by the lure and kill approach, where the human residents 
exploit the instinct of the mosquito to feed on sugar by placing natural attractants such 
as flower and fruit scents containing toxic substances that will lure the vector and 
ultimately lead to its death (Beier et al., 2012). 
Ivermectin 
Ivermectin is an endectocide which acts as a feed through insecticide. It is given as a 
single oral dose which remains in the human blood stream and can kill mosquitoes 
during a blood feed (Chaccour and Rabinovich, 2017). 
Genetically modified mosquito technique 
This refers to the impairment of the Plasmodium life cycle inside the mosquito by 
altering its genetic makeup. It involves the introduction of genetically altered 
mosquitoes, such as irradiated sterile male mosquitoes (Bouyer and Lefrancois, 2014, 
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Oliva et al., 2012) and insects carrying a dominant lethal (RIDL) mutation (Bourtzis et 
al., 2016), which compete with the wild type in order to reduce the mosquito population 
in nature. This technique is still in its preliminary phases and is highly unlikely to be 
available in the near future (Beier et al., 2018). 
 
 
Figure 1. 11: The trends and main challenges of current malaria vector control strategies. Figure 
adapted from Beier et al., 2018. 
 
1.5.3. Vaccines 
1.5.3.1. Introduction to malaria vaccines 
The employment of coordinated control interventions such as early diagnosis, 
combination drug therapies, indoor residual sprays and insecticide treated bed nets 
has remarkably reduced the global mortality and morbidity of malaria since 2000 (Bhatt 
et al., 2015). However, there is a challenge in maintaining their effectiveness due to 
increasing drug and insecticide resistance (Hemingway et al., 2016), and hence the 
need to develop a highly efficacious vaccine to complement the existing malaria 
eradication strategies (Healer et al., 2017). The development of antimalarial vaccines 
is based in part on the following two school of thoughts: (i) the understanding of 
mechanisms responsible for natural acquired immunity which takes long to develop 
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after stimulation by continuous parasite exposure in malaria endemic areas 
(McGregor, 1987) and (ii) the Jenner principle of vaccination which employs a 
formulation of a harmless target to provoke an immune response in healthy individuals 
thereby preventing successive infection (Renia and Goh, 2016). The focus in malaria 
vaccine development has been to prompt the cellular and humoral adaptive immune 
system to induce an efficacious and sterile response by targeting various points of 
intervention as shown in Figure 1.12 (Healer et al., 2017). 
 
 
Figure 1. 12: Possible points of intervention for an efficacious malaria vaccine. The susceptible 
areas to vaccine targets within the P. falciparum life cycle that would employ antibody mediated and 
cell mediated immune mechanisms are coloured in yellow and blue respectively. 
 
A vaccine can be comprised of protein subunits or entire parasites, termed as subunit 
vaccines or whole parasite vaccines respectively. Subunit vaccines contain selected 
antigens and are designed to provoke a desired immune response against the 
pathogen and are usually safe and easy to produce to scale and to administer in the 
field. On the other hand, whole parasite vaccines are considerably more successful 
because they contain all parasite antigens and allow the development of different type 
of immune responses. Nevertheless, many hurdles such as large scale production, 
delivery and administration in the field persist (Goh et al., 2019). 
Malaria vaccine development began more than 100 years ago when the Sergent 
brothers employed heat inactivated P. relictum sporozoites, the most common agent 
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of avian malaria, to immunize canary birds which developed partial protection from 
avian malaria (Sergent and Sergent, 1910). This was followed by immunization of 
domestic fowls by injections of serum and heat inactivated P. gallinaceum sporozoites 
to induce both humoral and cellular responses against malaria (Russell and Mohan, 
1942). In order to further boost the immune responses, a Freund’s adjuvant containing 
lanolin-like substances, paraffin oil and killed tubercle bacilli was invented and used to 
formulate vaccines by combining it with formalin-inactivated blood infected with P. 
lophurae (Freund et al., 1945a) and P. knowlesi (Freund et al., 1945b) which resulted 
to considerable resistance to homologous malaria infection in avian and monkey 
respectively. In 1946, the first attempt in humans was conducted, where formalin 
inactivated P. vivax infected blood was used to immunize volunteers but no protection 
was induced (Heidelberger et al., 1946). Unfortunately, the Freund’s adjuvant could 
not be used to boost immune responses because of its toxic effects in humans. In 
1967, irradiated P. berghei sporozoites were injected in mice and conferred sterile 
protective immunity at high dosage (Nussenzweig et al., 1967). In 1973, malaria-naïve 
human volunteers were vaccinated by irradiated infected Anopheles mosquitoes and 
showed low efficacy when challenged by infectious mosquito bites (Clyde et al., 1973). 
These preliminaries studies have paved way for malaria vaccine development. 
Various approaches and technologies have been employed to generate vaccines that 
have been tested in preclinical and clinical trials, but very few vaccine candidates have 
demonstrated vaccine efficacy in human as shown in Figure 1.13 (Renia and Goh, 
2016). 
 
1.5.3.2. Subunit vaccines 
Peptide and recombinant proteins 
The most clinically-advanced malaria vaccine is a liver stage subunit vaccine, 
RTS,S/ASO1, which has shown efficacy in malaria-naïve adults, semi-immune adults 
and children residing in malaria endemic areas (Rts, 2015, Cohen et al., 2010). The 
RTS,S vaccine also known as Mosquirix, is based on a recombinant protein and 
developed by GlaxoSmithKline scientists. It contains 19 copies of the central Arg-Ala-
Arg-Pro (NANP) repeats and 210-398 amino acids of the C-terminal domain of the 
CSP-NF54 P. falciparum strain. The CSP domains are genetically fused with hepatitis 
B virus surface antigen (HBsAg) which is co expressed in genetically engineered 
Saccharomyces cerevisiae yeast cells with three free HBsAgs (Draper et al., 2018, 
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Gordon et al., 1995). The exact immune mechanisms of RTS,S/AS01 vaccine is not 
known, however it is thought to elicit antibody responses towards the NANP amino 
acid repeat region (Oyen et al., 2017, White et al., 2015, Schwenk et al., 2003) and 
CD4 T cell response against the two CD4 T cell epitopes found in the C-terminal region 
(Kazmin et al., 2017).  
A major limitation with RTS,S is the inability to maintain high antibody titres (White et 
al., 2015), even after being administered with AS01 adjuvant which is the leading 
formulation for provoking high antibody titres in humans. Moreover, the RTS,S vaccine 
lacks a principal immunogenic epitope found in the junction of the N terminal part and 
the central repeat regions of the CSP protein, which has been shown to elicit effective 
antibody responses in humans vaccinated with whole irradiated sporozoites and can 
confer sterile protection in mice during passive transfer studies (Kisalu et al., 2018, 
Tan et al., 2018). Hence, several initiatives have already been executed to redesign 
the RTS,S vaccine to attain maximum vaccine efficacy, such as improving antibody 
responses to the central repeat by removing the four HBsAg and displaying a higher 
proportion of CSP, R21 vaccine, (Collins et al., 2017b) and using nearly the full length 
CSP containing the N terminal and novel adjuvants: FMP013 malaria protein (Genito 
et al., 2017). 
Blood stage antigens are often polymorphic and show limited efficacy when tested as 
single peptides vaccines. This has led to the development of several blood stage multi-
protein vaccines, such as: (i) PfAMA1-DiCo which aimed to cover diversity by 
containing three recombinant AMA1 variants. It has been tested in European and 
African adults inducing antibodies with strain transcending reactivity (Sirima et al., 
2017); (ii) PfAMA1-RON2L complex which contains AMA1 with its peptide ligand 
RON2 and has shown protection in Aotus monkeys inducing antibodies with high 
neutralising activity compared to AMA1 alone (Srinivasan et al., 2017); and (iii) 
VAR2CSA which consists of subunits against pregnancy-associated malaria and is 
the first placental vaccine (Pehrson et al., 2017).  
The challenge of long-standing polymorphism was consoled by the identification of the 
highly conserved PfRh5 which forms a significant interaction with basigin erythrocyte 
receptor during invasion (Crosnier et al., 2011). The PfRh5 has low natural 
immunogenicity and has been shown to induce antibodies conferring strain 
transcending protection in non-human primates that correlate to in vitro growth 
inhibition activity (Douglas et al., 2015, Draper et al., 2015). It can also confer in vivo 
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protection in humanized mouse model during passive transfer studies (Foquet et al., 
2018). Additionally, several multi-protein complexes containing PfRh5 have been 
revealed which may improve the vaccine potency, such as PfRH5-PfRipr-PfCyRPA-
basigin complex which is important for Ca2+ release and tight junction formation (Volz 
et al., 2016), PfRh5-PfP113 which anchors the N terminal of Rh5 to the merozoite 
surface (Galaway et al., 2017), PfRhopH3-cyclophilin B-basigin-PfRh5 multi-protein 
complex (Prakash et al., 2017) and PfRh5-PfRAP2 (Zhang et al., 2018) which aid in 
erythrocyte invasion. Furthermore, screening of novel merozoite antigens by reverse 
vaccinology have identified PfRAMA which elicit production of antibodies that 
synergize with anti-PfRh5 and anti-PfCyRPA (Bustamante et al., 2017). Apart from 
polymorphism and redundant erythrocyte invasion pathways, the blood stage vaccines 
development faces the hurdle of identifying blood target(s) that will produce long 
lasting, high quantity of functional antibodies (Draper et al., 2018). 
Transmission blocking vaccines have been developed to aid direct individual 
protection and arrest malaria transmission. Some of the subunit transmission blocking 
vaccines include: (i) the ookinete surface protein Pfs25/ISA 51, which was the first to 
progress clinically. It induced transmission blocking immunity in human that blocked 
parasite infectivity to mosquitoes but was reactogenic due to the formulation with 
Montanide ISA 51 (Wu et al., 2008). Hence, the delivery platform and efficacy was 
improved by employing EPA which is an exoprotein A of Pseudomonas aeruginosa 
(Shimp et al., 2013) and even IMX313 molecular adjuvant (Li et al., 2016); (ii) the 
female gamete-specific protein Pfs47, which is important in mediating evasion of the 
mosquito immune system (Molina-Cruz et al., 2013); (iii) the sexual stage protein 
Pfs230, which is expressed in gametocytes (MacDonald et al., 2016); and (iv) the 
gamete membrane fusion protein PfHAP2, which induces antibodies that confer strain 
transcending transmission blocking immunity (Angrisano et al., 2017). One major 
hurdle being faced by the transmission blocking vaccines is that the human humoral 
immune response cannot be enhanced by repeated infections because the gamete 
and ookinete stages are not present in the mammalian host during infection. 
DNA vaccines 
The insertion of DNA encoding an antigen to stimulate an immune response was first 
utilized as a vaccine delivery system in protection against influenza (Ulmer et al., 
1993). This approach was taken in malaria vaccine development, where a CSP-based 
DNA vaccine was developed, that induced antigen specific cytotoxic T cell responses 
 60 
(Wang et al., 1998b) but failed to induce antigen-specific antibodies during a phase 1 
clinical study (Le et al., 2000). A DNA construct encoding multiple genes was also 
developed (Haddad et al., 2004, Wang et al., 1998a). In order to improve the vaccine 
efficacy, the malaria DNA vaccines were developed together with DNA constructs 
encoding GM-CSF cytokine leading to increased immunogenicity and efficacy in 
mouse models (Weiss et al., 1998) but these didn’t confer protection against 
sporozoite challenge in humans (Richie et al., 2012). Despite DNA-based vaccines 
being easy to produce, cheap with long-shelf life, they are incapable of inducing good 
cellular and humoral adaptive responses.  
Recombinant vectored vaccines 
They are non-pathogenic, live replicating microorganisms engineered to carry 
immunogenic genes from a pathogen (Bull et al., 2019). In malaria, the viral vector is 
the most popular delivery system and have shown promising efficacy in animal 
models. These viral vectors used in malaria so far include: (i) recombinant influenza 
and vaccinia viruses expressing CD8 T and B cell epitopes of CSP (Rodrigues et al., 
1994), (ii) sindbis virus expressing a CD8 T cell epitope of CSP (Tsuji et al., 1998), (iii) 
Yellow fever virus expressing the B cell epitope of CSP (Bonaldo et al., 2002), (iv) 
replication-deficient adeno virus (Hollingdale et al., 2017) and (v) cytomegalovirus 
expressing CSP, AMA1, thrombospondin-related adhesive protein (TRAP) and MSP1 
antigens (Hansen et al., 2019).  
Moreover, several bacterial vectors have also shown good immunogenicity and confer 
protection against sporozoite challenge in mice, such as: (i) Bacille-Calmette Guerin 
(BCG) expressing CSP (Arama et al., 2012), (ii) Shigella flexneri 2A strain expressing 
the cell transversal protein for ookinetes and sporozoites (PfCelTOS) and CSP 
vaccine candidates (Bergmann-Leitner et al., 2013), and (iii) Salmonella expressing 
CSP (Aggarwal et al., 1990, Sadoff et al., 1988) which is also the first recombinant 
vectored vaccine to be evaluated in humans and appears safe and immunogenic 
(Gonzalez et al., 1994). Furthermore, parasites vectors expressing CSP such as 
Leishmania enriettii (Wang et al., 1995) and Toxoplasma gondii (Charest et al., 2000, 
Di Cristina et al., 1999) have conferred partial protection in mice. These delivery 
systems have been able to induce protection in animal models, and it remains to be 
seen if they will induce protection in humans. 
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Prime boost combinations 
This refers to the vaccination with a subunit vaccine or DNA construct followed by viral 
vector(s) containing one or multiple antigens (Hill et al., 2010, Webster et al., 2005). 
This approach has been used in several malaria vaccine development studies in 
mouse models (de Camargo et al., 2018, Arama et al., 2012, Stoyanov et al., 2010, 
Sedegah et al., 1998) but only those that express the TRAP liver antigen and not CSP 
have demonstrated vaccine efficacy in humans (Bliss et al., 2018, Rampling et al., 
2016, Ewer et al., 2015, McConkey et al., 2003). The most advanced prime-boost 
vaccine in malaria vaccine development is the heterologous ChAd63-MVA ME-TRAP, 
which contains the simian adenovirus 63 and the modified vaccinia Ankara viral 
vectors. Each vector expresses the liver stage malaria antigen thrombospondin 
related adhesion protein fused to a multiple epitope string. Multiple priming with 
ChAd63 ME-TRAP and boosting with MVA ME-TRAP has been shown to induce 
potent T cell and antibody responses respectively in phase II clinical trials in humans 
(Bliss et al., 2018). Another quite advanced prime boost vaccine is the ChAdOx1-MVA 
LS2 which employs the chimpanzee adenovirus and the modified vaccinia Ankara viral 
vectors each expressing the liver stage dual antigens (LSA1 and LSAP2) (Draper et 
al., 2018). These advanced prime boost combinations are still in clinical trials. 
 
1.5.3.3. Whole parasite vaccines 
Radiation attenuated  
Vaccination with radiation-attenuated sporozoites (RAS) is the most clinically 
advanced of whole parasite-based vaccines (Richie et al., 2015). This was facilitated 
by the ability to isolate a purified, aseptic, metabolically active and cryopreserved 
product of irradiated NF54 sporozoites and deliver into the humans by direct venous 
inoculation during clinical trials (PfSPZ vaccine) (Seder et al., 2013). This protective 
immune response induced by PfSPZ vaccine could be mediated by the PfSPZ-specific 
IFNγ-producing CD8 T cells as demonstrated by studies using animal models (Epstein 
et al., 2011). Additionally, passive transfer studies in liver-chimeric mouse models 
prevented liver infection (Ishizuka et al., 2016) and this could be mediated by 
complement fixing anti-sporozoite IgM (Zenklusen et al., 2018). However, the PfSPZ 
vaccine faces numerous challenges, such as: (i) the need for a high dose of 
sporozoites to induce a high efficacy level making it difficult for mass vaccination 
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(Richie et al., 2015, Seder et al., 2013), (ii) the route of administration providing robust 
CD8 T cell responses is the direct intravenous injection which requires professional 
expertise (Epstein et al., 2011), (iii) the induced protective immunity targets 
polymorphic antigens because sterile protection was attained against homologous 
challenge (Seder et al., 2013) and reduced efficacy against heterologous challenge 
(Lyke et al., 2017, Sissoko et al., 2017, Schats et al., 2015), and (iv) the delicate 
procedure of attenuation since over-irradiated sporozoites do not induce protection 
(Goh et al., 2019, Vanderberg et al., 1968).  
Genetically attenuated parasites (GAP) 
This refers to parasite that have been modified to attenuate their growth at a certain 
stage allowing the host immune system to be exposed to a wide repertoire of parasite 
antigens. In malaria vaccine studies so far, GAPs are modified to arrest liver 
development after hepatocyte infection. This modification is achieved by deleting 
essential genes but does not affect parasite viability in the host, mosquito infectivity 
and sporozoite production in animal models (Vaughan et al., 2010). Early arrest of 
liver stage development has been shown to offer long lasting and sterile protection in 
rodent models and this can be achieved by deleting various genes which play a critical 
role in completion of liver stage development, such as: (i) UIS3 (Mueller et al., 2005b), 
(ii) UIS4 (Mueller et al., 2005a) and (iii) P36p (van Dijk et al., 2005) genes. Moreover, 
two early arresting NF54 P. falciparum GAPs have been established by deletion of 
two (p52–/p36–) (Spring et al., 2013) and three p52–/p36–/sap1 (PfGAP3KO) (Kublin 
et al., 2017) liver stage genes which were administered by infective mosquito bites 
and conferred protection with and without breakthrough infections respectively in 
human subjects. To enhance further the efficacy of GAP vaccines, second generation 
genetically attenuated parasites (next generation), such as fabb/f- (Butler et al., 2011) 
and plasmei2-/LISP2- (Vaughan et al., 2018) have been developed and arrest during 
late stage liver development allowing the host to be exposed to a greater antigen 
repertoire, thereby conferring superior protection in rodent models. One major hurdle 
facing the further development of GAP vaccines is the difficulty in generating late 
arresting P. falciparum next generation GAPs. 
Chemically attenuated parasites 
This is a new approach employed in malaria vaccine development to inactivate whole 
parasites by use of chemicals either in vitro before vaccination or in vivo after 
vaccination with live parasites. Chemically attenuated sporozoites (CAS) were 
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established by in vitro treatment with a DNA alkylation agent, centanamycin, and their 
vaccination conferred sterile immunity and cross protection against heterologous 
challenge in mouse model (Purcell et al., 2008). Additionally, vaccination with 
chemically attenuated whole-parasite blood stage, that was treated in vitro using 
centanamycin and tafuramycin-A chemical attenuating agents, induced strong 
proliferative responses against homologous and heterologous parasites in mouse 
models (Raja et al., 2017). These in vitro chemically attenuated vaccines are yet to be 
examined in humans to determine their efficacy. The most studied in vivo 
chemoattenuated approach is the vaccination with live cryopreserved NF54 
(chloroquine sensitive strain) sporozoites administered by direct intravenous injection 
under chloroquine prophylaxis (PfSPZ-CVac) and has shown sterile protection against 
homologous CHMI (Mordmuller et al., 2017). Although this approach requires about 
10 to 100-fold less sporozoites compared to PfSPZ vaccine it is faced with a major 
hurdle on how to overcome the potential safety issues related to using a live vaccine 
that requires concurrent treatment to prevent disease. 
 
Figure 1. 13: Malaria vaccine candidates in clinical development. The vaccines target different 
stages of the parasite’s life cycle. Figure adapted from Draper et al., 2018.  
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1.5.3.4. Model systems for malaria vaccines 
Mouse model 
Mice are the most popular models used to initiate in vivo studies examining the 
development of vaccine candidates because of its affordability and availability. The 
use of mouse models has pioneered two significant vaccine studies, and these 
include: (i) the first demonstration that irradiated whole sporozoite vaccine induces 
sterile protection from infective sporozoites using a P. berghei mouse model 
(Nussenzweig et al., 1967), and (ii) the first evidence that vaccination with live 
sporozoites under chloroquine treatment offer promising efficacy. This was 
demonstrated using P. berghei and P. yoelli mouse models (Belnoue et al., 2004). 
Moreover, the examination of the efficacy of human malaria antigens has been 
facilitated in the mouse model (Kisalu et al., 2018, Espinosa et al., 2015, Kastenmuller 
et al., 2013) by the establishment of transgenic rodent malaria parasites, knock-in 
parasites, expressing P. falciparum (Tewari et al., 2002) or P. vivax genes (Espinosa 
et al., 2013). 
The main challenge with the mouse model is the inability to conclusively interpret 
findings obtained from the mouse model and translate these to the humans because 
of various reasons, such as: (i) the difference at genomic and proteomic levels 
between the rodent and human species which is illustrated by the rodent parasite 
lacking orthologs for more than 730 P. falciparum genes (Hall et al., 2005, Carlton et 
al., 2002), (ii) the difference in the liver stage during rodent and human malaria 
infection which takes 2-3 days and 7-10 days respectively and formation of 
hypnozoites during P. vivax infection (Vaughan et al., 2012, Krotoski et al., 1982), (iii) 
the limited MHC genetic repertoire in the genetically homogenous inbred mice which 
doesn’t imitate the large MHC diversity experienced in humans (Goh et al., 2019) and 
(iv) the laboratory mice are pathogen free and this may bias infection and vaccine 
studies because the cellular composition of the innate and adaptive system resembles 
neonates and not human adults (Beura et al., 2016). 
Non-human primates 
They share a lot more similarities with the humans compared to the mouse model 
(Beignon et al., 2014). The Aotus monkeys can support infection with P. falciparum 
and P. vivax (Collins et al., 2006, Herrera et al., 2002). Additionally, the Aotus and 
Samiri species are essential in examining P. vivax erythrocytic stage vaccines 
because of their capability to forming hypnozoites (Joyner et al., 2015). Moreover, 
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simian malaria parasites, for example P. cynomolgi and P. knowlesi, have been 
employed for immune and vaccine studies in macaques (Wijayalath et al., 2008, 
Deans, 1984). Furthermore, vaccination of Toque monkeys with live sporozoites under 
chloroquine treatment have shown promising vaccine efficacy (Wijayalath et al., 
2012). The hurdles facing the use of non-human primates include the high cost of 
colony maintenance, unavailability and restriction of utilization because of ethical 
issues (Goh et al., 2019). 
Humanized mouse 
They are immunodeficient mice which permit long-lasting establishment of 
components of human immunity by xenotransplantation of human hepatopoietic 
and/or erythropoietic cells and tissues. The following humanized mice have been used 
in malaria research: (i) the SCID/Alb-uPA mouse which is a human liver chimeric 
immunodeficient mouse transgenic for the urokinase plasminogen activator used to 
study pre erythrocytic stage vaccines (Morosan et al., 2006, Sacci et al., 2006), the (ii) 
FAH−/−Rag2−/−IL2Rγnull (FRG huHep) liver chimeric immunodeficient mouse which 
lacks the fumarylacetoacetate hydrolase and doesn’t suffer hepatotoxicity, thereby 
allowing transplantation of human erythrocytes and supports transition from liver stage 
to blood stage P. falciparum infection (Foquet et al., 2018, Vaughan et al., 2012), (iii) 
the TK-NOD model which is a NOD mouse (deficient for cytokine IL2Rγ gene) 
transgenic for thymidine kinase gene which can be engrafted by both human 
hepatocytes and erythrocytes allowing full P. falciparum development in the liver and 
transition to the blood stage (Soulard et al., 2015, Hasegawa et al., 2011) and (iv) HIS-
CD4/B model which possess the human immune system with a functional human CD4 
T cells and B cells and are important pre-clinical models used to unravel immune 
response against malaria by using transgenic rodent malaria parasites expressing 
certain P. falciparum antigens (Huang et al., 2015).  
Human volunteers  
The establishment of the controlled human malaria infection (CHMI) models have 
contributed remarkably to malaria research. They involves healthy human volunteers 
who are exposed to the parasite, either by infective mosquito bites or the direct 
intravenous route, and monitored for signs and symptoms after which they are treated 
upon detection of parasites and/or fever (Roestenberg et al., 2009, Dunachie et al., 
2006). The drawback of the CHMI study is that it does not reflect the natural field 
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setting because it is usually performed using one parasite strain and the parasite load 
is administered at one single dose (Goh et al., 2019).  
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1.5. Aim of the study 
Formative studies have been conducted to shed light on correlates of protective 
immunity during natural P. falciparum infections, with a major focus being on the highly 
immunogenic mature asexual blood stages. However, ring-infected erythrocytes which 
are the predominant forms detected in the peripheral circulation, have received very 
little attention in this context. The overall aim of this study was to investigate whether 
antibody mediated clearance of rIEs is a mechanism of protective immunity against P. 
falciparum infection. The hypothesis is that, the rIE gets in contact with parasite 
proteins which are shed and/or secreted by the merozoite during invasion, and thus 
possibly making the newly invaded erythrocyte a target of the immune system. Several 
approaches were employed to test the above hypothesis. 
Firstly, in chapter three, I investigated the immunogenicity of rIEs, and how this differs 
between lab and field parasite isolates. I used plasma samples from malaria-immune 
individuals from a malaria endemic area and tested their recognition of rIEs and 
compared it to antibody response to mIEs and merozoites. I also tested and compared 
the splenic retention of rIEs between lab and field parasite isolates. Secondly, in 
chapter four, I investigated the physiological relevance of the immunogenicity of the 
rIEs. I established an antibody mediated functional assay for rIEs in our lab and tested 
whether it correlated to outcome of infection in a CHMI study. Finally, in chapter five, 
I aimed to identify parasite proteins on the surface of ring-infected erythrocytes. I 
conducted a surface proteomics approach which involved surface trypsinization of the 
ring culture cells followed by mass spectrometry analysis of the obtained 
supernatants. 
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Chapter 2 
Materials 
3.1. Laboratory equipment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2. Soft ware 
 
 
 
 
 
 
Systec GmbH, Göttingen 
Heraeus Instruments, Hanau 
Becton Dickinson, Heidelberg 
Liebherr International Deutschland 
GmbH, Biberbach an der Riss 
 
Thermo Fischer Scientific, Karlsruhe 
Bosch, Stuttgart 
Heraeus Instruments, Hanau 
Heraeus Instruments, Hanau 
Heraeus Instruments, Hanau 
Zeiss, Jena 
VWR International GmbH, Darmstadt 
Thermo Fischer Scientific, Karlsruhe 
Eppendorf AG, Hamburg 
Mettler-Toledo GmbH, Gießen 
Gilson International, Bad Camberg 
Hirschmann, Labortechnik, Eberstadt 
Hewlett Packard, Heidelberg 
PerkinElmer, Waltham, USA 
VWR International GmbH, Darmstadt 
Labor Mannheim GmbH, Mannheim 
 
 
 
 
Autoclave 
Centrifuge, Megafuge 16R   
FACS Contour II    
Freezers -20°C 
 
Freezers -80°C 
Fridge 
Incubator, Cell star cytoperm 2 
Incubator CO2, BBD6620 
Laminar Flow Cell culture hood 
Light microscope, Axiolab 
Magnetic stirrer 
Microplate reader 
Multi-channel pipettes 
pH meter, Five Easy 
Pipetman Gilson P (2,10,20,200,1000) 
Pipettus* akku 
Printer hp LaserJet 1300  
Spinning disc confocal microscope 
Vortex 
Waterbath 
FlowJo version 10 
Gen 5 3.02 
GraphPad Prism version 7.0 
Inkscape 
ImageJ 
 
 
Volocity 5.1 
 
FlowJo, LLC, Ashland 
Thermo Fischer Scientific, Karlsruhe 
GraphPad software, San Diego, USA 
Freeware 
National Institute of Health, Bethesda, 
USA 
 
PerkinElmer, Waltham, USA 
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3.3. Consumables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4. Chemicals 
 
 
 
 
 
 
 
 
 
BD Falcon Round bottom tubes 5 ml 
Cell culture flasks 
Cover Glass (Haemocytometer) 
CS&T beads for research 
CS Columns for MACS 
DMSO Hybrimax 
Eppendorf (1.5 ml, 2 ml) tubes 
Falcon (15 ml and 50 ml) flasks 
Falcon 96 well plates round bottom 
Filter (0.2 µm pore size) 
Filter (Acrodisc 1.2 µm pore size) 
Filter (for dialysis) 
Gloves latex 
4HBX Nunc Immunolonplates 
Kimtech wipes 
Syringe 
Slides 
Pipette tips 
Plastic pipettes 
 
 
 
 
Becton Dickinson, Heidelberg 
Greiner Bio-One, Frickenhausen 
Neolab, Heidelberg 
Becton Dickinson, Heidelberg 
Miltenyi Biotec GmbH, Germany 
Sigma-Aldrich, Taufkirchen 
Neolab, Heidelberg 
Greiner Bio-One, Frickenhausen 
Neolab, Heidelberg 
Greiner Bio-One, Frickenhausen 
Pall, Deutschland GmbH, Dreieich 
Merck Millipore, Darmstadt 
VWR International GmbH, Darmstadt 
Thermo Fischer Scientific, MA, USA 
Greiner Bio-One, Frickenhausen 
Greiner Bio-One, Frickenhausen 
Paul Marienfeld GmbH, Lauda 
Gilson, Heidelberg, Germany 
Greiner Bio-One, Frickenhausen 
 
Thermo Fischer, MA, USA 
Sigma-Aldrich, Taufkirchen 
Becton Dickinson, Heidelberg 
Becton Dickinson, Heidelberg 
Becton Dickinson, Heidelberg 
Becton Dickinson, Heidelberg 
Becton Dickinson, Heidelberg 
Thermo Fischer Scientific, MA, USA 
Thermo Fischer Scientific, MA, USA 
 
 
 
Thermo Fischer, Heidelberg, Germany 
Sigma-Aldrich, Heidelberg, Germany 
 
Thermo Fischer, Heidelberg, Germany 
Albumax I 
Bovine Serum Albumin 
BD Perm/Wash (FACS)  
BD Clean (FACS) 
BD Flow (FACS) 
BD FACS Rinse solution (FACS) 
BD FACS Shutdown solution (FACS) 
Cell Trace Far Red fluorescent dye 
Cell Trace Violet fluorescent dye   
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Cytochalasin  
D-Glucose 
D-Sorbitol 
Dihydroartemisinin (DHA) 
Dihydroethidium Nucleic Acid stain 
Dimethyl sulfoxide (DMSO) 
Ethanol 100% 
FBS (Fetal Bovine Serum) 
Formaldehyde solution 
Gentamycin 10 mg/ml 
Glycerol 99% 
Heparin 
Hoechst 33342 (Nucleic Acid stain) 
Hypoxanthine 
Hydrochloric acid 
Methanol 100% 
Mito Tracker Deep Red 
o-Phenylenediamine dihydrochloride 
Penicillin-streptomycin 
Paraformaldehyde 
RAL 555 
Potassium Sulphate 
Skimmed milk 
Sodium Chloride 
SYBR Green I (Nucleic Acid stain) 
Trypan blue 
Trypsin inhibitor 
Trypsin Sequencing grade modified 
Tween 
 
 
 
 
 
 
 
 
 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
Abcam Limited, Cambridge 
Thermo Fischer, MA, USA 
VWR International GmbH, Darmstadt 
Invitrogen, Karlsruhe 
Thermo Fischer Scientific, MA, USA 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
Klinik Apo direkt, Heidelberg 
Thermo Fischer, MA, USA 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
Sigma-Aldrich, Taufkirchen 
Thermo Fischer Scientific, MA, USA 
Sigma-Aldrich, Taufkirchen 
Gibco, Heidelberg 
Alfa Aesar by Thermo Fischer Scientific 
RAL Diagnostics, Martillac, France 
Bio repair, Germany 
Carl Roth, Karlsruhe 
Sigma-Aldrich, Taufkirchen 
Thermo Fischer, MA, USA 
Carl Roth, Karlsruhe 
Promega, Madison, USA 
Promega, Madison, USA 
Merck, Darmstadt 
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3.5. Kits 
 
 
 
3.6. Antibodies 
 
 
 
 
 
3.7. Recombinant proteins 
 
 
 
 
 
 
3.8. Parasite strain and cell lines 
 
 
 
 
 
 
 
 
 
 
Quick Start Bradford Protein Assay 
FITC Annexin V Apoptosis Detection Kit 
Bio Rad, München 
Becton Dickinson, Pharmingen 
Alexa Flour 647 antihuman IgG (IFA) 
FITC anti-human CD235a (IFA) 
Mouse anti-human APC (FACS) 
Rabbit anti-human IgG, polyclonal, 
HRP 
 
Biolegend, UK LTD, London 
Biolegend, UK LTD, London 
Biolegend, UK LTD, London 
Agilent Technologies Deutschland, 
Böblingen  
PfAMA1 (3D7 strain, expi293F) 
PfEBA-175 (3D7 strain, expi293F) 
PfMSP-1 (3D7 strain, expi293F) 
PfMSP-2 (3D7 strain, expi293F) 
PfMSP-3 (3D7 strain, expi293F) 
CD45 (3D7 strain, expi293F) 
 
KEMRI Wellcome Trust, Kilifi, Kenya 
KEMRI Wellcome Trust, Kilifi, Kenya 
KEMRI Wellcome Trust, Kilifi, Kenya 
KEMRI Wellcome Trust, Kilifi, Kenya 
KEMRI Wellcome Trust, Kilifi, Kenya 
KEMRI Wellcome Trust, Kilifi, Kenya 
 
P. falciparum 3D7 
 
 
P. falciparum 3D7 (GFP tagged) 
P. falciparum FCR3 
 
 
P. falciparum NF54 
THP-1 monocytes 
Center of infectious diseases, 
Parasitology, Heidelberg 
 
MR4, BEI resources, USA 
Center of infectious diseases, 
Parasitology, Heidelberg 
 
KEMRI Wellcome Trust, Kilifi, Kenya 
KEMRI Wellcome Trust, Kilifi, Kenya 
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3.9. Buffer, solution and media 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Common buffers 
 
10x PBS 
 
 
 
1x PBS 
 
ELISA Assay 
 
PBST buffer 
Blocking buffer 
Substrate 
 
 
Stopping solution 
 
Microsphiltration 
 
Microsphere suspension 
 
Immunofluorescence Assay 
 
Fixing buffer 
 
Quenching solution 
Blocking buffer 
 
Antibody binding Assay 
 
FACS/Wash buffer 
 
 
 
1.4 M NaCl 
27 mM KCl 
100 mM Na2HP04 
18 mM K2HP04 
pH 7.4 
 
100 ml 10x PBS 
1 L ddH20 
 
 
 
0.05% Tween 20 in PBS 
1% skimmed milk powder in PBST 
o-Phenylenediamine dihydrochloride, 
OPD, (1 grey + 1 gold) tablet (Sigma-
Aldrich) in 20 ml dH20 
 
 
1 M HCl 
 
 
 
 
 
95.5% tin, 3.0% silver and 0.5% copper 
microspheres in incomplete culture 
media 
 
 
 
4% Paraformaldehyde & 0.0075% 
Glutaraldehyde in PBS 
 
125 mM Glycine in PBS 
 
3% Bovine Serum Albumin (BSA) in 
PBS  
 
 
 
 
0.5% Bovine Serum Albumin (BSA) in 
PBS  
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Ring Survival Assay 
 
Wash solution 
 
Dihydroartemisinin (DHA) stock 
 
Phagocytosis Assay 
 
THP1 incomplete medium 
 
 
Dilution/Wash buffer 
 
Red cell Lysis buffer 
 
Cell culture of P. falciparum 
 
Human erythrocytes, blood group o+ 
Parasite culture medium 
 
 
 
 
Thawing solutions 
 
 
Freezing solution 
 
 
D-Sorbitol solution 
 
Cell culture of THP1 cells 
 
THP1 culture medium 
 
 
 
RPMI 1640 media with L-Glutamine 
and 25 mM HEPES 
 
1 mM DHA in DMSO 
 
 
 
 
 
RPMI 1640 (500 ml) 
2mM L-Glutamine 
10mM HEPES 
1% Penicillin-streptomycin 
 
0.5% Bovine Serum Albumin (BSA) in 
PBS  
 
Biolegend, UK LTD, London 
 
 
 
 
Blood bank. Heidelberg 
 
RPMI 1640 (500 ml) 
L-Glutamine 
25 mM HEPES 
0.1 mM Hypoxanthine 
20 µg/ml Gentamycin 
0.25% (v/v) Albumax I 
 
1) 12% NaCl in ddH20 
2) 1.6% NaCl in ddH20 
3) 0.9% NaCl & 0.2% Glucose in ddH20 
 
 
56% (v/v) Glycerol 
3% (v/v) Sorbitol 
0.65% (w/v) NaCl 
 
5% (w/v) Sorbitol in ddH20 
 
 
 
 
RPMI 1640 (500 ml) 
2mM L-Glutamine 
10mM HEPES 
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Cell culture of THP1 cells 
 
THP1 culture medium 
 
 
 
 
Thawing solution 
 
Freezing solution 
 
RPMI 1640 with L-Glutamine & HEPES 
 
 
 
 
RPMI 1640 (500 ml) 
2mM L-Glutamine 
10mM HEPES 
1% Penicillin-streptomycin 
10% Fetal Bovine Serum (FBS) 
 
50% FBS in incomplete THP1 medium 
 
10% DMSO in FBS 
 
Invitrogen, Heidelberg; Germany 
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Chapter 3 
The immunogenicity of Plasmodium falciparum ring-infected erythrocytes 
 
3.1. Introduction  
Plasmodium species have a complex life cycle that alternates between the female 
Anopheles mosquito and the vertebrate host (Cowman et al., 2016). The blood stage 
of P. falciparum life cycle is responsible for the clinical symptoms of malaria in humans 
(Yazdani et al., 2006, Neva et al., 1970). In the blood stage, the ring-infected 
erythrocytes (rIEs) are found primarily in circulation, whereas the mature stages 
sequester in the microvasculature avoiding clearance by the spleen (White, 2017). 
The rIEs are therefore the most predominant asexual blood stage detected in the 
peripheral blood smear during P. falciparum malaria diagnosis (White, 2017). 
However, it is important to note that peripheral blood smear can only account for 
parasitemia but not total parasite burden, because the sequestered parasites are not 
enumerated (White et al., 1992). Interestingly, during natural asymptomatic infections, 
P. falciparum rIEs are maintained at low densities and do not manifest the anticipated 
exponential growth every 48 hours (Anand and Puri, 2005, Farnert et al., 1997).  
The availability of the rIEs in circulation during P. falciparum malaria may suggest that 
they are not immunogenic. P. falciparum rIEs have been shown to have a unique 
ability to cytoadhere to the endothelial cells of micro vessels and to placental 
syncytiotrophoblasts possibly via ring surface proteins: RSP1 and/or RSP2 (Douki et 
al., 2003, Pouvelle et al., 2000). The rIEs has also been shown to have reduced 
deformability (Nash et al., 1989) that could be responsible for their splenic retention in 
experimental studies (Safeukui et al., 2008, Buffet et al., 2006) and clinical infections 
(Prommano et al., 2005, Lee et al., 1989). Moreover, the detection of antibody binding 
on rIEs has been reported in peripheral blood smears during acute P. falciparum 
malaria infection in humans (Chotivanich et al., 2002, Angus et al., 1997, Perlmann et 
al., 1984), and even in the P. chabaudi mouse model (Perlmann et al., 1984). In order 
to shed light on the possible contribution of rIEs to parasite clearance and protective 
immunity, I began by evaluating the immunogenicity of rIEs using different P. 
falciparum parasite isolates and plasma samples from semi-immune adults from 
malaria endemic areas. 
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3.2. Rationale 
In this chapter, I sought to investigate the immunogenicity of rIEs, and whether this 
differs between laboratory (lab) and field isolates. To test this, I used various methods 
namely; i) an antibody binding detection assay, ii) a ring-stage survival assay and iii) 
an artificial splenic assay. For the antibody binding assay and the in-vitro ring-stage 
survival assay, I used; a pool of hyper immune plasma from malaria-immune adults, 
individual plasma samples from malaria exposed adults from Junju sub-location, Kilifi, 
Kenya and a pool of plasma from malaria-naïve individuals as a negative control. I 
also used the P. falciparum FCR3 laboratory isolate for all the experiments, and a 
clinical isolate from Kilifi Kenya (P0000072) for the antibody binding assay and the 
splenic retention assay. 
Antibody binding detection assay  
I employed the antibody binding assay to investigate whether antibodies from malaria-
immune plasma bound to rIEs. The ability of antibody to bind on infected erythrocytes 
(IEs) has been successfully detected by use of an immunofluorescence assay (IFA) 
(Awah et al., 2011, Sterkers et al., 2007, Douki et al., 2003) and a flow cytometry assay 
(Awah et al., 2009, Layez et al., 2005). I therefore expected that malaria-immune 
antibodies capable of recognising rIEs would be detected by a fluorophore-conjugated 
secondary antibody specific for the fragment crystallizable region (Fc region). 
Merozoite based Enzyme-Linked Immunosorbent Assay (ELISA)  
I used the merozoite based ELISA in order to estimate the immune levels of the 
individuals from Junju sub-location and formed a good basis for comparison with 
antibody response to rIEs. I used merozoites from the P. falciparum NF54 lab isolate, 
which were conveniently available in our laboratory. I expected that plasma samples 
from individuals with high and low immune levels would have high and low antibody 
responses to merozoites respectively. 
In-vitro Ring-stage Survival Assay (RSA0-3h) 
I employed the ring survival assay to investigate the effect of malaria-immune plasma 
on survival of rIEs. This method has been used to evaluate the susceptibility of P. 
falciparum to artemisinin (Witkowski et al., 2013). The survival of the parasite reflects 
the effect of the drug on the ring stage, which is the only parasite stage that comes in 
contact with the treatment. I therefore expected that antibodies with detrimental effect 
on rIEs would prevent ring survival and maturation. 
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Artificial splenic assay (Microsphiltration) 
I used the microsphiltration method to determine the splenic retention rates of rIEs. 
This method is based on the filtration of IEs through a mixture of metal microspheres 
of different sizes that mimic the geometry of the narrow and short inter-endothelial 
splenic slits and is shown to mimic the ex-vivo splenic perfusion system (Deplaine et 
al., 2011). I expected rIEs with reduced deformability to be retained within the micro-
spherical beads. 
 
3.3. Overall objective 
To investigate the immunogenicity of P. falciparum rIEs. 
 
3.4. Specific objectives 
• To investigate the ability of antibody to bind to rIEs and whether this was 
correlated with antibody responses to other asexual blood stages. 
• To find out whether malaria-immune plasma had a direct inhibitory effect on the 
survival of rIEs. 
• To compare splenic retention of rIEs between lab and field parasite isolates. 
 
3.5. Laboratory methods 
3.5.1. P. falciparum culture and synchronization 
The P. falciparum FCR3 laboratory isolate and the P0000072 clinical isolate were 
maintained in in vitro culture through infection of human O+ erythrocytes (with less 
than 2 weeks of storage at 4°C). Culture media, which consisted of RPMI 1640 media 
supplemented with L-Glutamine, 25 mM HEPES, 0.25% (v/v) Albumax I, 0.1 mM 
hypoxanthine, and 20 µg/ml gentamycin, at 2% haematocrit. The cultures were gassed 
with 5% (v/v) O2 and 5% (v/v) CO2 balanced with N2 at 37°C in a dark incubator. The 
parasite developmental stages were determined using thin blood smears stained with 
Giemsa, and subcultured in order to maintain a parasitemia of 8-10%.  
Parasite synchronization was done every 46 hours using the D-sorbitol lysis method. 
Prewarmed 5% D-Sorbitol (10 volumes of culture pellet volume) was added to the 
pellet in 15 ml conical flask followed by vigorously vortexing for 30 seconds, and then 
incubated at 37°C for 10 minutes before further vortexing. Trophozoite and schizont 
infected erythrocytes are mature-infected erythrocytes (mIEs) and are known to be 
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highly permeable compared to rIEs, and thus take up sorbitol to a higher extent leading 
to lysis of the mIEs (Radfar et al., 2009). The resultant cultures (with predominantly 
single and multiple rIEs) were further synchronised by 30 IU of heparin to inhibit 
parasite invasion until most of the parasites progressed to the mature schizont stage, 
when culture supernatant was removed by centrifugation at 800 xg for 4 minutes at 
room temperature. Heparin ensures invasion inhibition because released merozoites 
will bind to the soluble heparin in culture, preventing the merozoite surface proteins 
(MSP142 and MSP133) from binding to heparin-like invasion receptors found on the 
surface of erythrocytes (Boyle et al., 2010). Fresh media was added to the culture to 
allow merozoite invasion for 10 hours and then synchronized further with 5% D-sorbitol 
to get rid of the unruptured schizont infected erythrocytes. However, for the study of 
rIEs and mIEs, the final sorbitol synchronization step was omitted, and the two 
population were differentiated by flow cytometry gating. 
 
 
Figure 3. 1: An overview of the synchronization method. 1) The ring form present in the culture is 
2) treated with D-sorbitol to selected it before development to trophozoite stage. 3) Heparin is introduced 
to the culture to inhibit merozoite invasion. 4) Heparin is removed from culture when most of the 
parasites have progressed to mature schizont stage. 5) The second D-sorbitol treatment stops 
merozoite invasion and defines the synchronization window. Figure adopted from Koboyashi and Kato 
2016. 
 
3.5.2. Antibody binding detection assay  
Parasite cultures of approximately 5-10% parasitemia and 4% hematocrit were used 
in the experiments. For the detection of antibody binding by flow cytometry; 0.5 µl of 
culture were stained with 1X SYBR Green I (SG) DNA dye for 30 minutes at 37°C 
followed by opsonization with plasma samples of individuals from Junju sub-location, 
diluted 1:12.5, for 30 minutes at room temperature and washed thrice with the wash 
buffer. After the secondary antibody staining with mouse anti-human allophycocyanin 
(APC) conjugated IgG (diluted 1:50) and washing, the cells were fixed in 0.5% 
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paraformaldehyde (PFA) on ice for 20 minutes and washed twice with the wash buffer. 
The cells were then resuspended in 200 µl of the wash buffer. Fluorescence was 
measured with a FACSCanto II flow cytometer fitted with 488 nm and 640 nm solid 
state lasers and analysed using FlowJo software, version 10. The erythrocytes were 
selected according to the forward and side scatter properties using erythrocytes alone 
as a control. The uninfected erythrocytes (uEs), rIEs and mIEs were easily and clearly 
distinguished since they displayed different SYBR Green fluorescent intensities on 
fluorescence dotplots. The erythrocyte bound by antibody from the three different 
erythrocytes population were defined by a region set for red APC fluorescence. The 
sample acquisition was set to stop when at least 2,000 events of antibody bound rIEs 
were collected for each plasma sample. 
For the detection of antibody binding by immunofluorescence; 100 µl of packed ring 
infected erythrocyte cells were suspended in fixation buffer (10 volumes of the cell 
pellet) and incubated with light shaking at 37°C for 30 minutes. The fixation solution 
was replaced by 1 ml quenching buffer and incubated at room temperature for 15 
minutes. They were then incubated with a pool of hyper immune plasma from malaria-
immune adults and plasma samples from malaria-naïve individuals, diluted 1:1000, 
overnight at 4°C. The cells were washed and incubated with mouse anti-human IgG 
Alexa Fluor 647-conjugated antibody and mouse anti-human CD235a (Glychophorin 
A) fluorescein Isothiocyanate (FITC) conjugated monoclonal antibody, diluted 1:500, 
for 1 hour at room temperature. Glychophorin A is a sialoglycoprotein present in the 
cell membrane of erythrocytes. 
The cells were finally washed two times with wash buffer and finally with buffer 
containing 1 µg/ml Hoechst dye and mounted on concavalin A coated slides. 
Concavalin A is a carbohydrate binding protein, lectin, and thus the glycophorin on the 
erythrocyte membrane would bind and ensure that a monolayer of erythrocytes forms 
on the slides for optimal microscopic visualization. Pictures were acquired on 
PerkinElmer UltraVIEW VoX spinning disc confocal with Nikon TiE using a 
Hamamatsu Ocra Flash 4 camera controlled by Volocity software. Images were 
visualised with 60X oil-immersion objective lens and processed using the FIJI open-
source software.  
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3.5.3. Merozoite based Enzyme-Linked Immunosorbent Assay (ELISA) 
To measure the anti-P. falciparum antibody titre of the 37 individuals from Junju sub-
location: 100 µl of 5.0 X 106 merozoites/ml P. falciparum NF54 isolate were coated 
per well and incubated overnight at 4°C. After washing, the 96 well plates were blocked 
with casein for 2 hours at 37°C, followed by incubation of each well with 100 µl of 
plasma samples of the individuals, diluted 1:500, for 2 hours at 37°C. A pool of 
hyperimmune plasma from malaria-immune adults and plasma samples from malaria-
naïve individuals were included in each plate as positive and negative controls 
respectively. The plates were washed, and each well was incubated with 100 µl 
horseradish peroxidase (HRP) conjugated goat anti-human IgG antibody, diluted 
1:2500, for 1 hour at 37°C. After washing, each well was incubated with 100 µl of O- 
phenylenediamine dihydrochloride (OPD) substrate for 30 minutes at room 
temperature. The OPD is a water-soluble chromogenic substrate that yields a yellow 
colour during degradation of hydrogen peroxide by HRP enzyme. 30 µl of 1M 
hydrochloric acid (HCl) was added to each well to stop the reaction and produced a 
very stable orange end solution whose absorbance was read at 490nm using the 
CYTATION|3 imaging reader and analysed using the Gen5 v3.02 software. 
 
3.5.4. In-vitro Ring-stage Survival Assay RSA0-3h 
The P. falciparum FCR3 isolate was cultured and synchronised as explained in section 
3.5.1. Ring stage parasite cultures (0-3 hours synchronization window) of 0.5-1% 
parasitemia and 2% hematocrit were used in the experiments. A pool of hyperimmune 
plasma from malaria-immune adults, purified immunoglobulin G (MIG) from malaria-
immune adults, and plasma from malaria-naïve and 3 randomly selected malaria 
exposed individuals from Junju sub-location were used in the experiment. For the ring-
stage survival assay: 5 µl of dialysed only or dialysed plus heat-inactivated plasma 
sample was added to each well, containing 45 µl of ring stage parasite culture. Dialysis 
and heat-inactivation was aimed to free the plasma from drugs and complement 
components respectively. A concentration of 700 nM Dihydroartemisinin (DHA) and 
1% dimethyl sulfoxide (DMSO) were included in each plate as a positive and negative 
control respectively. The plates were incubated at standard culture conditions as 
described in section 3.5.1 for exactly 6 hours. After thorough washing and removal of 
the treatments, the cells were transferred to new 96 well plates and maintained in 
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culture for exactly 66 hours, followed by staining with 1X SG / 0.6 µM MitoTracker 
(MT) deep red for 30 minutes at 37°C. The SG fluoresces upon intercalation of double-
stranded deoxyribonucleic acid (DNA) whereas MT stains live mitochondria. Human 
erythrocytes contain neither nuclei nor mitochondria and thus the SG and MT dyes are 
specific for the parasites. The cells were washed and then resuspended in 200 µl of 
the wash buffer. Parasitemia was counted by measuring fluorescence with a 
FACSCanto II flow cytometer, counted 20,000 events of infected erythrocytes, and the 
flow cytometry data was analysed using FlowJo version 10 software. 
 
Figure 3. 2: Procedure of in-vitro RSA0-3h assay. The P. falciparum-FCR3 strain (0-3 hours and 0.5-
1% parasitemia) was co-cultured with dialysed plasma samples for 6 hours and then washed and 
transferred to a new 96 well plate for 66 hours. The parasitemia level and viability was detected and 
quantified by flow cytometry. 
 
3.5.5. Artificial splenic assay (Microsphiltration) 
Calibrated metal microbeads; 96.5% tin, 3.0% silver and 0.5% copper, with 5-15 µm 
and 15-25 µm diameter dimensions were used in the experiment. For the artificial 
splenic assay: 600 µl of the bead suspension, composed of 2 g of dry microbeads of 
each sort suspended in 8 ml complete culture medium, was poured into an inverted 1 
ml filtered pipette tip and allowed to settle forming a 5-6 mm thick sphere layer above 
the filter. After introducing 600 µl of rIEs culture (2% hematocrit and less than 10% 
parasitemia) upstream from the microbead layer, the cells were perfused through the 
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bead layer at 60 ml/h flow rate using an electric pump. The bead layer was washed 
with 6 ml of complete media and the downstream sample for each isolate was 
retrieved. To obtain the retained IEs: the inverted filter tip was vortexed to allow the 
beads to release the retained cells which were separated by 3 successive settling 
steps. Schizont infected erythrocytes and fresh uEs were used as positive and 
negative control respectively. Thin giemsa-stained smears were used to observe the 
retained rIEs. The cells in the upstream and downstream were stained with 1X SG for 
30 minutes at 37°C in order to measure the parasitemia using flow cytometry, and 
consequently determine the splenic retention rates. To determine the background 
retention, the amount of uninfected erythrocyte from the upstream and downstream 
samples were detected by haemoglobin count whose absorbance was read at 540nm 
using the CYTATION|3 imaging reader and analysed using the Gen5 v3.02 software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 3: Procedure of microsphiltration assay. (A) The test culture was injected as upstream 
sample into an inverted 1 ml filtered pipette tip containing 5-6 mm thick micro spherical bead layer 
above the filter (B). The less deformed erythrocytes were retained within the layer and the more 
deformable pass through the layer and collected in the conical flask (C) as downstream sample. Figure 
modified from Deplaine et al., 2011. 
 
3.6. Statistical analysis 
All analysis was done using GraphPad PRISM (version 7.0). The Kruskal-Wallis H test 
was used to analyse the trend between antibody responses and different plasma 
samples. The Mann-Whitney U test was used to compare; the percentage of antibody 
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binding to IEs between the malaria-immune and malaria-naïve categories using 
different parasite isolates, and the antibody responses to merozoites between the 
malaria-immune and malaria-naïve categories. The Spearman’s rank correlation 
coefficient test was used to measure the linear relation between; antibody binding to 
rIEs and antibody responses to merozoites, and antibody binding to rIEs and antibody 
binding to mIEs. The Student’s t-test was used to determine whether they were any 
statistically significant difference between effect of malaria exposed and malaria-naïve 
plasma on ring survival, and splenic retention of lab and field rIEs isolates.  
 
3.7. Ethics statement  
Ethical approval has been granted by the institutional research ethics committee, 
Kenya Medical Research Institute Scientific and Ethics Review Unit (KEMRI/SERU/ 
CGMR-C/029/3190) and by the sponsor of the study (University of Oxford) through 
the Oxford Tropical Research Ethics Committee (OxTREC, 2–16). Informed consent 
was obtained from participants. It was also approved for the samples to be used in 
Germany. 
 
3.8. Results 
3.8.1. Detection of antibody binding to ring-infected erythrocytes (rIEs) 
The ability of antibodies of malaria-immune plasma to bind to rIEs was detected by 
use of immunofluorescence microscopy and flow cytometry assays as described in 
the methods above. To ensure that the detection of antibody binding was indeed on 
the surface of the rIEs, the periphery of the erythrocyte was localized using the major 
intrinsic membrane protein of the erythrocyte: Glychophorin A, using a FITC-
conjugated anti-Glycophorin A antibody. The detection of antibody binding to mIEs 
using malaria-immune plasma was used as a positive control, whereas the detection 
of antibody binding to rIEs using secondary antibody (2°Ab) only in the absence of 
malaria-immune plasma was considered as a negative control for validation of the 
assay. 
There was no visual detection of antibody binding to rIEs following opsonization with 
malaria-naïve plasma and in the negative control, 2°Ab only. However, we observed 
a low and modest level of antibody binding to rIEs and mIEs respectively, in the 
presence of malaria-immune plasma (Figure 3.4-A). Similarly, a negligible proportion 
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of rIEs were recognised by antibody when tested using malaria-naïve plasma and with 
the negative control. However, we observed a low and moderate percentage of rIEs 
and mIEs respectively that were recognised by antibody when using malaria-immune 
plasma (Figure 3.4-B). The antibody in the test plasma bound to the rIEs and mIEs in 
a dose dependent manner (Appendix 3.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 4: Images showing detection of antibody binding to ring-infected erythrocytes. A) 
Immunofluorescent assay images show no or low detection of antibody binding to rIEs in the presence 
of malaria-naïve immune plasma and malaria-immune plasma respectively, modest detection of 
antibody binding to mIEs in the presence of malaria-immune plasma as a positive control, and no 
detection of antibody binding with 2°Ab only in absence of immune plasma as a negative control for the 
assay validation. B) Flow cytometry scatterplots show negligible and low levels of antibody binding to 
rIEs when using malaria-naïve and malaria-immune plasma respectively, moderate antibody binding to 
mIEs with malaria-immune plasma and negligible antibody binding to rIEs in case of 2°Ab only in 
absence of immune plasma as a negative control for the assay validation.  
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3.8.2. Correlation of antibody binding to ring-infected erythrocytes to antibody 
responses to other asexual blood stages 
Malaria-immune plasma samples of adults from a malaria endemic area, Junju sub-
location in Kilifi, Kenya, were used to assess how the antibodies in individual test 
samples would bind to rIEs, and also this would correlate to antibody binding to mIEs 
and antibody responses to merozoites. Detection of antibody binding to IEs was 
conducted using FCR3-lab strain (known to have high binding phenotype) and a lab 
adapted field strain obtained from Kilifi Kenya and required a consistent flow cytometry 
gating strategy (Appendix 3.1). Antibody response to merozoites was measured using 
the NF54 lab strain which was conveniently available in the laboratory. 
Antibody binding of all the Junju adult plasma samples to lab and field rIEs isolates 
was significantly higher (P<0.0001) compared to that using malaria-naïve plasma 
(Figure 3.5-A & Figure 3.6-A respectively). Similar findings were observed when these 
data were categorized based on top and average response to merozoites (Figure 3.5-
B & Figure 3.6-B respectively). It is important to note that detection of secondary 
antibody binding in absence of plasma was negligible and thus a good control to 
ensure that the signal to noise ratio is indeed high and thus the detection of antibody 
binding is specific to the test plasma. Antibody binding to lab rIEs and mIEs showed a 
strong positive correlation of r=0.7581; P<0.0001 (Figure 3.5-C), while the correlation 
was positive but lower between antibody binding to field rIEs and mIEs r=0.5232; 
P=0.0009 (Figure 3.6-C). Similarly, antibody responses to merozoites showed a strong 
positive correlation of r=0.8462; P<0.0001 and r=0.6902 P<0.0001 with antibody 
binding to lab (Figure 3.5-D) and field (Figure 3.6-D) rIEs respectively.  
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Figure 3. 5: Antibody binding to FCR3-lab isolate ring-infected erythrocytes. A) Detection of 
antibody binding using all Junju adult’s plasma was significantly higher (P<0.0001, Mann Whitney test) 
compared to malaria-naïve plasma, and detection of secondary antibody binding in absence of plasma 
was negligible indicating a high signal to noise ratio. B) Detection of antibody binding focussing on the 
different categories of the Junju adults based on the antibody response to merozoites was significantly 
higher compared to malaria-naïve plasma (P<0.0001, Kruskal-Wallis test), specifically; the top and 
average responders (P<0.0001 and P=0.0057 respectively, Dunn’s multiple comparison test). C) 
Antibody binding to rIEs showed a strong positive correlation (spearman r=0.7581; P<0.0001), with 
antibody binding to mIEs, and D) antibody binding to rIEs showed a strong positive correlation 
(spearman r=0.8462; P<0.0001), with antibody response to NF54 merozoites. The positive control was 
a pool of hyper immune plasma samples of Junju adults from Kilifi Kenya. The dotted horizontal line in 
graphs A and B is the seropositivity mark = {mean of the antibody binding to rIEs using naïve plasma + 
3(STDEV)}. Statistics was calculated using GraphPad PRISM version 7.0. 
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Figure 3. 6: Antibody binding to field isolate ring-infected erythrocytes obtained from Kilifi. A) 
Detection of antibody binding using all Junju adult’s plasma was significantly higher (P<0.0001, Mann 
Whitney test) compared to malaria-naïve plasma, and detection of secondary antibody binding in 
absence of plasma was negligible indicating a high signal to noise ratio. B) Detection of antibody binding 
focussing on the different categories of the Junju adults based on the antibody response to merozoites 
was significantly higher compared to malaria-naïve plasma (P<0.0001, Kruskal-Wallis test), specifically; 
the top and average responders (P=0.0005 and P=0.0025 respectively, Dunn’s multiple comparison 
test). C) Antibody binding to rIEs showed a strong positive correlation (spearman r=0.5232; P=0.0009), 
with antibody binding to mIEs and D) antibody binding to rIEs showed a strong positive correlation 
(spearman r=0.6902; P<0.0001), with antibody response to NF54 merozoites. The positive control was 
a pool of hyper immune plasma samples of Junju adults from Kilifi Kenya. The dotted horizontal line in 
graphs A and B is the seropositivity mark = {mean of the antibody binding to rIEs using naïve plasma + 
3(STDEV)}. Statistics was calculated using GraphPad PRISM version 7.0.  
 
The percentage of antibody binding to field rIEs as compared to lab rIEs was 
significantly higher for all Junju adults, average and bottom responders (P<0.0001, 
P<0.0001 and P=0.0012 respectively), (Figure 3.7-A). However, there was no 
significant difference between antibody binding to field and lab rIEs when considering 
the top responder’s category. In general, antibody binding to field and lab rIEs showed 
a strong positive correlation, r=0.8396; P<0.0001 (Figure 3.7-B). 
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Figure 3. 7: Comparison of antibody binding between laboratory and field isolate ring-infected 
erythrocytes. A) The percentage of antibody binding to field rIEs was significantly higher focussing for 
all Junju adults, average and bottom responders (P<0.0001, P<0.0001 and P=0.012 respectively, Mann 
Whitney test) as compared to antibody binding to lab rIEs. B) Antibody binding to field rIEs showed a 
strong positive correlation (spearman r=0.8396; P<0.0001), with antibody binding to lab rIEs. Statistics 
was calculated using GraphPad PRISM version 7.0.  
 
3.8.3. Effect of malaria-immune plasma on ring survival using 
Dihydroartemisinin (DHA) 
The relevant controls for the ring survival assay were important to obtain for 
meaningful data interpretation. The percentage survival of parasites after exposure to 
DHA drug was calculated relative to the DMSO exposed parasites {percentage 
survival = (% viable after DHA exposure/%viable after DMSO exposure) x 100}. The 
percentage ring survival after exposure to DHA was 3.27% (Figure 3.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 8: Flow cytometry scatterplots of (A) DHA - and (B) DMSO - exposed P. falciparum 
FCR3 parasites. The percentage of viable and pyknotic parasites in 10,000 events is shown in the 
upper right and upper left quadrant respectively. The percentage ring survival in this case is 
0.091%/2.13% multiplied by 100 = 4.27%. 
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Exposure of rIEs to dialysed only or dialysed plus heat-inactivated plasma enhanced 
parasite growth in a similar manner, unlike exposure to DHA which inhibited parasite 
growth (Appendix 3.7). Dialysis and heat-inactivation was aimed to free the plasma 
from drugs and complement components respectively. The percentage survival of rIEs 
after exposure to plasma was calculated relative to the DMSO exposed parasites. The 
survival rate was comparable when rIEs were exposed to naïve plasma, a pool of 
hyperimmune serum, purified malaria immunoglobulins and plasma from randomly 
selected malaria-immune adults from Kilifi, Kenya (Figure 3.9 and Appendix 3.8). The 
parasite survival rates were similar when exposed to the dialysed only or dialysed and 
heat-inactivated state of each of the test plasma (Appendix 3.9). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 9: Effect of dialysed immune plasma on ring survival. Percentage survival of rIEs when 
treated with dihydroartemisinin (DHA, positive control), naïve plasma (negative control), PHIS (pool of 
hyper immune plasma), MIG (purified malaria immunoglobulins) and randomly selected plasma of 
malaria-immune adults from Kilifi (JA031, JA137, JA155). The percentage survival rate was comparable 
when parasites were exposed to naïve plasma, pool of hyper immune serum, purified malaria 
immunoglobulins and plasma from randomly selected malaria-immune adults from Kilifi, Kenya, (P = 
0.1528, one-way ANOVA). n= 4 independent replicates. Statistics was calculated using GraphPad 
PRISM version 7.0. 
 
3.8.4. Splenic retention of ring-infected erythrocytes of lab and field isolates  
The micro beads retained the erythrocytes from the upstream sample that had reduced 
deformability, whereas the deformable erythrocytes were collected downstream. The 
parasitemia of the downstream and upstream samples was measured by flow 
cytometry and the obtained values were used to calculate the retention rates {retention 
rate = 1 – (parasitemia downstream/parasitemia upstream) x 100}. Retention in the 
DHA Naive PHIS MIG JA031 JA137 JA155 
0
20
40
60
80
100
120
Sample Treatments
Pe
rc
en
ta
ge
 S
ur
vi
va
l 
Dialysed Only 
ns
 90 
microbeads was complete at the (40-48) hrs in mIEs stages as expected for the 
positive control, and partial for the fresh uEs (negative control) which was lower than 
that of (0-10) hrs rIEs (Figure 3.10). However, there was no significant difference 
between the (0-10) hrs rIEs retention rates of field isolates adapted in culture and lab 
isolates (Figure 3.10). The erythrocytes retained within microbeads were retrieved by 
sedimentation, because the microbeads are denser, leaving the erythrocytes in 
suspension. The retained fraction was stained by Giemsa to visualise the retained rIEs 
(Figure 3.10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 10: Retention rate of mature-infected erythrocytes and ring-infected erythrocytes in an 
artificial spleen. Retention rate of 40-48 hrs mIEs (positive control), comparison between (0-10 hrs) 
rIEs retention of a lab and field isolate determined by flow cytometry, and retention of fresh uEs 
determined by haemoglobin count using spectrophotometry (negative control). There was no significant 
difference in the rIEs retention between the lab and field isolate (P= 0.1530, unpaired t-test), but there 
was a difference between background retention (fresh uEs) and retention of rIEs of the lab isolate 
(P=0.0469, unpaired t-test). Microscopic images depict Giemsa-stained smears of retained fractions 
showing rIEs of the lab and field isolate. n= 3 independent replicates. Statistics was calculated using 
GraphPad PRISM version 7.0. 
  
Lab
40-48hrs
Lab
0-10hrs
Field
0-10hrs
0
20
40
60
80
100
120
R
et
en
tio
n 
ra
te
 (%
)
THE ONE Splenic retention with correct parasitemia and young uEs 
hemoglobin coun
ns
Fresh uEs
Parasite Isolate
Lab isolate 
0-10hrs 
Field isolate 
0-10hrs 
Retained fraction smears 
 91 
3.9. Discussion 
Malaria-immune antibody binding to the surface of rIEs  
Antibody from a pool of hyperimmune plasma was detected on the surface of rIEs 
using immunofluorescence (Figure 3.4) and this confirmed previous findings which 
showed membrane staining of rIEs in in vitro cultures with P. falciparum hyperimmune 
sera (Perlmann et al., 1984) . This previous observation gave rise to the ‘pitting’ 
phenomenon, where immunostaining of peripheral blood smears revealed positive 
membrane staining of the circulating P. falciparum rIEs and uEs when tested with ring-
infected surface antigen (RESA) monoclonal antibody and pool of hyperimmune sera 
(Chotivanich et al., 2000, Perlmann et al., 1984). The positive staining of uEs for 
malaria antigens was suggested to be an indication of the pitted circulating rIEs and 
was used to explain the decline of circulating rIEs after treatment with artemisinin 
(White, 2017, Angus et al., 1997). This supports the idea that the detection of antibody 
binding using in vitro parasite cultures is physiologically relevant.  
The percentage of rIEs parasite cultures that were recognised by the malaria-immune 
plasma were quantified (±6%) and varied depending on the malaria specific antibody 
titres of the individuals. Individuals with high antibody responses to rIEs also showed 
high antibody responses to merozoites and mIEs (Figure 3.5 and Figure 3.6 
respectively). Despite of the low level of antibody binding to rIEs in both lab and field 
parasite cultures, the strong positive correlation to antibody response to merozoites 
and mIEs suggests possibility of shared targets between these stages and may 
suggest a modest contribution to protective immunity against P. falciparum malaria. 
Individuals with very low anti-merozoite titres had rIEs antibody binding detection 
similar to the naïve individuals, and this confirms previous observation: sera with low 
ELISA reactivity to total P. falciparum antigens displayed negative membrane staining 
of peripheral blood smears (Perlmann et al., 1984). These individuals may have lacked 
repeated or prolonged exposure to P. falciparum which is a prerequisite for high 
antibody titres against the parasite. 
Effect of malaria-immune antibodies on survival of rIEs 
Antibodies against various essential merozoite surface proteins that are neither 
cleaved nor shed during invasion; MSP119, MSP2 and MSP4, have been shown to be 
internalized into the erythrocyte during invasion (Beeson et al., 2016, Boyle et al., 
2014). One important question is whether these malaria specific antibodies have a 
direct effect on the survival of the resultant rIEs after merozoite invasion. In this study, 
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antibodies obtained from malaria-immune plasma had a negligible effect on early rIEs 
(Figure 3.9; Appendix 3.7 and Appendix 3.8), as compared to treatment with 
dihydroartemisinin which is known to have a detrimental effect on rIEs survival in an 
in vitro ring survival assay (Witkowski et al., 2013). This suggests that direct inhibition 
of rIEs survival by antibodies may not be an important mechanism of parasite 
clearance. However, it is important to note that antibodies have been shown to inhibit 
parasite growth, particularly the development of mature forms, and the merozoite 
invasion of erythrocytes using the growth inhibition assay and invasion inhibition assay 
respectively (Teo et al., 2016). 
Splenic retention of rIEs parasite isolates 
Retention of rIEs was evident in the Giemsa-stained smears of the retained fraction 
(Figure 3.10), and the retention rates confirmed findings from previous studies which 
demonstrated that rIEs are retained in an artificial spleen albeit at a lower rate than 
mIEs (Deplaine et al., 2011). In addition, this study also showed that the retention of 
rIEs was comparable between the lab and field parasite isolates. The retention of rIEs 
could be explained by its reduced deformability and slight cell membrane stiffening 
(White, 2017, Nash et al., 1989). Other findings from ex vivo perfusion assays, showed 
that a fraction of rIEs was retained in isolated-perfused human spleens and 
accumulated upstream from interendothelial sinus wall slits of the open, slow red pulp 
microcirculation (Safeukui et al., 2008, Buffet et al., 2006). Moreover, pathology 
studies in fatal malaria demonstrated the accumulation of parasitized erythrocytes of 
all stages including the rIEs (White, 2017, Prommano et al., 2005). The observed 
artificial splenic retention of rIEs in vitro may have a physiological relevance by 
contributing to parasite clearance and thus protective immunity as previously 
hypothesized (Buffet et al., 2006). Of note, the artificial splenic assay in this study was 
conducted without antibodies, which may further enhance splenic clearance as 
demonstrated by Lee et al., 1989, where IgG sensitized infected erythrocytes were 
rapidly removed from circulation in patients with uncomplicated P. falciparum malaria. 
The clearance of IgG labelled rIEs could be facilitated by interaction with other cell 
types such as macrophages.  
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Summary 
I confirm that malaria-immune antibodies bound to rIEs surface and show that the 
binding was strongly correlated with antibody response to merozoites and mIEs. I also 
show that recognition of rIEs by antibodies did not lead to direct inhibition of rIEs 
survival. I also confirm that rIEs were retained in an artificial spleen, and that the 
retention was comparable between lab and field isolates. My work confirms and 
extends previous publication reports and in chapter 4, I investigate the significance of 
antibody binding to rIEs on the outcome of P. falciparum infection. 
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Chapter 4 
The physiological relevance of the immunogenicity of the ring-infected 
erythrocyte 
 
4.1. Introduction 
In malaria endemic populations, young children have the highest risk of severe 
disease and death (Cowman et al., 2016). Although morbidity and mortality rapidly 
decrease with age, individuals remain susceptible to uncomplicated malaria as they 
get older and to asymptomatic infections in adulthood without achieving sterilizing 
immunity (Langhorne et al., 2008). In endemic areas, immunity to malaria is reflected 
both by a lower prevalence of infection with age and lower rates of disease (Marsh 
and Kinyanjui, 2006). Immunity to malaria has been defined as either natural which is 
the hosts’ inherent property or acquired which could be as a result of previous 
exposure or passive transfer of protective substances to the host (Doolan et al., 2009). 
Long-standing evidence suggests that natural acquired immunity to P. falciparum 
malaria is largely mediated by immunoglobulin G (IgG) (Sabchareon et al., 1991, 
Cohen et al., 1961). 
Naturally acquired and vaccine-induced functional antibodies targeting various 
antigens of the P. falciparum asexual blood stages have been associated with 
protection from clinical symptoms and protective immunity respectively (Teo et al., 
2016). For example: 1) anti-merozoite surface protein 119 (MSP119) antibodies 
inhibited merozoite invasion in an invasion inhibition assay (O'Donnell et al., 2001); 2) 
antibodies against merozoite proteins: erythrocyte binding antigens (Chitnis et al., 
2015, Irani et al., 2015), apical membrane antigen 1 (AMA1) (Mugyenyi et al., 2013, 
Remarque et al., 2012) and rhoptry binding homologue (Tran et al., 2014, Richards et 
al., 2013) prevented parasite growth in growth-inhibition assays; 3) cytophilic 
antibodies against merozoite surface protein 2 (MSP2) fixed C1q component in a 
complement fixation assay (Boyle et al., 2015); 4) merozoite opsonising antibodies 
targeting merozoite surface proteins interacted with phagocytic cells (Osier et al., 
2014); 5) anti-merozoite surface protein 5 (MSP5) antibodies interacted with 
neutrophils in an antibody dependant respiratory burst assay (Perraut et al., 2014); 
and 6) antibodies targeting mIEs prevented cytoadherence (Turner et al., 2015, Fried 
et al., 1998), inhibited rosette formation (Carlson et al., 1990), and arrested schizont 
rupture (Raj et al., 2014). On the contrary, antibodies targeting rIEs have been shown 
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to mediate opsonic phagocytosis of rIEs (Chan et al., 2012, Awah et al., 2011, Awah 
et al., 2009, Celada et al., 1982) but this has not been explored in the context of 
possible parasite clearance and correlation with protective immunity. I therefore 
sought to uncover the physiological relevance of opsonic phagocytosis of rIEs on 
outcome of P. falciparum malaria infection. 
 
4.2. Rationale 
In this chapter, I investigated whether the antibody binding to rIEs demonstrated in 
chapter 3 was likely to be physiologically relevant in P. falciparum malaria infections. 
I employed the opsonic phagocytosis assay (OPA) of rIEs and plasma samples from 
individuals in a controlled malaria infection (CHMI) study in order to investigate 
whether in vitro OPA of rIEs could predict outcome of malaria challenge in the clinical 
study. The CHMI study site was in Kenya, specifically Kilifi and Nairobi where malaria 
transmission is moderate and low respectively. The study was conducted over several 
years (2013, 2016, 2017 and 2018), and involved a total of 189 adults. At screening, 
participants were included if they were malaria parasite negative, not pregnant, free of 
immunosuppressive infections, did not have genetic diseases associated with malaria 
resistance and had not taken systemic antibiotics with known antimalarial activity. In 
the study design (Figure 4.1), the participants were challenged intravenously by 
administration of 3,200 sporozoites of NF54 strain obtained from Sanaria (Inc). The 
samples used for my study were those collected one day before challenge. The 
parasitemia was monitored by quantitative Polymerase Chain Reaction (qPCR) twice 
daily, and individuals who had more than 500parasites/µl and/or symptoms of malaria 
were treated. The symptoms included fever above 37°C, hypotension, tachycardia, 
chills, rigor, sweating, headache, nausea, vomiting, fatigue, lower back pain, myalgia 
and arthralgia. Eventually after the end of the study, 21 days post challenge, all the 
participants were treated (Kapulu et al., 2018).  
Several outcomes of the malaria challenge emerged from the analysis of the qPCR 
parasitemia data and symptoms obtained during the study period. These were defined 
as follows: 1) treated - 81 individuals who had more than 500 parasites/µl and /or 
symptoms, 2) slow growth - 51 individuals who had patent parasitemia but less than 
500 parasites/µl, 3) cleared - 18 individuals who had patent parasitemia that 
spontaneously resolved by day 10 and 4) high immune - 39 individuals who did not 
develop parasitemia during the entire follow up period (Figure 4.2). 
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Figure 4. 1: Overview of the Controlled Human Malaria Infection challenge procedure. The CHMI 
study was conducted in Kenya in 2013, 2016, 2017 and 2018, and involved 189 individuals who met 
the inclusion criteria: malaria parasite negative, nonpregnant, and free of immunosuppressive 
infections, genetic diseases that cause malaria resistance and systemic antibiotics of antimalarial 
activity. The participants were challenged intravenously by 3200 sterile sporozoites and were followed 
up for parasitemia monitoring by qPCR twice daily, and those with 500 parasites/µl and/or symptoms 
(>37°C, hypotension, tachycardia, chills, rigor, sweating, headache, nausea, vomiting, fatigue, lower 
back pain, myalgia and arthralgia) were treated. All individuals were treated at the end of the study. 
Blood samples collected one day before challenge were used for functional studies in our laboratory. 
 
Figure 4. 2: Categories of the Controlled Human Malaria Infection study individuals based on 
parasitemia patterns during the study. Treated - 81 individuals who had >500 parasites/µl and /or 
symptoms, slow growth - 51 individuals who had recurrent parasitemia but <500 parasites/µl, cleared - 
18 individuals who were cleared parasites by day 10, and high immune - 39 individuals who parasite 
negative during the entire follow up period. 
 
Opsonic phagocytosis assay (OPA) 
Non-opsonic and opsonic phagocytosis of infected erythrocytes has been successfully 
conducted using human/murine monocytes-derived macrophages (Ayi et al., 2005) 
and human monocytic THP-1 cell line (Chan et al., 2012) respectively. I established 
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the OPA of rIEs using the THP-1 cell line in our lab in order to investigate whether the 
opsonization of rIEs with the CHMI plasma samples could lead to phagocytosis.  
Antigen based Enzyme-Linked Immunosorbent Assay (ELISA) 
The CHMI plasma samples were pre-incubated with known recombinant merozoite 
antigens, and then used to compare the effect of the merozoite specific antibody 
depletion to the opsonic phagocytosis of ring culture cells. The demonstration of the 
depletion of antigen specific antibodies was detected by ELISA, where antibody 
responses to the various antigens were analysed. This was important in order to 
ensure that the effect of using plasma samples pre-incubated with the recombinant 
antigens in opsonic phagocytosis of ring culture cells could indeed be linked to the 
depletion of the merozoite specific antibodies. 
Competition phagocytosis assay 
The comparison of opsonic phagocytosis of ring culture cells between non competed 
and competed plasma samples was important in order to find out the origin of the 
antigens responsible for opsonic phagocytosis of the ring culture cells. The merozoite 
was considered a possible source of the parasite proteins on the ring culture cells 
because it sheds and secrets various proteins during invasion into the erythrocyte. 
Some merozoite proteins have been suggested to be transferred to the surface of rIEs 
and uEs during invasion, for example ring surface protein 2/ rhoptry associated protein 
2 (RSP2/RAP2) as demonstrated by Douki et al., 2003. 
 
4.3. Overall objective 
To investigate the physiological relevance of the immunogenicity of P. falciparum rIEs. 
 
4.4. Specific objectives 
• To investigate whether the observed antibody binding to rIEs mediated opsonic 
phagocytosis by THP-1 cells. 
• To find out whether opsonic phagocytosis of rIEs predicted the outcome of 
infection in a CHMI study. 
• To find out the source of the antigens responsible for opsonic phagocytosis of 
the ring culture cells.  
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4.5. Laboratory methods 
4.5.1. P. falciparum culture and synchronization 
The P. falciparum NF54 laboratory isolate was used for the functional assay because 
it was the same strain that was intravenously challenged to the individuals who took 
part in the CHMI study. The parasites were cultured and synchronized as explained in 
chapter 3 (section 3.5.1), in order to obtain a final ring stage parasite culture (0-10 
hours synchronization window) of at least 10% parasitemia. 
 
4.5.2. THP-1 culture 
THP-1 is a human leukaemia cell line (cultured from the blood of a one-year old boy 
who had acute monocytic leukaemia) with Fc receptors and thus has the ability of 
phagocytose opsonized particles. The non-adherent THP-1 human monocyte cell line 
was maintained in vitro in 150 ml culture flasks with THP-1 culture media, which 
consists of RPMI 1640 media supplemented with 2 mM L-Glutamine, 10 mM HEPES, 
10% (v/v) fetal bovine serum and 1% pen strep (10,000 units/ml penicillin and 10,000 
µg/ml streptomycin). The culture was kept in a humidified 37°C incubator which was 
gassed with 5% (v/v) C02 and 95% (v/v) air. The cells were counted by a 
haemocytometer in order to maintain a cell density of between 1 X 105 cells/ml to 1 X 
106 cells/ml. 
 
4.5.3. Opsonic phagocytosis assay (OPA) 
The ring stage parasite cultures of at least 10% parasitemia were used in the 
experiment. For phagocytosis experiments, the ring stage culture was centrifuged at 
800g for 4 minutes, and the pellet was resuspended in 1X Potassium Buffered Saline 
(PBS) containing 5 µg/ml Dihydro ethidium (DHE) and 2 µM Cell TraceTM Violet for 20 
minutes at 37°C. The DHE is a reduced form of ethidium bromide (EtBr) which is 
dehydrogenated inside the cell to form the ethidium cation that intercalates into the 
DNA, whereas Cell TraceTM Violet is cleaved by intracellular esterases resulting to a 
highly fluorescent compound that stains the cell cytoplasm. The dual labelling was 
used to distinguish between uEs and rIEs in the ring culture, which stained positive for 
the Cell TraceTM Violet only and both dyes respectively. The dual labelled parasites 
were opsonised with heat inactivated (incubated at 56°C for 30 minutes) plasma 
samples of the individuals from the CHMI study, diluted 1:12.5, for 30 minutes at room 
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temperature, and washed twice with wash buffer. A pool of heat inactivated 
hyperimmune plasma from malaria-immune adults and heat inactivated plasma 
samples from malaria-naïve individuals were included in each plate as positive and 
negative controls respectively. The opsonised, dual labelled ring culture (4.0 X 106 
cells) was added to wells containing 150 µl of 2.0 X 106 THP-1 cells and incubated for 
4 hours at 37°C in 5% (v/v) CO2 and 95% (v/v) air. The THP-1 monocytes (effector) to 
erythrocytes (target) ratio was 1E:200T. The cells were centrifuged at 500g for 4 hours 
at 4°C to stop the phagocytosis reaction and resuspended in 200 µl of red cell lysis 
buffer at 37°C for 8 minutes with frequent agitation to lyse the un-phagocytosed 
erythrocytes before being washed twice with THP-1 culture media. The cells were then 
fixed in 1X Paraformaldehyde (PFA) at room temperature for 30 minutes and finally 
resuspended in 200 µl wash buffer for flow cytometric analysis. Fluorescence was 
measured using FACSCanto II fitted with 405 nm and 488 nm solid state lasers, and 
analysed using FlowJo software, version 10. The THP-1 cells alone were used as a 
control to select the THP-1 population using the forward and side scatter properties. 
The gated events were displayed on violet versus red fluorescence dotplots, where 
the THP-1 containing phagocytosed uEs erythrocytes (positively labelled with Cell 
TraceTM Violet) were defined in a region gated for violet fluorescence and those THP-
1 containing phagocytosed rIEs (positively labelled with both Cell TraceTM Violet and 
DHE) were defined by a region gated for double positive violet and red fluorescence. 
The sample acquisition was set to stop when at least 2,000 events of the THP-1 
containing phagocytosed rIEs was collected for each sample. 
In experiments to validate the successful establishment of the assay in our lab and 
investigate whether antibody binding to rIEs mediates opsonic phagocytosis of rIEs, 
THP-1 monocytes were incubated with dual labelled; fresh uEs cultured in fresh 
media, fresh uEs cultured in used media (centrifuged at 4000 g for 15 minutes) and 
ring culture under the following conditions. To increase phagocytosis, labelled 
erythrocytes were opsonised with heat-inactivated hyperimmune plasma (malaria-
immune adults from Kilifi, Kenya) for 30 minutes at room temperature and washed 
twice before phagocytosis. As a control, labelled erythrocytes were opsonised with 
heat-inactivated plasma from malaria-naïve individuals in a similar manner, and also 
non opsonised erythrocytes were employed. To inhibit phagocytosis, THP-1 
monocytes were pre-incubated with 5 µM cytochalasin D for at least 1 hour at 37°C 
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before the addition of the labelled erythrocytes. Cytochalasin D is an actin polymerase 
inhibitor which would prevent the monocytes from phagocytosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 3: Procedure of opsonic phagocytosis of ring-infected erythrocytes assay. Ring culture 
of 15% ring-infected erythrocytes was dual stained with DHE - DNA stain and Cell Trace - erythrocyte 
cytoplasmic dye and opsonised with heat-inactivated plasma samples for 30 minutes before exposure 
to THP-1 monocytes for 4 hours. The phagocytosis read-out was obtained by flow cytometry which 
differentially detected and quantified the percentage of THP-1 cells that phagocytised uEs and rIEs 
because they stained positive for Cell Trace positive only and DHE and Cell Trace dual positive 
respectively. E: T refers to the effector (THP1 monocytes) to target (erythrocytes) ratio. 
 
4.5.4. Depletion of merozoite specific antibodies  
We randomly selected six CHMI study individuals who had varied antibody responses 
to merozoites: 1) those with high (18A0012 and 16K0036 with optical densities (ODs) 
of 2.925 and 2.081, respectively), 2) those with medium (17K0005 and 17K0028, ODs 
1.831 and 1.333, respectively), and 3) those with low (17K0074 and 17K0084, ODs 
0.802 and 0.557, respectively). Each of these randomly selected plasma samples 
were incubated overnight at 4°C with 100 µg/ml (the concentration was previously 
optimised in our lab) of recombinant merozoite antigens. The antigens used were 
Merozoite Surface Protein 1 (MSP1), Merozoite Surface Protein 2 (MSP2), Merozoite 
Surface Protein 3 (MSP3), Erythrocyte Binding Antigen-175 (EBA-175) and Apical 
Membrane Antigen 1 (AMA1). We used these antigens because they were available 
in our laboratory at the time and are also known potential malaria vaccine candidates. 
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4.5.5. Antigen based Enzyme-Linked Immunosorbent Assay (ELISA)  
To investigate the depletion of anti-merozoite specific antibodies from the randomly 
selected plasma samples of the CHMI study individuals: each recombinant merozoite 
antigen was coated per well at previously optimized coating concentrations: MSP1, 
MSP2, MSP3, EBA-175 and AMA1 were coated at 19.2 µg/ml, 0.5 µg/ml, 0.5 µg/ml, 
10 µg/ml and 0.5 µg/ml respectively, and incubated overnight at 4°C. After washing, 
the 96 well plates were blocked with 1% skimmed milk for 5 hours at room 
temperature, followed by incubation of each well with 100 µl of plasma samples of the 
randomly selected CHMI study individuals, diluted 1:100, overnight at 4°C. Each 
recombinant protein was tested for each individual sample before and after 
competition in order to access the difference between the antigen specific antibody 
responses in the two conditions. The plates were washed, and each well was 
incubated with 100 µl horseradish peroxidase (HRP) conjugated goat anti-human IgG 
antibody, diluted 1:5000, for 3 hours. After washing, each well was incubated with 100 
µl of O- phenylenediamine dihydrochloride (OPD) substrate for 30 minutes at room 
temperature. OPD is a water-soluble chromogenic substrate that yields a yellow colour 
during degradation of hydrogen peroxide by HRP enzyme. 30 µl of 1M hydrochloric 
acid (HCl) was added to each well to stop the reaction and produced a very stable 
orange end solution whose absorbance was read at 490nm using the using the 
CYTATION|3 imaging reader and analysed using the Gen 5 3.02 software. 
 
4.5.6. Competition phagocytosis assay 
The assay procedure was similar to the opsonic phagocytosis described in section 
4.5.3. Additionally, phagocytosis was compared between non competed and 
competed (preincubated with recombinant merozoite proteins) plasma samples in 
order to investigate the origin of parasite proteins on the ring culture cells that mediate 
the opsonic phagocytosis of rIEs and uEs in the ring culture. 
 
4.6. Statistical analysis 
All analysis was done using GraphPad PRISM (version 7.0). Kruskal-Wallis H test and 
Dunn’s Multiple Comparison post hoc test were used to analyse the statistical 
significance of differences in opsonic phagocytosis between the different groups of the 
CHMI study.  
 102 
4.7. Ethics 
Ethical approval has been granted by the institutional research ethics committee, 
Kenya Medical Research Institute Scientific and Ethics Review Unit (KEMRI/SERU/ 
CGMR-C/029/3190) and by the sponsor of the study (University of Oxford) through 
the Oxford Tropical Research Ethics Committee (OxTREC, 2–16). Informed consent 
was obtained from participants. It was also approved for the samples to be used in 
Germany. 
 
4.8. Results 
4.8.1. Establishment of the opsonic phagocytosis assay (OPA) of ring-infected 
erythrocytes in our lab 
To establish the OPA of rIEs assay in our laboratory, I tested hyperimmune plasma, 
naïve plasma, unopsonized and cytochalasin D treatment on using a set of different 
cultures conditions: uEs in fresh media, ring culture and uEs in used media. The 
proportion of THP-1 cells that phagocytosed uEs and rIEs were distinctly separated 
using a uniform flow cytometry gating strategy (Appendix 4.1) where the THP-1 
stained positive for only the CellTrace dye and dual positive for both CellTrace and 
DHE dye respectively. The effector to target ratio (E:T) which was the monocyte to 
erythrocyte ratio, and the phagocytosis duration were optimized in order to yield an 
optimal condition for our assays that allowed a good difference of phagocytosis 
between opsonization of culture with hyperimmune plasma and naïve plasma 
(Appendix 4.2). 
The validation of the successful establishment of the opsonic phagocytosis assay of 
rIEs in our lab was demonstrated by the percentage phagocytosis observed in the 
different culture conditions (Figure 4.4). In the culture of uEs in fresh media, the 
percentage of THP-1 cells that phagocytosed uEs was similar regardless of the 
different treatments, except for Cytochalasin D which was a negative control. In the 
ring culture (15% rIEs), the percentage of THP-1 cells that phagocytosed uEs and rIEs 
was higher especially after treatment with hyperimmune as compared to the naïve 
plasma and unopsonized conditions. However, the proportion of THP-1 cells that have 
phagocytosed uEs was higher compared to rIEs in all the treatment conditions. In the 
culture of uEs in used media (centrifuged at 4000 g for 15 minutes), the percentage of 
THP-1 cells that phagocytosed uEs was higher especially after treatment with 
hyperimmune as compared to the naïve plasma and unopsonized conditions.  
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Figure 4. 4: Establishment of opsonic phagocytosis assay in our laboratory. A) Flow scatter plots 
showing the proportion of THP-1 cells that have phagocytosed uEs (stained positive for CellTrace Violet 
dye only - top left quadrant) and THP-1 cells that have phagocytosed rIEs (stained positive for both 
CellTrace Violet and DHE dyes - top right quadrant) after treatment of the different cultures (uEs in fresh 
media, ring culture and uEs in used media) with either hyperimmune plasma, naïve plasma, 
unopsonized or Cytochalasin D. In the culture of uEs in fresh media, the percentage of THP-1 cells that 
phagocytosed uEs was similar regardless of the different treatments, except for Cytochalasin D which 
was a negative control. In the ring culture (15% rIEs), the percentage of THP-1 cells that phagocytosed 
uEs and rIEs was higher especially after treatment with hyperimmune as compared to the naïve plasma 
and unopsonized conditions. However, the proportion of THP-1 cells that phagocytosed uEs was higher 
as compared to rIEs in all the treatment conditions. In the culture of uEs in used media (centrifuged at 
4000 g for 15 minutes), the percentage of THP-1 cells that phagocytosed uEs was higher especially 
after treatment with hyperimmune as compared to the naïve plasma and unopsonized conditions. B) & 
C) graphical representation of the above flow scatterplots. B) The pattern of the percentage of THP-1 
cells that phagocytosed uEs in ring culture or in used media was similar. C) The percentage of THP-1 
cells that phagocytosed rIEs was higher after treatment with hyperimmune plasma.  
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4.8.2. Effect of opsonic phagocytosis of ring-infected erythrocytes on outcome 
of infection  
Plasma samples from 189 individuals in the CHMI study were used to assess how the 
antibodies in the different test plasma would mediate in vitro phagocytosis of rIEs and 
how the opsonic phagocytosis of rIEs would correlate to the outcome of the study; 
symptoms, parasite density pattern and treatment. Individuals who were non-
symptomatic had significantly higher (P<0.0001) phagocytosis of rIEs as compared to 
symptomatic individuals (Figure 4.5-A). Individuals whose parasite densities were 
>500 parasites/µl (treated category) had significantly lower opsonic phagocytosis of 
rIEs compared to individuals who had patent parasitemia although <500 parasites/µl 
(slow growth category), those who cleared the parasites by day 10 of the study 
(cleared category) and those who were parasite negative during the entire follow up 
period (highly immune category), P<0.0001, P<0.0001 and P=0.0004, respectively 
(Figure 4.5-B). Moreover, treated individuals who had high opsonic phagocytosis of 
rIEs were significantly fewer (P<0.0001) at any day beyond the tenth day post 
challenge compared to those with mid or low levels of opsonic phagocytosis of rIEs 
(Figure 4.5-C). 
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Figure 4. 5: Opsonic phagocytosis of ring-infected erythrocytes predicts outcome in a 
Controlled Human Malaria Infection (CHMI) study. A) Non-symptomatic individuals were shown to 
have significantly higher (P<0.0001, Mann Whitney test) phagocytosis of rIEs as compared to 
symptomatic individuals. B) Opsonic phagocytosis of rIEs was determined to be significantly lower in 
individuals who had >500 parasites/µl during the study as compared to those who had <500 parasites/µl 
(P<0.0001, Kruskal-Wallis test), specifically the slow growth category where the individuals had 
recurrent parasitemia although <500 parasites/µl, the cleared category where the individuals cleared 
the parasites by day 10 of the study and the high immune category where the individuals were parasite 
negative during the entire follow up period (P<0.0001, P<0.0001 and P=0.0004, Dunn’s multiple 
comparison test) respectively. C) Treated individuals who had high opsonic phagocytosis of rIEs were 
significantly fewer (P<0.0001, Mantel-Cox test) at any day beyond the tenth day post challenge as 
compared to those with mid or low levels of opsonic phagocytosis of rIEs. The dotted horizontal line in 
graphs A and B is the seropositivity mark = {mean of the phagocytosis of rIEs using naïve plasma + 
3(STDEV)} Statistics was calculated using GraphPad PRISM version 7.0.  
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Opsonic phagocytosis of rIEs showed a: 1) strong positive correlation of r=0.7796; 
P<0.0001 to IgG antibody response to merozoites, especially IgG1 and IgG3 
(r=0.7774; P<0.0001 and r=0.6267; P<0.0001) respectively, but 2) weak correlation to 
IgG2 and IgG4 (Spearman r=0.451; P<0.0001 and Spearman r=0.1767; P=0.0150) 
respectively (Figure 4.6). A similar pattern was observed between opsonic 
phagocytosis of uEs to antibody responses to merozoites (Appendix 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 6: Correlation of opsonic phagocytosis of ring-infected erythrocytes to antibody 
responses to merozoites. Opsonic phagocytosis of rIEs showed; a positive correlation (Spearman 
r=0.7796; P<0.0001) to IgG antibody responses to merozoites, especially IgG1 and IgG3 (Spearman 
r=0.7774; P<0.0001 and Spearman r=0.6267; P<0.0001) respectively, and a weak correlation to IgG2 
and IgG4 (Spearman r=0.451; P<0.0001 and Spearman r=0.1767; P=0.0150) respectively. Statistics 
was calculated using GraphPad PRISM version 7.0. 
 
Interestingly, individuals who were not treated had significantly (P<0.0001) high 
opsonic phagocytosis of uEs as compared to those who were treated (Figure 4.7-A) 
which is similar to that observed in regard to opsonic phagocytosis of rIEs. Generally, 
the opsonic phagocytosis of uEs was significantly higher (P<0.0001) compared to 
opsonic phagocytosis of rIEs between the treated and untreated groups (Figure 4.7-
B). Moreover, I also observed a strong positive correlation (Spearman r=0.6418; 
P<0.0001) between the relative phagocytosis index of uEs to relative phagocytosis 
index of rIEs (Figure 4.7-C). 
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Figure 4. 7: Comparison of opsonic phagocytosis of uninfected erythrocytes and opsonic 
phagocytosis of ring-infected using samples from the Controlled Human Malaria Infection study. 
A) Individuals who were not treated were shown to have a significantly high (P<0.0001, Mann Whitney 
test) opsonic phagocytosis of uEs compared to those who were treated, and this was similar in regard 
to opsonic phagocytosis of rIEs. B) Opsonic phagocytosis of uEs was determined to be significantly 
higher (P<0.0001, Mann Whitney test) compared to opsonic phagocytosis of rIEs in both the treated 
and untreated categories. C) Relative phagocytosis index of uEs showed a strong positive correlation 
(Spearman r=0.6418; P<0.0001) to relative phagocytosis index of rIEs. Statistics was calculated using 
GraphPad PRISM version 7.0. 
 
4.8.3. Origin of the antigens responsible for opsonic phagocytosis of the ring 
culture cells 
Plasma samples of six individuals from the CHMI study were randomly selected based 
on their antibody responses to merozoites (18A0012 & 16K0036 - high; 17K0005 & 
17K0028 - mid and 17K0074 & 17K0084 - low) for the competition opsonic 
phagocytosis assay. The selection of the merozoite recombinant antigens (CD4 
tagged) for competition was guided by their availability in our lab and their potential as 
vaccine candidates (MSP1, MSP2, MSP3, EBA175 and AMA1). Pre-incubation of the 
individual plasma samples with the respective recombinant antigens showed a 
reduction in antibody response to the specific antigens, especially MSP1, EBA175 and 
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AMA1 (Figure 4.8). This validation was important before using the plasma samples for 
the competition opsonic phagocytosis assay. 
 
Figure 4. 8: Confirmation of depletion of merozoite specific antibodies. Pre-incubation of the 
individual plasma samples with the respective recombinant antigens showed a reduction in antibody 
response to the specific merozoite recombinant antigens, especially MSP1, EBA175 and AMA1. The 
CHMI study plasma samples used for the assay were selected based on their known antibody 
responses to merozoites (18A0012 & 16K0036 - high; 17K0005 & 17K0028 - mid and 17K0074 & 
17K0084 - low). The selection of the merozoite recombinant antigens (CD4 tagged) for competition was 
guided by their availability in our lab and their potential as vaccine candidates. 
 
The percentage phagocytosis of the ring culture using 1:100 dilution of the control 
plasma samples was higher after opsonization with hyperimmune plasma as 
compared to naïve plasma and unopsonized conditions (Figure 4.9-A). Additionally, 
opsonic phagocytosis in the presence of a pool of the recombinant antigens was 
similar to opsonic phagocytosis during the unopsonized condition (Figure 4.9-A). 
Relative phagocytosis index of uEs using individual plasma samples that were each 
pre-incubated with a pool of the merozoite recombinant antigens (competed) was 
significantly lower (P=0.0003) compared to using non-competed individual plasma 
samples (Figure 4.9-B). Relative phagocytosis index of rIEs using individual plasma 
samples that were each pre-incubated with a pool of the merozoite recombinant 
antigens (competed) was significantly lower (P=0.004) compared to using non-
competed individual plasma samples (Figure 4.9-C). However, the significant 
difference observed in the relative phagocytosis index of the ring culture could not be 
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explained by pre-incubation of the individual plasma samples with a single merozoite 
recombinant antigen, except EBA175 which showed a similar finding as with pool of 
the antigens (Appendix 4.4 & Appendix 4.5). 
 
Figure 4. 9: Competition opsonic phagocytosis of the ring culture. A) The percentage 
phagocytosis of the ring culture using 1:100 dilution of the control plasma samples was higher after 
opsonization with hyperimmune plasma as compared to naïve plasma and unopsonized conditions. 
Relative phagocytosis index of (B) uEs and (C) rIEs using individual plasma samples that were each 
pre-incubated with a pool of the merozoite recombinant antigens (competed) was significantly lower 
(P=0.0003 and P=0.004, paired t-test) respectively, compared to using non-competed individual plasma 
samples. Statistics was calculated using GraphPad PRISM version 7.0. 
 
In order to understand further which blood stage would be responsible for the observed 
opsonic phagocytosis of uEs cultured in used media, I compared phagocytosis of 
supernatant obtained from synchronized parasites of different blood stages of similar 
parasitemia. I found that the supernatant obtained from the parasite period between 
mature stage (35 hours) to the next cycle at about 10 hours post-invasion showed a 
higher percentage phagocytosis of uEs, especially when opsonized with hyperimmune 
plasma and malaria-immune IgG, as compared to supernatant obtained in the parasite 
period between ring stage (10 hours) to mature stage (34 hours) which was 
comparable to opsonic phagocytosis of uEs cultured in fresh media (Figure 4.10). 
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Figure 4. 10: Late blood stage parasite proteins mediate opsonic phagocytosis of uninfected 
erythrocytes. The supernatant obtained from the parasite period between mature stage (35 hours) to 
the next cycle at about 10 hours post-invasion showed a higher percentage phagocytosis of uEs, 
especially when opsonized with hyperimmune plasma and malaria-immune IgG, as compared to 
supernatant obtained in the parasite period between ring stage (10 hours) to mature stage (34 hours) 
which was comparable to opsonic phagocytosis of uEs cultured in fresh media. 
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4.9. Discussion 
Establishment of opsonic phagocytosis assay (OPA) of rIEs in our laboratory 
The successful establishment of the flow cytometry based OPA of rIEs was validated 
using various controls (Figure 4.4), and the observations confirmed previous findings 
which showed that phagocytosis of rIEs was elevated after incubation of the ring 
culture cells with hyperimmune sera (Chan et al., 2012). However, an older study 
showed no difference on phagocytosis of rIEs after incubation with malaria-immune 
serum (Celada et al., 1982). This could be explained by the limitation of the methods 
they used in quantifying for monocyte cells that have phagocytosed rIEs. The Giemsa-
peroxidase stained smear is far less sensitive compared to the flow cytometry 
detection that was employed in my study. Flow cytometry differentiates between THP1 
monocyte cells that have phagocytosed uEs from those that had phagocytosed young 
rIEs based on the different stains taken up by the uEs and rIEs in the ring culture.  
Effect of OPA of rIEs on outcome of infection 
The study participants employed were malaria-exposed volunteers who participated 
in a CHMI study (Kapulu et al., 2018). This study design is gaining prominence 
compared to cross sectional surveys of children living in malaria endemic areas for 
analyses aimed at identifying the correlates of protection. 
Opsonic phagocytosis of rIEs in this study correlated with outcome of infection in the 
CHMI study. Findings from this study shows that the individuals whose plasma 
samples were capable of inducing high opsonic phagocytosis of rIEs were able to 
maintain low or no parasitemia, remain asymptomatic and require no treatment (Figure 
4.5). Findings from this in vitro study could explain observations of previous in vivo 
studies which showed that IgG sensitized rIEs were rapidly cleared from peripheral 
circulation by the spleen during recovery from uncomplicated P. falciparum malaria in 
Thai adults (Lee et al., 1989), and thus confirming what was earlier hypothesised, 
circulating erythrocytes labelled with antibodies likely result in splenic clearance by 
interaction with Fc receptors (Douki et al., 2003). The findings from this study suggest 
that the correlation of the in vitro opsonic phagocytosis of rIEs to outcome of infection 
could highly likely contribute to parasite clearance and protection from clinical 
symptoms and treatment as manifested by the CHMI individuals. However, as other 
stages of the infection have been shown in other analyses to also correlate with 
protection, it would be important to try to calculate the contribution of the ring-stages 
to the total protection observed.  
 112 
Understanding the OPA of uEs in ring culture and uEs incubated in used media 
In this study, we did not employ 100% rIEs for the phagocytosis assay, but rather a 
ring culture of about 15% rIEs for technical reasons. Therefore, the phagocytosis of 
uEs in the ring culture was simultaneously analysed alongside rIEs, because the two 
populations were differentially detected by the flow cytometer based on their distinctive 
staining patterns. Phagocytosis of uEs in ring culture was shown to be elevated 
especially after opsonization with hyperimmune plasma (Figure 4.4) as shown in 
previous studies (Chan et al., 2012, Awah et al., 2011). This could explain the eventual 
consequence of earlier observations from other studies which reported that P. 
falciparum specific antibodies recognized the surface of uEs in ring culture (Layez et 
al., 2005, Douki et al., 2003), in a parasite dependent manner (Awah et al., 2009). The 
findings from my study further shows that the opsonic phagocytosis of uEs incubated 
in used media was also elevated after opsonization with hyperimmune plasma but this 
was not observed in case of uEs incubated in fresh media (Figure 4.4-B). This 
suggests that opsonic phagocytosis of uEs in ring culture and uEs incubated in used 
media is parasite specific and not a random phenomenon. 
Opsonization of the ring culture cells using the CHMI plasma samples induced 
phagocytosis of uEs at a greater proportion than rIEs (Figure 4.7). This observation 
confirms findings from previous studies which implicated malarial anaemia to 
clearance of uEs (Awah et al., 2011, Awah et al., 2009), since the majority of 
erythrocytes lost during human malaria are actually uEs (Lamikanra et al., 2007), and 
specifically 10 fold greater than parasitized erythrocytes in case of severe malaria 
anaemia (Barnwell, 2006, Jakeman et al., 1999). Interestingly, findings from my study 
show that individuals who were not treated had higher level of phagocytosis of uEs 
(Figure 4.7). This is somehow consistent with earlier findings which showed that, in 
malaria endemic areas, the loss of uEs is coherent with the ability to clear parasite in 
children (Evans et al., 2006). Thus, an obvious question is the impact of the observed 
opsonic phagocytosis of uEs on anaemia in the CHMI study, and this can be answered 
by correlating the function, OPA of uEs, to haemoglobin levels of the individuals once 
the haematological data of the CHMI study are made available. 
Origin of the antigens responsible for opsonic phagocytosis of ring culture cells 
Opsonic phagocytosis of the ring culture cells showed a strong positive correlation to 
IgG antibody responses to merozoites, especially the cytophilic ones, IgG1 and IgG3, 
(Figure 4.6 and Appendix 4.3). Findings from this study also show that the parasite 
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proteins secreted in the media during the mature blood stages and merozoite invasion 
of the erythrocyte are responsible for opsonic phagocytosis of uEs incubated in used 
media (Figure 4.10). These findings support previous observations which showed that 
the ring surface protein 2 (RSP2) found on the surface of rIEs and uEs in ring culture 
was indeed of merozoite rhoptry origin (Douki et al., 2003), which was later confirmed 
to be similar to the rhoptry associated protein 2 (RAP2) (Sterkers et al., 2007).  
Depletion of merozoite specific antibodies from the CHMI plasma samples showed a 
significant decrease in the phagocytosis of the ring culture cells (Figure 4.9). This 
observation is consistent with findings from a previous study which showed that 
competing off parasite specific antibodies by incubating a strongly positive immune 
serum with soluble fractions of sonicated P. falciparum merozoite preparation 
completely abolished surface immunofluorescence of young rIEs, and this inhibition 
was compensated by passaging the competed immune serum over an 
immunoadsorbent made from IgG fraction of serum of a healthy but P. falciparum 
hyperimmune Liberian donor (Perlmann et al., 1984). The findings from my study 
suggest that opsonic phagocytosis of ring culture cells and uEs incubated in used 
media is mediated by Plasmodium antigens on the surface of the ring culture cells and 
uEs incubated in used media which are highly likely of merozoite origin. 
Summary 
I successfully established the flow cytometry based opsonic phagocytosis assay of 
rIEs in our laboratory. I show for the first time that opsonic phagocytosis of rIEs in vitro 
was correlated with the outcome of infection (parasite densities, symptoms and need 
for treatment) in a CHMI study. Interestingly, I show that phagocytosis of uEs was 
higher in untreated individuals as compared to the treated category. It is thereby 
important to investigate the impact of OPA of uEs on malarial anaemia in this CHMI 
study, and this will be addressed once the haematological data of the study are 
available. Additionally, I also show that merozoite specific antibodies mediated the 
observed opsonic phagocytosis of the ring culture cells and uEs incubated in used 
media. In Chapter 5, I investigate the specific parasite antigens on the surface of ring 
culture cells and uEs incubated in used media.  
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Chapter 5 
The identification of parasite proteins on ring culture cells and uninfected 
erythrocytes incubated in used media 
 
5.1. Introduction 
The human erythrocyte gets modified after P. falciparum invasion (Przyborski and 
Lanzer, 2005). The parasite increases the permeability of the host’s plasma 
membrane by inducing new permeability pathways (NPPs) needed for growth and 
propagation of the parasite (Krugliak and Ginsburg, 2006, Staines et al., 2006), and 
remodels the host cell by trafficking proteins to the erythrocyte compartment which 
play a role in the pathogenesis of the disease and immune acquisition (Knuepfer et 
al., 2005). The trafficking of the parasite proteins is made possible by the maturation 
of membranous structures of parasite origin within in the host erythrocyte cytoplasm, 
Maurer’s clefts, which begins from the young trophozoite stage (Mundwiler-Pachlatko 
and Beck, 2013, Gruring et al., 2011), and thus expressed on the surface of mIEs 
during the intraerythrocytic development of P. falciparum (Kriek et al., 2003). The 
majority of these surface antigens are highly polymorphic and encoded by multigene 
families (Chan et al., 2014), and are thought to mediate vascular adhesion, 
sequestration and rosette formation (Chen et al., 2004). 
The initial dogma, the presence of antigenic determinants on the surface of late 
intracellular asexual blood stages of P. falciparum (Hommel et al., 1982), was 
challenged by findings from early studies which gave the first evidence of the 
possibility of parasite proteins on the surface of rIEs (Perlmann et al., 1984). The 
findings from the study showed that some of the antigens previously shown to be 
released during schizont rupture and merozoite invasion are deposited on the 
erythrocyte surface during invasion probably because of their affinity of receptors 
structures on the erythrocyte membrane. Following this preliminary evidence, other 
studies confirmed the hypothesis using immunofluorescence assays, (Douki et al., 
2003, Thompson et al., 2001, Sam-Yellowe and Perkins, 1991, Sam-Yellowe et al., 
1988, Klotz et al., 1989) suggesting that antigens found on the surface of rIEs are 
transferred during merozoite invasion into the erythrocyte. Moreover, the parasite 
antigens have also been observed on the surface on uEs in culture or used culture 
media using radio labelling and immunofluorescence techniques (Sterkers et al., 2007, 
Camus and Hadley, 1985). It is therefore important to explore current technology to 
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identify new and/or previously described parasite antigens on the surface of rIEs and 
uEs in culture and used media.  
 
5.2. Rationale 
In this chapter, I investigated whether there are parasite proteins on the surface of ring 
culture cells and uninfected erythrocytes incubated in used media. To test this, I 
employed a surface trypsinization method, followed by mass spectrometry analysis of 
the supernatant containing peptides. Due to technical challenges, I decided to focus 
on the ring culture and not to sort out the rIEs from the ring culture because only small 
volumes (2 µl cells/ml which is equivalent to 10 Million cells/ml) of the ring culture can 
be reliably sorted using the fluorescent cells sorting (FACS) at low flow rates (90 
minutes/ml). This was technically impractical because large volumes of the rIEs were 
required in the surface trypsinization protocol. Moreover, I considered it reasonable to 
work on the ring culture based on my hypothesis: the immunogenicity of the rIEs and 
uEs in the ring culture are comparable, because the rIE is not known to transport any 
parasite proteins to its surface and only comes in contact with parasite proteins during 
merozoite invasion and rupture of mIEs similarly to the uEs in the ring culture. I was 
also interested to find out whether the shaved parasite proteins identified on the 
surface of ring culture cells would be similar to those obtained from shaving uEs 
incubated in used media. 
Surface trypsinization 
Surface trypsinization of infected erythrocytes has been previously used to 
quantitatively remove P. falciparum Erythrocyte Membrane Protein 1 (PfEMP1) with 
limited cleavage of major human erythrocyte proteins (Fernandez et al., 1999), and 
shave off a novel polymorphic antigen, SURFIN, encoded by the surface-associated 
interspersed genes (surf genes) (Winter et al., 2005). 
Mass spectrometry assay 
The assay was conducted at the Deutsches KrebsForschungszentrum (DKFZ)-
genomics & proteomics core facility at Heidelberg, where the shaved surface proteins 
were identified using a mass spectrometry-based proteomics approach which 
employed nano-flow (high performance liquid chromatography) HPLC, a Q-Exactive 
HF-X mass spectrometer and a combination of specialized workflows that ensured a 
very sensitive and in-depth analysis of the proteins.  
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5.3. Overall objective 
To investigate parasite proteins on the surface of the ring culture cells and uEs 
incubated in used media. 
 
5.4 Specific objectives 
• To investigate whether the surface trypsinization method efficiently removes 
surface proteins on the different cultures. 
• To investigate the presence of known and/or novel parasite proteins on the ring 
culture and uEs incubated in used media.  
• To investigate the difference between identified parasite proteins on the surface 
of the ring culture and uEs incubated in used media. 
 
5.5. Laboratory methods 
5.5.1. P. falciparum culture and synchronization 
The P. falciparum 3D7 strain was used for surface trypsinization and mass 
spectrometry analysis because its genome is well annotated and available at the 
Plasmodium database (Plasmodb). The parasites were cultured as explained in 
chapter 3 (section 3.5.1). Parasite synchronization and stage specific separation was 
done using D-sorbitol lysis method and label free magnetic-activated cell sorting 
(MACS) method respectively. Cultures were maintained at high parasitemia and 
synchronized every 46 hours with 5% D-sorbitol as described in chapter 3 (section 
3.5.1). Once a parasitemia of at least 20% of mIEs was achieved, the mIEs was further 
separated by MACS in order to get rid of the uEs. The mIEs contain larger 
paramagnetic hemozoin crystals (non-toxic and polymerized form of haem, obtained 
from the catabolism of host haemoglobin by the parasite) compared to rIEs and uEs, 
and thus mIEs can be purified from culture by use of commercial magnets. The eluate 
containing mIEs (40-45 hours) was incubated with two times volume of fresh uEs and 
cultured as explained in chapter 3 (section 3.5.1) for 12 hours to allow invasion by the 
released merozoites from the ruptured mIEs. The resultant ring culture (containing 
rIEs of 0-12 hours) was purified by MACS in order to get rid of any possible mIEs that 
did not rupture, followed by a slight D-sorbitol treatment to further get rid of any mIEs 
still present in the ring culture flow through after the MACS as shown in Appendix 5.1.  
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Fresh uEs were incubated in media that was previously used for 24 hours. The used 
media was obtained from a mixed culture (where merozoite invasion was evident & 
contained at least 10% rIEs). The used media was centrifuged at 4000 rpm for 15 
minutes (allows erythrocytes and merozoites to precipitate/pellet) and used to 
incubate fresh uEs for 24 hours. Fresh uEs were also incubated in fresh/unused media 
to serve as a control. 
 
5.5.2. Surface trypsinization of the ring culture 
Surface trypsinization for each experimental condition (ring culture containing 
approximately 20% rIEs of ≤ 12 hours, uEs in used media and uEs in fresh media) 
was done in four independent replicates. A mock-shaved condition of the exact trypsin-
shaved ring culture was also included to control for the experiment. The cultures were 
washed gently with ice cold 1X PBS. The washed cells, 300 µl, were resuspended to 
make a final volume of 1 ml and digested with 1 µg/ml of porcine-modified trypsin at 
37°C for 30 minutes. The modified trypsin specifically cleaves at the carboxylic side of 
lysine and arginine residues which is essential for protein identification, and most 
importantly modifies the lysine residues by reductive methylation to ensure that it is 
stable and resistant to autolytic cleavage. The trypsinization reaction was terminated 
by addition of 10 mg/ml of soybean trypsin inhibitor, and the cells were centrifuged at 
725 g for 30 seconds in order to pellet the erythrocytes. The resultant supernatant was 
centrifuged again at 16,000 g for 3 minutes at 4°C and quantified using the 
CYTATION|3 imaging reader and analysed using the Gen 5 3.02 software.  
 
5.5.3. Mass spectrometry assay 
The samples (10 µg/sample) were applied to 1 dimensional - sodium dodecyl sulfate- 
polyacrylamide gel (1D-SDS-PAGE) in order to fractionate, followed by excision of the 
gel pieces whose cysteine residues were reduced (disulphide bond breakage) and 
carbamidomethylated by addition of dithiothreitol (DTT) and iodoacetamide 
respectively. Carbamidomethylation is a deliberate post-translational modification 
(alkylation) introduced to cysteine residues to allow identification and characterization 
of proteins in peptide mass fingerprinting. The processed gel pieces were digested 
overnight with trypsin. The resulting peptides were loaded on a cartridge trap column 
packed with Acclaim PepMap300 C18, 5 µm, 300 Å wide pore and separated in a 120 
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min gradient from 3% to 40% ACN on a nanoEase MZ Peptide analytical column (300 
Å, 1.7 µm, 75 µm x 200 mm, Waters). Eluting peptides were analysed by an online 
coupled Q-Exactive-HF-X mass spectrometer. A tandem mass spectrometer generally 
generates numerous ions from the test sample, separates the ions based on their 
mass-to-size ration (m/z), and finally records the relative abundance of each unique 
ion type (MSMS). 
 
5.6. Statistical analysis 
Data analysis was carried out by MaxQuant (version 1.6.3.3). Match between runs 
option was enabled to allow transfer of peptide identification across raw files based on 
accurate retention time and m/z. Quantification was done using a label free 
quantification approach based on the MaxLFQ algorithm which employed delayed 
normalization and extraction of maximal ratio information from peptide signals in order 
to attain the highest possible accuracy of quantification (Cox et al., 2014). 
 
5.7. Results 
5.7.1. Quantification of sample protein concentration before mass 
spectrometry 
As a requirement of the mass spectrometry facility, the protein concentration of the 
test samples was measured using a nanodrop, and readings recorded as shown in 
Table 5.1. There was no distinct difference in the measurement of the protein 
concentration of samples among the different experimental conditions. However, the 
supernatant obtained after trypsinization of uEs incubated in fresh media appeared to 
have a low concentration compared to the other experimental conditions (uEs 
incubated in used media, trypsin-shaved and mock-shaved ring culture).  
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Table 5. 1: Quantification of protein concentration of the trypsin shaved samples 
 
5.7.2. Identification of peptides and proteins by mass spectrometry 
A total of 2882 peptides and 478 proteins were identified by MSMS based on a false 
detectable rate (FDR) cut off of 0.01 on peptide level and 0.01 on protein level (Figure 
5.1-A and Figure 5.1-B respectively). A minimum number of quantified peptides was 
required for protein quantification and thus a total of 472 proteins could be quantified. 
Proteins that had 2 identified razor or unique peptides (based on Occam’s razor 
principle) were referred to as identified protein2peptides (Figure 5.1-B). The number 
of identified peptides, proteins, protein2peptides, and quantified proteins appeared to 
be lower in the mock-shaved ring culture category compared to the other experimental 
groups (uEs in used media, uEs in fresh media and trypsin-shaved ring culture). 
Sample 
Number 
Sample name
Protein 
Concentration 
[µg/µl]
Sample 
Volume [µl]
Buffer 
composition Comment
1 uEs in used medium 0.655 700 1X PBS Shaved with tripsin
2 uEs in used medium 0.607 700 1X PBS Shaved with tripsin
3 uEs in used medium 0.514 700 1X PBS Shaved with tripsin
4 uEs in used medium 0.417 700 1X PBS Shaved with tripsin
5 uEs in fresh medium 0.494 700 1X PBS Shaved with tripsin
6 uEs in fresh medium 0.445 700 1X PBS Shaved with tripsin
7 uEs in fresh medium 0.592 700 1X PBS Shaved with tripsin
8 uEs in fresh medium 0.365 700 1X PBS Shaved with tripsin
9 Ring culture shaved 0.761 700 1X PBS Shaved with tripsin
10 Ring culture shaved 2.098 700 1X PBS Shaved with tripsin
11 Ring culture shaved 1.012 700 1X PBS Shaved with tripsin
12 Ring culture shaved 0.743 700 1X PBS Shaved with tripsin
13 Ring culture mock-shaved 0.583 700 1X PBS Final supernatant tripsinized
14 Ring culture mock-shaved 2.138 700 1X PBS Final supernatant tripsinized
15 Ring culture mock-shaved 1.249 700 1X PBS Final supernatant tripsinized
16 Ring culture mock-shaved 0.747 700 1X PBS Final supernatant tripsinized
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Figure 5. 1: Identified peptides and proteins by MSMS. A total of (A) 2882 peptides and (B) 478 
proteins were identified by MSMS based on a false detectable rate (FDR) cut off of 0.001 on both 
peptide and protein level. However, only 472 protein were quantified since they had the minimum 
number of quantified peptides required for protein quantification. Protein2peptides were proteins that 
had 2 identified razor or unique (based on Occam’s razor principle). The samples were supernatant 
obtained after shaving the different cultures: samples 01-04 from uEs in used media; samples 05-08 
from uEs in fresh media; samples 09-12 from trypsin-shaved ring culture and samples 13-16 from mock-
shaved ring culture. Samples obtained from the mock-shaved ring culture category showed the least 
number of detectable proteins and peptides. 
 
The identified peptides were searched using MaxQuant-andromeda peptide search 
engine, which matched the MSMS spectra to peptide sequences in the Human and 
Plasmodium genome databases, based on a probabilistic scoring of peptides 
spectrum matches. The identified proteins included 444 human proteins and 34 
Plasmodium proteins. The human proteins were categorised based on the gene 
ontology of biological processes: 19 - for actin cytoskeleton organization, 49 - for 
activation of the immune system, 159 - for biological regulation processes, 154 - for 
metabolic activities and 63 - for other cellular biological processes. The Plasmodium 
proteins were divided between proteins that were differentially identified (12 proteins) 
and those that were comparably identified (22 proteins) across the different 
experimental conditions. The comparably identified Plasmodium proteins resembled 
proteins from other Plasmodium species: 2 - P. inui San Antonio, 2 - P. yoelli yoelli, 1 
- P. berghei, 1- P. knowlesi, 3 - P. cymologi, 3 - P. vivax and 11 - P. falciparum. Ten 
of the differentially identified Plasmodium proteins resembled P. falciparum and only 
one resembled P. cymologi (Figure 5.2).  
A B 
 121 
 
Figure 5. 2: Categorization of the identified proteins. Among the 478 identified peptides, there were 
444 human proteins and 34 Plasmodium proteins. The human proteins were categorised based on the 
gene ontology of biological processes; 19 - for actin cytoskeleton organization, 49 - for activation of the 
immune system, 159 - for biological regulation processes, 154 - for metabolic activities and 63 - for 
other cellular biological processes. The Plasmodium proteins were divided between proteins that were 
differentially identified (12) and those that were comparably identified (22) across the different 
experimental conditions. The comparably identified Plasmodium proteins resembled proteins from 
various Plasmodium species; 2 - P. inui San Antonio, 2 - P. yoelli yoelli, 1 - P. berghei, 1- P. knowlesi, 
3 - P. cymologi, 3 - P. vivax and 11 - P. falciparum. Ten of the differentially identified Plasmodium 
proteins resembled P. falciparum and only one resembled P. cymologi. 
 
The Plasmodium proteins were categorised based on two major categories: 1) the 
differentially identified proteins which referred to proteins that had a higher LFQ 
intensities/upregulated in the positive control experimental conditions (uEs in used 
media and trypsin-shaved ring culture) compared to the negative control experimental 
conditions (uEs in fresh media and mock-shaved ring culture), and 2) the comparably 
identified proteins which referred to proteins that had a similar LFQ intensities/no 
change in the positive control conditions (uEs in used media and trypsin-shaved ring 
culture) as well as the mock-shaved ring culture negative control condition (Table 5.3). 
The differentially identified proteins and the comparably identified proteins were 
predicted to be mainly involved in the entry of the parasite into the host cell and 
metabolic biological processes respectively. Most of the differentially identified 
proteins were predicted to have signal peptide and/or transmembrane helix, unlike the 
comparably identified proteins where majority were predicted to have neither signal 
peptide nor a transmembrane helix (Table 5.2). 
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The data quality of the samples had to be validated using two approaches before 
proceeding with the statistical analysis: 1) the distribution of the quantitative data had 
to be close to the normal distribution and centred around the same value over the 
different samples (Appendix 5.2), and 2) the samples had to have a good general 
correlation of the LFQ intensities (Appendix 5.3). Moreover, the identified proteins had 
to pass a selection criterion in order to merit for statistical analysis: 1) they had to have 
a minimum number of 2 unique peptides in order to get a LFQ value, and 2) the LFQ 
values needed not to be 0 in three out of four independent replicates for at least one 
experimental condition. Therefore, out of the 34 identified Plasmodium proteins, there 
were 8 differentially identified proteins and 3 comparably identified proteins that 
proceeded for further statistical analysis (Table 5.4). 
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      Table 5. 2: Table showing the 34 identified Plasmodium proteins 
PlasmoDB  
identifier 
Product description Molecular 
weight 
(kDa) 
Protein 
length 
Signal 
peptide 
Trans-
membrane 
Helix 
prediction 
Predicted function 
PF3D7_1324900 Lactate dehydrogenase 
 
34.107 316 yes yes carbohydrate metabolic process 
PF3D7_0929400 High molecular weight 
rhoptry protein 2 
 
162.663 1378 yes no entry into host cell 
PF3D7_0905400 High molecular weight 
rhoptry protein 3 
 
104.854 897 yes no entry into host cell, host cell surface 
receptor binding 
PF3D7_0731500 Erythrocyte binding 
antigen 175 
 
174.586 1502 yes yes entry into host cell; host cell surface 
receptor binding 
PF3D7_1301600 Erythrocyte binding 
antigen 140 
 
140.594 1210 yes yes host cell surface receptor binding 
ENO Enolase 
 
50 446   entry into host cell 
PF3D7_1410400 Rhoptry-associated 
protein 1 
 
90.052 782 yes no protein binding 
PF3D7_0501600 Rhoptry-associated 
protein 2 
  
46.738 398 yes no entry into host cell; protein binding 
PF3D7_0302500 Cytoadherence linked 
asexual protein 
 
167.240 1417 yes no cytoadherence to microvasculature, 
mediated by symbiont protein 
PF3D7_1027300 Peroxiredoxin 
 
43.929 393 no no entry into host cell & antioxidant activity 
PCYB_112350 Elongation factor 1 
 
48.011 434 no no translational elongation 
PF3D7_0818900 Heat shock protein 
70;70kDa 
 
73.914 677 no no response to stress; ATPase activity 
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PF3D7_0917900 Heat shock protein 
70;78kDa 
72.386 652 yes no response to drug 
PF3D7_0626800 Pyruvate kinase 
 
55.660 511 no no carbohydrate metabolic process 
PF3D7_0216400 Vacuolar protein sorting 
associated protein 45 
 
86.255 722 no no vesicle docking involved in exocytosis 
PF3D7_1311800 M1-family alanyl 
aminopeptidase 
 
126.061 1085 no yes Proteolysis; response to drug 
PF3D7_1029600 Adenosine deaminase 
 
42.465 367 no no purine ribonucleoside monophosphate 
biosynthetic process; deaminase activity 
PF3D7_1012400 Hypoxanthine-guanine 
phosphoribosyl 
Transferase 
 
26.362 231 no no purine ribonucleoside salvage; 
hypoxanthine phosphoribosyltransferase 
activity 
PF3D7_1451100 Elongation factor 2 
 
93.521 832 no no translational elongation 
PF3D7_1406500 WD repeat-containing 
protein 65 
 
181.532 1527 no no cytoskeletal protein binding 
PF14_0425 Fructose-bisphosphate 
aldolase 
 
40.104 369 no no carbohydrate metabolic process; 
cytoskeleton organisation 
PF3D7_1462800 Glyceraldehyde 3-
phosphate 
dehydrogenase 
 
36.635 337 no no carbohydrate metabolic process 
PKH_093790 Myosin heavy chain 
subunit 
 
199.670 1718 no no Myosin complex 
PY07151 Uncharacterized protein 
 
81.098 690 no no no data available 
PVX_089505 Suppressor of Ras1 3-9 
 
30.220 262 no no protein domain specific binding 
PVX_123890 Uncharacterized protein 
 
137.424 1265 no no chromatin binding; DNA binding 
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PVX_081792 Uncharacterized protein 
 
576.792 5031 no no microtubule-based movement; ATPase 
activity 
C922_03767 CTP synthase 
 
95.801 850 no no pyrimidine nucleotide biosynthetic 
process 
C922_03524 Uncharacterized protein 398.898 3500 no no Protein binding 
PCYB_147060 Actin  
 
39.931 356 no no no data available 
PCYB_142080 ATP synthase subunit 
gamma 
 
31.331 274 no no ATP synthesis coupled proton transport 
PCYB_053170 Uncharacterized protein 
 
660.712 5758 no no no data available 
PY02078 Uncharacterized protein 
 
79.631 674 no yes no data available 
PBANKA_134200 SNARE protein 
 
44.948 416 no yes no data available 
       KEY:      
 
differentially identified across the experimental groups comparably identified across the experimental groups 
 
  
orange green 
 126 
Table 5. 3: Table showing number of razor + unique peptides and Label free quantification values (LFQ) of the 34 identified Plasmodium proteins 
 
PlasmoDB 
identifier 
 
Product description 
Razor + unique peptides Label Free Quantification (LFQ) Log2 values 
uEs_used uEs_fresh Ring 
culture 
_shaved 
Ring 
culture 
_mock 
shaved 
uEs_used uEs_fresh Ring 
culture 
_shaved 
Ring 
culture 
_mock 
shaved 
PF3D7_1324900 Lactate 
dehydrogenase 
 
0,3,3,3 0,0,0,0 3,3,3,3 0,1,1,0 0,22.9, 
23.9,24.3 
0,0,0,0 23.8,23.5 
24.1,25.3 
0,0,0,0 
PF3D7_0929400 High molecular weight 
rhoptry protein 2 
 
1,3,0,0 0,0,0,0 4,3,2,8 1,0,0,1 0,0,0,0 0,0,0,0 25,23.7, 
23.8,24.2 
0,0,0,0 
PF3D7_0905400 High molecular weight 
rhoptry protein 3 
 
0,2,0,1 0,0,0,0 4,3,2,5 2,1,1,0 0,21.7,0,0 0,0,0,0 24.2,22.4, 
22.7,23.4 
23.9,0,0,0 
PF3D7_0731500 Erythrocyte binding 
antigen 175 
 
9,15,10,9 0,0,0,0 4,9,7,10 3,5,4,5 26.8,26.3, 
26.3, 25.9 
0,0,0,0 22.5,25, 
23.8,25.3  
23.1,23.6, 
24,24.9 
PF3D7_1301600 Erythrocyte binding 
antigen 140 
 
8,11,7,7 0,0,0,0 3,9,6,12 1,1,0,1 26.1,26.3 
26.1,26.4 
0,0,0,0 24.4,25.6 
25.4,26.1 
0,0,0,0 
ENO Enolase 0,0,0,0 0,0,0,0 3,5,3,5 0,0,0,0 0,0,0,0 0,0,0,0 23,22.8, 
22.6,24.8 
0,0,0,0 
PF3D7_1410400 Rhoptry-associated 
protein 1 
 
0,1,0,0 0,0,0,0 0,1,0,2 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,21.5 0,0,0,0 
PF3D7_0501600 Rhoptry-associated 
protein 2 
 
1,1,1,1 0,0,0,0 0,1,1,2 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,22.7 0,0,0,0 
PF3D7_0302500 Cytoadherence linked 
asexual protein 
 
0,0,0,0 0,0,0,0 3,1,1,1 1,0,0,0 0,0,0,0 0,0,0,0 24.5,0,0,0 0,0,0,0 
PF3D7_1027300 Peroxiredoxin 
 
0,0,0,0 0,0,0,0 0,2,2,4 0,0,0,0 0,0,0,0 0,0,0,0 0,20.9,0, 
23 
0,0,0,0 
PCYB_112350 Elongation factor 1 
 
1,2,1,1, 0,0,0,0 1,2,2,4 0,0,1,1 0,23.8,0,0 0,0,0,0 0,24, 
24.7,25.1 
0,0,0,0 
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PF3D7_0818900 Heat shock protein 
70;70kDa 
 
0,0,0,0 0,0,0,0 3,0,2,3 0,1,0,0 0,0,0,0 0,0,0,0 23.6,0, 
23.7,24 
0,0,0,0 
PF3D7_0917900 Heat shock protein 
70;78kDa 
 
3,3,2,2 3,2,3,3 5,6,6,9 3,4,4,2 27.8,27.7, 
27.1,27 
27.8,27, 
27.7,27.3 
28.3,28.1, 
27.7,27 
28.7,28.6, 
28.4,27.4 
PF3D7_0626800 Pyruvate kinase 
 
0,0,0,0 0,0,0,0 0,0,0,2 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,21.6 0,0,0,0 
PF3D7_0216400 Vacuolar protein 
sorting-associated 
protein 45 
 
1,1,1,1 1,1,1,1 1,1,1,1 1,1,1,1 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,26.8 
PF3D7_1311800 M1-family alanyl 
aminopeptidase 
 
0,0,0,0 0,0,0,0 0,0,0,1 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,20.8 0,0,0,0 
PF3D7_1029600 Adenosine deaminase 
 
0,0,0,0 0,0,0,0 0,1,1,1 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,21 0,0,0,0 
PF3D7_1012400 Hypoxanthine-guanine 
phosphoribosyl 
Transferase 
 
0,0,0,0 0,0,0,0 0,0,0,2 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,21.7 0,0,0,0 
PF3D7_1451100 Elongation factor 2 
 
1,1,2,1 0,0,0,0 0,0,0,2 0,1,1,0 0,0,0,0 0,0,0,0 0,0,0,22.1 0,0,0,0 
PF3D7_1406500 WD repeat-containing 
protein 65 
 
1,1,1,1 1,1,1,1 1,1,1,1 1,1,1,1 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,26.8 
PF14_0425 Fructose-bisphosphate 
aldolase 
 
0,0,0,0 0,0,0,0 0,0,0,1 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,22.5 0,0,0,0 
PF3D7_1462800 Glyceraldehyde 3-
phosphate 
dehydrogenase 
 
1,2,2,1 1,0,1,1 1,1,2,4 0,1,0,0 0,0,0,0 0,0,0,0 0,0,27.6,0 0,0,0,0 
PKH_093790 Myosin heavy chain 
subunit 
 
1,1,1,1 1,1,1,1 1,1,1,1 1,1,1,1 25.6,25, 
25.8,26 
26,0, 
26.3,0 
25.4,25.1, 
26,25.5 
26.1,26.3, 
26.2,25.6 
PY07151 Uncharacterized 
protein 
1,1,1,1 1,1,1,1 1,1,1,1 1,1,1,1 28.6,28.4, 
0,28.6 
0,28.7, 
29,0 
29,0, 
0,28.7 
0,0, 
0,28.8 
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PVX_089505 Suppressor of Ras1 3-
9 
 
0,0,0,0 0,0,0,0 0,0,0,1 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,21.5 0,0,0,0 
PVX_123890 Uncharacterized 
protein 
 
1,0,1,0 1,1,1,1 1,0,1,0 0,1,1,1 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,23 
PVX_081792 Uncharacterized 
protein 
 
0,0,0,0 0,0,1,1 0,1,0,0 0,0,1,1 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,0 
C922_03767 CTP synthase 
 
1,1,1,1 1,1,1,1 1,1,1,1 1,1,1,1 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,24.3 
C922_03524 Uncharacterized 
protein 
 
1,0,0,1 0,0,0,0 1,0,0,0 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,0 
PCYB_147060 Actin  
 
0,1,0,1 0,0,0,0 0,1,0,0, 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,22.3 0,0,0,0 
PCYB_142080 ATP synthase subunit 
gamma 
 
1,0,0,1 0,0,0,0 1,1,0,0 0,1,1,0 0,0,0,0 0,0,0,0 0,0,0,0 0,0,23.0,0 
PCYB_053170 Uncharacterized 
protein 
 
0,0,1,1 0,0,0,0 0,0,0,0 0,0,0,1 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,22.5 
PY02078 Uncharacterized 
protein 
 
0,0,1,1 1,1,1,1 0,0,1,1 0,1,1,0 0,0,0,0 0,0,0,0 0,0,0,0 0,0,24.3,0 
PBANKA_134200 SNARE protein 
 
0,0,0,0 0,0,0,0 1,1,0,0 0,1,1,1 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,27.9 
 
KEY: 
      
differentially identified across the experimental groups comparably identified across the experimental groups 
  
orange green 
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Table 5. 4: Table showing list of Plasmodium proteins that passed the selection criterion for further statistical analysis 
 
PlasmoDB 
identifier 
 
 
Product description 
Razor + unique peptides Label Free Quantification (LFQ) Log2 values 
 
uEs_used uEs_fresh Ring 
culture 
_shaved 
Ring 
culture 
_mock 
shaved 
uEs_used uEs_fresh Ring 
culture 
_shaved 
Ring 
culture 
_mock 
shaved 
PF3D7_1324900 Lactate 
dehydrogenase 
0,3,3,3 0,0,0,0 3,3,3,3 0,1,1,0 0,22.9, 
23.9,24.3 
0,0,0,0 23.8,23.5 
24.1,25.3 
0,0,0,0 
PF3D7_0929400 High molecular weight 
rhoptry protein 2 
1,3,0,0 0,0,0,0 4,3,2,8 1,0,0,1 0,0,0,0 0,0,0,0 25,23.7, 
23.8,24.2 
0,0,0,0 
PF3D7_0905400 High molecular weight 
rhoptry protein 3 
0,2,0,1 0,0,0,0 4,3,2,5 2,1,1,0 0,21.7,0,0 0,0,0,0 24.2,22.4, 
22.7,23.4 
23.9,0,0,0 
PF3D7_0731500 Erythrocyte binding 
antigen 175 
9,15,10,9 0,0,0,0 4,9,7,10 3,5,4,5 26.8,26.3, 
26.3, 25.9 
0,0,0,0 22.5,25, 
23.8,25.3  
23.1,23.6, 
24,24.9 
PF3D7_1301600 Erythrocyte binding 
antigen 140 
8,11,7,7 0,0,0,0 3,9,6,12 1,1,0,1 26.1,26.3 
26.1,26.4 
0,0,0,0 24.4,25.6 
25.4,26.1 
0,0,0,0 
ENO Enolase 
 
0,0,0,0 0,0,0,0 3,5,3,5 0,0,0,0 0,0,0,0 0,0,0,0 23,22.8, 
22.6,24.8 
0,0,0,0 
PCYB_112350 Elongation factor 1 
 
1,2,1,1, 0,0,0,0 1,2,2,4 0,0,1,1 0,23.8, 
0,0 
0,0,0,0 0,24, 
24.7,25.1 
0,0,0,0 
PF3D7_0818900 
 
Heat shock protein 
70;70kDa 
0,0,0,0 0,0,0,0 3,0,2,3 0,1,0,0 0,0,0,0 0,0,0,0 23.6,0, 
23.7,24 
0,0,0,0 
PF3D7_0917900 Heat shock protein 
70;78kDa 
3,3,2,2 3,2,3,3 5,6,6,9 3,4,4,2 27.8,27.7, 
27.1,27 
27.8,27, 
27.7,27.3 
28.3,28.1, 
27.7,27 
28.7,28.6, 
28.4,27.4 
PKH_093790 Myosin heavy chain 
subunit 
1,1,1,1 1,1,1,1 1,1,1,1 1,1,1,1 25.6,25, 
25.8,26 
26,0, 
26.3,0 
25.4,25.1, 
26,25.5 
26.1,26.3, 
26.2,25.6 
PY07151 Uncharacterized 
protein 
1,1,1,1 1,1,1,1 1,1,1,1 1,1,1,1 28.6,28.4, 
0,28.6 
0,28.7, 
29,0 
29,0, 
0,28.7 
0,0, 
0,28.8 
NOTE: 
To pass the selection criterion, the proteins had to have: 
• a minimum of 2 unique peptides in order to get a LFQ value. 
• LFQ values (not 0) in three out of four independent replicates for at least one experimental condition.  
KEY: 
differentially identified across the experimental groups comparably identified across the experimental groups orange green 
 130 
The 11 selected Plasmodium proteins were displayed using a principle component 
analysis (PCA) and a heatmap (Figure 5.3 and Figure 5.4 respectively). The PCA 
reduced the dimensionality of the multivariable data by finding the best projection to 
represent the LFQ intensity variance in between the samples in two dimensions giving 
an overview about the similarity of the samples and the general discrimination 
complexity. The samples obtained from uEs in used media (used_01-04) show some 
similarity to samples obtained from trypsin-shaved ring culture (shaved_09-12) 
because they tend to cluster together, and samples obtained from uEs in fresh media 
(fresh_05-08) show some similarity to samples obtained from mock-shaved ring 
culture (mock_13-16) which also tend to cluster together (Figure 5.3). However when 
we considered all the selected human and Plasmodium proteins together the PCA 
analysis showed that the shaved samples; uEs in used media (used_01-04), uEs in 
fresh media (fresh_05-08) and trypsin-shaved ring culture (shaved_09-12) showed 
some similarity by clustering together and away from the mock-shaved ring culture 
(mock_13-16) as shown in Appendix 5.4.  
The heatmaps was generated using Log-2 LFQ values that had been Z-score 
normalized and hierarchical clustering was performed on row and columns using the 
Euclidean distance and ward.D2 (the default parameters on the Z-scored LFQ values 
were used to calculate the Euclidean distance and the branch length which represents 
the average distance to the next sample). It allowed global visualization of the data in 
order to identify clusters of proteins and/or samples with consistent behaviour and 
gave an overall view of relative protein LFQ intensities across the samples. Generation 
of heatmap using only the selected Plasmodium proteins, the samples clustered well 
based on their experimental conditions and the 3 comparably identified Plasmodium 
proteins had similar protein LFQ intensities across the samples in the different 
experimental conditions whereas the 8 differentially identified Plasmodium proteins 
were relatively upregulated in the trypsin-shaved ring culture and uEs in used media 
and absent/down regulated in uEs in fresh media and mock-shaved ring culture. 
(Figure 5.4). Moreover, generation of heatmap using all the selected human and 
Plasmodium proteins, the samples clustered well based on their experimental 
conditions as observed previously with the PCA analysis where the mock-shaved ring 
culture was clearly discriminated from the other three groups (uEs in used media, uEs 
in fresh media and trypsin-shaved ring culture) which clustered fairly well within their 
respective groups (Appendix 5.5).  
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Figure 5. 3: Principle component analysis using only the selected Plasmodium proteins. 
The samples obtained from uEs in used media (used_01-04) show some similarity to samples obtained from trypsin-shaved ring culture (shaved_09-12) 
because they tend to cluster together, and samples obtained from uEs in fresh media (fresh_05-08) show some similarity to samples obtained from mock-
shaved ring culture (mock_13-16) which also tend to cluster together. The proteins used for the principal component analysis were those that passed the 
selection criterion for statistical analysis.  
12 
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Figure 5. 4: Heatmap generated using only the selected Plasmodium proteins. The heatmap was 
generated using Log-2 LFQ values that had been Z-score normalized and hierarchical clustering was 
performed on row and columns using the Euclidean distance and ward.D2. Quantitative values have 
been colour coded according to the colour key shown on the top. Protein are labelled by their gene-
name and accession number. Sample names are shown on the top of the plot. The samples clustered 
well based on their experimental conditions, and the 3 comparably identified Plasmodium proteins had 
similar protein LFQ intensities across the samples in the different experimental conditions whereas the 
8 differentially identified Plasmodium proteins were relatively upregulated in the trypsin-shaved ring 
culture and uEs in used media and down regulated in uEs in fresh media and mock-shaved ring culture. 
The samples were supernatant obtained after shaving the different cultures: used_01-04 from uEs in 
used media; fresh_05-08 from uEs in fresh media; shaved_09-12 from trypsin-shaved ring culture and 
mock_13-16 from mock-shaved ring culture. The proteins used to generate the heatmap were those 
that passed the selection criterion for statistical analysis. 
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5.7.3. Identification of significantly upregulated Plasmodium proteins between 
the different experimental conditions 
The mean LFQ values of the selected human and Plasmodium proteins were 
compared between all the possible combinations of the experimental conditions using 
student’s t-test in order to determine how each identified protein differs between any 
two possible experimental groups. The obtained p-values were used to generate 
volcano plots so as to determine the significantly upregulated protein(s) between any 
two experimental conditions. There were no significantly upregulated Plasmodium 
proteins identified in uEs in fresh media culture when compared to uEs in used media 
or trypsin-shaved ring culture, and there were also no significantly upregulated 
Plasmodium proteins identified in mock-shaved ring culture when compared to trypsin-
shaved ring culture. Thus, these findings validated the assay because they passed 
well as controls. There were significantly upregulated Plasmodium proteins identified 
in trypsin-shaved ring culture as compared to mock-shaved ring culture and uEs in 
fresh media, and there were also significantly upregulated Plasmodium proteins 
identified in uEs in used media as compared to uEs in fresh media. Moreover, there 
were two rhoptry associated proteins (PF3D7_0929400 - High molecular weight 
rhoptry protein 2 and PF3D7_0905400 - High molecular weight rhoptry protein 3) that 
were significantly upregulated in trypsin-shaved ring culture compared to uEs in used 
media (Figure 5.5). Similar findings we observed when generating volcano plots using 
only selected Plasmodium proteins (Appendix 5.6). 
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Figure 5. 5: Volcano plots generated using all the selected human and Plasmodium proteins. The volcano plots were generate using the -Log p values 
derived from the p-values obtained during Student’s t-test analysis where the mean LFQ values of each of the selected human and Plasmodium proteins were 
compared between all the possible combinations of the experimental conditions. There were significantly upregulated Plasmodium proteins identified in (A) uEs 
in used media (B) trypsin-shaved ring culture when compared to uEs in fresh media culture. Additionally, (C) there were also significantly upregulated 
Plasmodium proteins identified in trypsin-shaved ring culture when compared to mock-shaved ring culture. (D) There were two rhoptry associated proteins that 
were significantly upregulated in trypsin-shaved ring culture compared to uEs in used media. The significantly upregulated proteins denoted in blue and red 
were from human and Plasmodium respectively, whereas the proteins in grey were the human proteins that were not significantly upregulated between any 
given two experimental conditions. The gene names of the various accession numbers of the Plasmodium hits are as follows; PF3D7_0929400 - Lactate 
dehydrogenase, PF3D7_0929400 - High molecular weight rhoptry protein 2, PF3D7_0905400 - High molecular weight rhoptry protein 3, PF3D7_0731500 - 
Erythrocyte binding antigen 175, PF3D7_1301600 - Erythrocyte binding antigen 140, ENO - Enolase, PCYB_112350 - Elongation factor 1, PF3D7_0818900 - 
Heat shock protein 70;70kDa, PF3D7_0917900 - Heat shock protein 70;78kDa, PKH_093790 - Myosin heavy chain subunit and PY07151 - Uncharacterized 
protein. The proteins used to generate the volcano plots were those that passed the selection criterion for statistical analysis.Key: red - significantly upregulated 
Plasmodium proteins; blue - significantly upregulated human proteins and grey - proteins with no change between any given two experimental conditions. 
A 
 
B 
D C 
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5.8. Discussion 
Evaluation of the success of the surface proteomics approach 
This being the first surface proteomics study conducted on ring culture cells, it was 
important to assess the successful establishment of the assay in our laboratory. 
Findings from the following control strategies validated the assay: 1) the mock-shaved 
ring culture category had the least number of identified proteins and peptides (Figure 
5.1 and Appendix 5.5), 2) the samples clustered well depending on whether they were 
obtained from experimental conditions that contained parasite material or not (Figure 
5.3 and Appendix 5.4), 3) there were no significantly upregulated Plasmodium proteins 
identified in uEs in fresh media culture when compared to uEs in used media or 
trypsin-shaved ring culture (Figure 5.5), and 4) there were also no significantly 
upregulated Plasmodium proteins identified in mock-shaved ring culture when 
compared to trypsin-shaved ring culture (Figure 5.5). 
Differentially identified Plasmodium proteins 
The differentially identified parasite proteins in the study were of utmost interest 
because they were relatively upregulated in the uEs in used media and/or trypsin-
shaved ring culture but absent/down regulated in uEs in fresh media and mock-shaved 
ring culture. Moreover, most of them have already been identified in previous different 
studies as possible surface parasite proteins discharged on the early intracellular 
asexual blood stage from merozoite organelles during invasion, and some have been 
proposed to bind to uEs in culture and in used media. 
The components of the high molecular weight rhoptry complex, RhopH2 and RhopH3, 
were upregulated in trypsin-shaved ring culture, whereas the first member of the 
complex, cytoadherence linked asexual protein (CLAG3.1 ) also known as RhopH1, 
was interestingly identified only in the trypsin shaved ring culture but didn’t merit the 
criteria for further statistical analysis (Figure 5.3). The RhopH3 was first suggested to 
be inserted into the membrane of the host erythrocyte during invasion where 
immunofluorescence findings showed that the rhoptry protein was discharged from 
the merozoite and spread around the surface of the erythrocyte upon contact with the 
merozoite (Sam-Yellowe et al., 1988). Moreover, the entire high molecular weight 
rhoptry complex was found to bind to newly infected erythrocyte membranes ghost 
(Sam-Yellowe and Perkins, 1991) and remained intact for at least 18 hours post-
invasion (Lustigman et al., 1988). Recent findings have clarified that RhopH3 performs 
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a major role in invasion (Ito et al., 2017), and the entire RhopH complex contributes to 
the new permeability pathway (NPP) which serves as a nutrient channel important for 
parasite growth and proliferation (Counihan et al., 2017, Ito et al., 2017). 
The members of the low molecular weight rhoptry complex, rhoptry-associated 
proteins 1 and 2 (RAP1 and RAP2 respectively), were upregulated in trypsin-shaved 
ring culture and identified in both trypsin-shaved ring culture and uEs in used media 
(Figure 5.3). However, they didn’t meet the criteria for further statistical analysis. The 
RAP2, was first identified as ring-surface protein 2 (RSP2) by immunoprecipitation 
assay of surface-iodinated rIEs extracts (Pouvelle et al., 2000). Other 
immunofluorescence studies confirmed that RSP2 is indeed a rhoptry-derived protein 
and is discharged on the membrane of a newly invaded erythrocyte during contact 
with merozoites (Douki et al., 2003), and RAP1 and RAP2/RSP2 were described to 
positively stain the membrane of uEs in culture (Sterkers et al., 2007). Recently, RAP2 
has been shown to be a ligand of a receptor on the erythrocyte membrane, basigin, 
whose interaction inhibition completely abolished parasite invasion (Zhang et al., 
2018). This confirms why RAP2 was considered refractory to deletion (Sterkers et al., 
2007). 
The merozoite micronemal proteins, erythrocyte binding antigens 140 and 175 
(EBA140 and EBA 175 respectively), were upregulated in both trypsin-shaved ring 
culture and uEs in used media (Figure 5.3). The EBA175 protein was first suggested 
to bind to erythrocytes after incubation with supernatant fluids of a cultured human 
malaria parasite containing a 175KDa merozoite binding antigen which was shown to 
be depleted after the supernatants were absorbed on normal human erythrocytes 
(Camus and Hadley, 1985). On the other hand, EBA140 protein was first described to 
bind to erythrocyte surface by incubating erythrocytes with radiolabelled supernatants 
from merozoites (Thompson et al., 2001). The parasite ligands, EBA175 and EBA140 
bind to specific erythrocyte sialoglycoprotein receptors, glycophorin A (Sim, 1995), 
and glycophorin C (Thompson et al., 2001) respectively, during merozoite invasion. 
However, EBA140 has been suggested not to be essential for normal growth and 
merozoite invasion in P. falciparum infection (Thompson et al., 2001). Recently, the 
interaction of EBA175 and glycophorin A has been shown to be the major invasion 
and evasion pathway for P. falciparum merozoites (Jaskiewicz et al., 2019).  
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Additionally, another merozoite protein, peroxiredoxin, was upregulated in the trypsin-
shaved ring culture and interestingly identified only in the trypsin-shaved ring culture 
(Figure 5.3). However. it didn’t meet the criteria for further statistical analysis. 
Peroxiredoxin was previously known as merozoite capping protein 1 (MCP1) which 
was first described to be located at the attachment site between the erythrocyte and 
the merozoite apical region (Klotz et al., 1989). The immunofluorescence findings from 
the study showed that MCP1 moved in the plane of the membrane around merozoites 
during invasion and persisted at the pole in newly invaded erythrocyte and was 
speculated to be among the components that form the tight junction complex. 
However, other contradictory findings recently showed that MCP1 was localized to the 
nucleus and thus it was renamed peroxiredoxin (PfnPrx) and suggested its putative 
role in the nuclear DNA protection against oxidative stress (Richard et al., 2011). 
Despite this controversy, an obvious question would be whether peroxiredoxin/MCP1 
serves any role in parasite growth because it is polymorphic and has been recently 
shown to be refractory to deletion (Sanderson and Rayner, 2017). 
Finally, one of the highly expressed enzymes associated with multiple subcellular 
compartments, P. falciparum enolase, was upregulated in the trypsin-shaved ring 
culture and interestingly identified only in the trypsin-shaved ring culture (Figure 5.3). 
Enolase was previously detected in every stage of the P. falciparum life cycle 
(Bhowmick et al., 2009), and interestingly shown to be located on the cell membrane 
of the three main invasive stages of the P. falciparum parasite: merozoite (Pal-
Bhowmick et al., 2007), sporozoite (Bhowmick et al., 2009) and ookinetes (Ghosh et 
al., 2011). Moreover, P. falciparum enolase could be a potential protective antigen 
because findings from other studies showed that it: was a correlate of natural 
protective immunity, played a role in the growth of P. falciparum in vitro cultures, and 
conferred partial protection against malaria in mice during vaccination with 
recombinant P. falciparum enolase (Pal-Bhowmick et al., 2007). The moonlighting 
functions of P. falciparum enolase have been recently implicated to be mediated by 
tryptophan residues present in a pentapeptide insert of the enzyme (Dutta et al., 2017). 
The findings from my study, identification of enolase as one of the parasite proteins 
on ring culture cells, is consistent with previous hypothesis which stated that its 
localization on the merozoite may indicate a possible role in red blood cell invasion 
(Bhowmick et al., 2009). I therefore speculate that it could be transferred on the 
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surface of newly infected erythrocytes during invasion, but this could be confirmed by 
immunofluorescence assay. 
Summary 
I conducted the first surface proteomics study on ring culture cells and in this one study 
I identified all the parasite proteins on rIEs and uEs that were previously identified in 
isolation. My data conclusively shows that the merozoite is the main source of the 
surface parasite proteins on ring culture cells and uEs in used media. I speculate 
highly that this proteins could be responsible for the opsonic phagocytosis of ring 
culture cells observed in the previous chapter, because antibody depletion of one of 
the differentially identified merozoite protein, EBA175, showed a reduction of the 
opsonic phagocytosis of ring culture cells similar to competition with the pool of several 
merozoite recombinant proteins (Appendix 4.4 and Appendix 4.5). Most of these 
differentially identified proteins are already predicted to be involved in invasion and/or 
shown to be correlates of protective immunity. However, there are two interesting 
parasite proteins identified only in the trypsin-shaved ring culture: 1) enolase, whose 
presence on the surface of newly invaded erythrocytes have not been previously 
shown, and 2) peroxiredoxin, whose possible role in parasite clearance and protective 
immunity has not been explored. It is thereby noteworthy for future studies to be 
conducted as this could inform vaccine development. 
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Chapter 6 
Conclusion and recommendations 
 
6.1. Summary of findings 
The blood stage is responsible for the clinical symptoms of P. falciparum malaria, 
possibly due to the exponential parasite growth every 48 hours. However, individuals 
in malaria endemic areas, maintain low levels of circulating ring-infected erythrocytes 
(rIEs) during natural asymptomatic infections. The low parasite densities were thought 
to result from the host’s immune defence against the mature asexual blood stages, 
and the potential contribution of rIEs to parasite clearance had not been explored. The 
experiments and analyses presented in this thesis were aimed at addressing this 
knowledge gap by investigating the significance of the clearance of rIEs in protective 
immunity. 
I found out that a proportion of rIEs are comparably retained between lab and field 
isolates in an artificial spleen, suggesting that this may be a mechanism of parasite 
clearance that contributes to the low parasite densities observed in malaria endemic 
areas. Although antibodies had no direct killing effect on rIEs, they bound on the 
erythrocyte and mediated in vitro opsonic phagocytosis. This activity predicted clinical 
outcome in a malaria challenge study and provides the first evidence that it may be 
important for protective immunity. Additionally, I discovered parasite proteins of 
biological relevance on the surface of the ring culture cells which could highly likely be 
responsible for the proposed role of rIEs in protective immunity. However, the 
possibility that some of these antigens could be involved in anaemia during malaria 
infection cannot be ruled out due to the clearance of the tagged uEs by the immune 
system. 
 
6.2. Recommendations 
This study contributes to the understanding of the role of rIEs in protective immunity 
by correlating an in vitro antibody mediated function of rIEs to outcome of P. falciparum 
infection in a CHMI study. However, it will be important to determine the proportion 
contribution of the rIEs clearance in the overall protective immunity observed in the 
CHMI study. This can be done by mathematical modelling where all the antibody 
mediated functions that are being investigated in the CHMI study could be analysed 
in a model and by use of mathematical concepts help predict the individual contribution 
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of each function to the total protective immunity. Additionally, in regard to the observed 
opsonic phagocytosis of uEs in the ring culture, it will be important to investigate its 
impact on anaemia in the CHMI study. This can be done by correlating the observed 
clearance of uEs to haemoglobin levels of the individuals during the study once the 
haematological data are available. This will be essential to inform vaccine 
development, especially because this study shows evidence of shared targets 
between the ring culture cells and the merozoite which is one of the most studied 
invasive form of the parasite. Measures to compensate the possible loss of circulating 
uEs during malaria infection can be considered during the implementation of potential 
vaccine candidates that are known to be shared immune targets between the 
merozoites and the uEs during malaria infection. Furthermore, it would be of prime 
importance to investigate whether circulating rIEs and uEs during malaria infection are 
indeed phagocytosed in vivo. This can be done by conducting opsonic phagocytosis 
using peripheral blood samples freshly obtained from individuals in malaria endemic 
areas. This would strengthen the evidence of the physiological relevance of rIEs in 
protective immunity demonstrated in this study.  
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Appendix 3. 1: Flow cytometry gating strategy for antibody binding to ring-infected erythrocytes 
and mature-infected erythrocytes. (A) The photomultiplier tube PMT voltages of the forward scatter 
and side scatter were adjusted to ensure that the entire population of interest (red blood cells) was 
visible within the scatter plot. (B) Only single cells that passed the laser beam in the flow cell were 
gated. (C) The PMT voltage for the SYBR Green channel was also adjusted using relevant controls to 
identify the uEs and IEs populations, and further distinguish between the single invaded rIEs and mIEs. 
The PMT voltage for the APC channel was also adjusted using relevant controls to ensure that the 
antibody binding to IEs was correctly detected. The percentage of rIEs and mIEs that were detected by 
antibody in malaria-immune plasma were gated (D) and (E) respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3. 2: Antibody binding to FCR3-lab isolate infected erythrocytes is dose dependant. 
The percentage of antibody binding to (A) rIEs and (B) mIEs, decreased with increase in the dilution of 
test samples; Pool of hyper immune plasma (PHIS) obtained from Kenyan individuals, Malaria-immune 
immunoglobulins obtained from Malawian individuals (MIG) and malaria-naïve plasma obtained from 
German individuals. 
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Appendix 3. 3: Antibody response to NF54 merozoites. A) Detection of antibody response to NF54 
merozoites using all Junju adult’s plasma was determined to be significantly higher (P=0.0002, Mann 
Whitney test) compared to malaria-naïve plasma. B) The Junju adults were categorized based on their 
merozoite ELISA OD values; top, average and bottom with (>1.5, 0.7-1,5 and <0.7) OD ranges 
respectively, and the antibody responses to the merozoites of the different categories of the Junju adults 
was determined to be significantly higher compared to malaria-naïve plasma (P<0.0001, Kruskal-Wallis 
test), specifically; the top and average responders (P=0.0002 and P=0.0597 respectively, Dunn’s 
multiple comparison test). The positive control was a pool of hyper immune plasma samples of Junju 
adults from Kilifi Kenya. The dotted horizontal line is the seropositivity mark = {mean of the antibody 
binding to rIEs using naïve plasma + 3(STDEV)}. Statistics was calculated using GraphPad PRISM 
version 7.0.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3. 4: Antibody binding to FCR3-lab isolate mature-infected erythrocytes. A) Detection 
of antibody binding using all Junju adult’s plasma was determined to be significantly higher (P<0.0001, 
Mann Whitney test) compared to malaria-naïve plasma, and detection of secondary antibody binding in 
absence of plasma was negligible indicating a high sound to noise ratio. B) Detection of antibody binding 
focussing on the different categories of the Junju adults based on the antibody response to merozoites 
was determined to be significantly higher compared to malaria-naïve plasma (P<0.0001, Kruskal-Wallis 
test), specifically; the top and average responders (P=0.0001 and P=0.0012 respectively, Dunn’s 
multiple comparison test). C) Antibody binding to mIEs showed a strong positive correlation (spearman 
r=0.6631; P<0.0001), with antibody response to NF54 merozoites. The positive control was a pool of 
hyper immune plasma samples of Junju adults from Kilifi Kenya. The dotted horizontal line in graphs A 
and B is the seropositivity mark = {mean of the antibody binding to rIEs using naïve plasma + 
3(STDEV)}. Statistics was calculated using GraphPad PRISM version 7.0.  
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Appendix 3. 5: Antibody binding to field isolate mature-infected erythrocytes obtained from 
Kilifi. A) Detection of antibody binding using all Junju adult’s plasma was determined to be significantly 
higher (P<0.0001, Mann Whitney test) compared to malaria-naïve plasma, and detection of secondary 
antibody binding in absence of plasma was negligible indicating a high sound to noise ratio. B) Detection 
of antibody binding focussing on the different categories of the Junju adults based on the antibody 
response to merozoites was determined to be significantly higher compared to malaria-naïve plasma 
(P<0.0001, Kruskal-Wallis test), specifically; the top and average responders (P=0.0001 and P=0.0012 
respectively, Dunn’s multiple comparison test). C) Antibody binding to mIEs showed a strong positive 
correlation (spearman r=0.7758; P<0.0001), with antibody response to NF54 merozoites. Positive 
control was a pool of hyper immune plasma samples of Junju adults from in Kilifi Kenya. The dotted 
horizontal line in graphs A and B is the seropositivity mark = {mean of the antibody binding to rIEs using 
naïve plasma + 3(STDEV)}. Statistics was calculated using GraphPad PRISM version 7.0.  
Appendix 3. 6: Comparison of antibody binding between laboratory and field isolate mature-
infected erythrocytes. A) The percentage of antibody binding to field rIEs was determined to 
significantly higher focussing on all Junju adults, top, average and bottom responders (P<0.0001, 
P=0.0005, P<0.0001 and P=0.0003 respectively, Mann Whitney test) as compared to antibody binding 
to lab rIEs. B) Antibody binding to field mIEs showed a strong positive correlation (spearman r=0.6618; 
P<0.0001), with antibody binding to lab mIEs. Statistics was calculated using GraphPad PRISM version 
7.0.  
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Appendix 3. 7: Effect of dialysed only and dialysed plus heat-inactivated plasma on parasitemia. 
Exposure of rIEs to dialysed only or dialysed plus heat-inactivated plasma enhanced parasite growth is 
a similar manner in contrary to exposure to DHA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3. 8: Effect of dialysed and heat-inactivated immune plasma on ring survival. 
Percentage survival of rIEs when treated with dihydroartemisinin (DHA, positive control), naïve plasma 
(negative control), PHIS (pool of hyper immune plasma), MIG (purified malaria immunoglobulins) and 
randomly selected plasma of malaria-immune adults from Kilifi (JA031, JA137, JA155). The percentage 
survival rate was comparable when parasites were exposed to naïve plasma, pool of hyper immune 
serum, purified malaria immunoglobulins and plasma from randomly selected malaria-immune adults 
from Kilifi, Kenya, (P = 0.2691, one-way ANOVA). Statistics was calculated using GraphPad PRISM 
version 7.0. 
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Appendix 3. 9: Comparison of the effect of dialysed only or dialysed plus heat-inactivated 
immune plasma on ring survival. The parasites survival rates were similar, determined by unpaired 
t-test, when exposed to the dialysed only or dialysed and heat-inactivated state of the each of the test 
plasma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4. 1: Flow cytometry gating strategy for opsonic phagocytosis of ring-infected 
erythrocytes. A) The photomultiplier tube PMT voltages of the forward scatter and side scatter were 
adjusted to ensure that the population of THP-1 cells and red blood cells were well discriminated based 
on their difference in size and complexity. B) Only the single cells of our population of interest (THP-1 
cells) that passed the laser beam in the flow cell were gated. The PMT voltage of CellTrace Violet and 
DHE dyes were adjusted using relevant controls in order to identify and correctly discriminate the true 
population of THP-1 cells that phagocytosed uEs (top right quadrant) from those that phagocytosed 
rIEs (top left quadrant) after opsonization with (C) hyperimmune and (D) naïve plasma. 
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Appendix 4. 2: Optimization of effector to target ratio and phagocytosis duration. A) The effect 
of different effector to target ratios (1E:100T & 1E:200T) and phagocytosis durations (one & four hours) 
on the percentage of THP-1 cells that have taken up uEs which are positive for CellTrace dye only, and 
B) the percentage of THP-1 cell that have taken up rIEs which are positive for both CellTrace Violet and 
DHE dyes was determined. The plasma samples used during the optimization were: two pools of 
hyperimmune plasma from Kenya (PHIS and TRP), naïve plasma from German donors, and four 
randomly selected individuals obtained from the CHMI study (17K0002, 17K0003, 17K0005 AND 
17K0071). The effector to target ratio: 1E:200T, and four hours of phagocytosis was considered 
optimum for a good difference of phagocytosis of rIEs between opsonization of culture with 
hyperimmune and naïve plasma. The percentage parasitemia of the ring culture used was 8%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4. 3: Correlation of opsonic phagocytosis of uninfected erythrocytes to antibody 
responses to merozoites. Opsonic phagocytosis of uEs showed; a positive correlation (spearman 
r=0.7222; P<0.0001) to IgG antibody responses to merozoites, especially IgG1 and IgG3 (spearman 
r=0.6863; P<0.0001 and spearman r=0.6015; P<0.0001) respectively, but a weak correlation to IgG2 
(spearman r=0.4416; P<0.0001) and IgG4 (spearman r=0.2521; P=0.0005). The data was statistically 
analysed by GraphPad PRISM version 7.0. 
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Appendix 4. 4: Merozoite specific antibodies mediate opsonic phagocytosis of ring-infected 
erythrocytes. Relative phagocytosis index of rIEs using individual plasma samples that were each pre-
incubated with individual merozoite recombinant antigens and a pool of the recombinant antigens. The 
CHMI study plasma samples used for the assay were selected based on their known antibody 
responses to merozoites (18A0012 & 16K0036 - high; 17K0005 & 17K0028 - mid and 17K0074 & 
17K0084 - low). The selection of the merozoite recombinant antigens for competition was guided by 
their availability in our lab and their potential as vaccine candidates. 
 
Appendix 4. 5: Merozoite specific antibodies mediate opsonic phagocytosis of uninfected 
erythrocytes. Relative phagocytosis index of uEs using individual plasma samples that were each pre-
incubated with individual merozoite recombinant antigens and a pool of the recombinant antigens. The 
CHMI study plasma samples used for the assay were selected based on their known antibody 
responses to merozoites (18A0012 & 16K0036 - high; 17K0005 & 17K0028 - mid and 17K0074 & 
17K0084 - low). The selection of the merozoite recombinant antigens for competition was guided by 
their availability in our lab and their potential as vaccine candidates. 
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Appendix 5. 1: Experimental flow of how to obtain ring culture for mass spectrometry study. 
Culture of about 20% mIEs was obtained after previous D-sorbitol synchronization 46 hours apart (A). 
The mIEs are separated from uEs by magnetic cell sorting to obtain almost 90% pure mIEs (B) and 
maintained in culture until the mIEs reach about 40 hours post-invasion before adding fresh uEs to 
allow invasion by the released merozoites after schizont rupture. About 12 hours post invasion (C), 
magnetic cell sorting followed by sorbitol synchronization was conducted to get rid of mIEs that did not 
rupture, yielding a ring culture (0-10 hours post-invasion) which was used for mass spectrometry assays 
(D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5. 2: Histograms showing data quality of samples. The graphs show the log2 transformed 
LFQ intensities on x-axis and the count per bin on y-axis. The width of each bin was set to 0.25. The 
red-dotted line marks the median of the data. The data was close to normal distribution and centred 
around the same value over the different samples, which was a prerequisite for further statistical testing 
of the data. The samples were supernatant obtained after shaving the different cultures: samples 01-
04 from uEs in used media-samples; samples 05-08 from uEs in fresh media; samples 09-12 from 
trypsin-shaved ring culture and samples 13-16 from mock-shaved ring culture. 
 
A C B D 
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Appendix 5. 3: Multi-scatterplot showing data quality of samples. Pairwise scatter plots of log2 
transformed LFQ intensities of each sample combination on the lower left half of the figure, density plot 
of each sample on the diagonal, and Pearson correlation for all sample combinations on the upper-right 
half. The samples show strong positive general correlation with each other, which was a prerequisite 
for further statistical testing of the data. The samples were supernatant obtained after shaving the 
different cultures: samples 01-04 from uEs in used media-samples; samples 05-08 from uEs in fresh 
media; samples 09-12 from trypsin-shaved ring culture and samples 13-16 from mock-shaved ring 
culture.
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Appendix 5. 4: Principle component analysis using all the selected human and Plasmodium proteins. The shaved samples; uEs in used media (used_01-
04), uEs in fresh media (fresh_05-08) and trypsin-shaved ring culture (shaved_09-12) showed some similarity by clustering together and away from the mock-
shaved ring culture (mock_13-16). The proteins used for the principal component analysis were those that passed the selection criterion for statistical analysis.
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Appendix 5. 5: Heatmap generated using all the selected human and Plasmodium proteins. The 
heatmap was generated using Log-2 LFQ values that had been Z-score normalized and hierarchical 
clustering was performed on row and columns using the Euclidean distance and ward.D2. Quantitative 
values have been colour coded according to the colour key shown on the top. Protein are labelled by 
their gene-name and accession number. Sample names are shown on the top of the plot. The samples 
clustered well based on their experimental conditions as observed previously with the PCA analysis 
where the mock-shaved ring culture was clearly discriminated from the other three groups (uEs in used 
media, uEs in fresh media and trypsin-shaved ring culture) which clustered fairly well within their 
respective groups. The samples were supernatant obtained after shaving the different cultures: 
used_01-04 from uEs in used media-samples; fresh_05-08 from uEs in fresh media; shaved_09-12 
from trypsin-shaved ring culture and mock_13-16 from mock-shaved ring culture. The proteins used to 
generate the heatmap were those that passed the selection criterion for statistical analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5. 6: Volcano plots generated using only selected Plasmodium proteins. The volcano plots were generate using the -Log p values derived from 
the p-values obtained during Student’s t-test analysis where the mean LFQ values of each of the selected human and Plasmodium proteins were compared 
between all the possible combinations of the experimental conditions. There were significantly upregulated Plasmodium proteins identified in (A) uEs in used 
media (B) trypsin-shaved ring culture when compared to uEs in fresh media culture. Additionally, (C) there were also significantly upregulated Plasmodium 
proteins identified in trypsin-shaved ring culture when compared to mock-shaved ring culture. (D) There were two rhoptry associated proteins that were 
significantly upregulated in trypsin-shaved ring culture compared to uEs in used media. The significantly upregulated proteins denoted in blue and red were 
from human and Plasmodium respectively. The gene names of the various accession numbers of the Plasmodium hits are as follows; PF3D7_0929400 - Lactate 
dehydrogenase, PF3D7_0929400 - High molecular weight rhoptry protein 2, PF3D7_0905400 - High molecular weight rhoptry protein 3, PF3D7_0731500 - 
Erythrocyte binding antigen 175, PF3D7_1301600 - Erythrocyte binding antigen 140, ENO - Enolase, PCYB_112350 - Elongation factor 1, PF3D7_0818900 - 
Heat shock protein 70;70kDa, PF3D7_0917900 - Heat shock protein 70;78kDa, PKH_093790 - Myosin heavy chain subunit and PY07151 - Uncharacterized 
protein. The proteins used to generate the volcano plots were those that passed the selection criterion for statistical analysis. 
Key: red - significantly upregulated Plasmodium proteins; blue - significantly upregulated human proteins and grey - proteins with no change between any given 
two experimental conditions. 
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